Exhibit 2

	Page 328
1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	UNITED STATES DISTRICT COURT
	FOR THE SOUTHERN DISTRICT OF NEW YORK
3	
	In re:
4	: Master File No.
	Global Brokerage, Inc. : 1:17-cv-00916-RA
5	F/k/a FXCM, Inc. :
	Securities Litigation :
6	:
7	
8	REMOTE VIDEO DEPOSITION OF:
9	ADAM WERNER, Ph.D.
10	FRIDAY, JUNE 4, 2021
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	REPORTED BY:
	SILVIA P. WAGE, CCR, CRR, RPR
25	JOB NO. 4577228

	Page 329		Pac	ge 331
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.	50 331
2		2 3	I N D E X WITNESS: ADAM WERNER, Ph.D. PAGE	
3		4	EXAMINATION BY MR. ISAJIW 334	
	JUNE 4, 2021	5	EXHIBITS	
4	11:03 a.m.	6	NO. DESCRIPTION PAGE	
5	Remote Videotape deposition via Zoom of	7	NO. DESCRIPTION PAGE	
6	ADAM WERNER, Ph.D., pursuant to agreement before	8	Exhibit Werner 8 Report of Loss Causation 336	
7	SILVIA P. WAGE, a Certified Shorthand Reporter,	0	and Damages by Dr. Adam Werner April 21, 2021	
8	Certified Realtime Reporter, Registered	9	Exhibit Werner 9 Rebuttal Report on 341	
9	Professional Reporter, and Notary Public for the	10	Market Efficiency by Dr. Adam Werner July 27,	
10	States of New Jersey and New York.	11	2020 Exhibit Werner 10 Report and 351	
11	states of the weekey and the will follow		Recommendations to the	
12		12	Honorable Ronnie Abrams Exhibit Werner 11 Order Adopting Report & 351	
13		13	Recommendation	
14		14	Exhibit Werner 12 Order Instituting 452 Proceedings Pursuant to	
15		17	Sections 6(c) and 6(d)	
16		15	of the Commodity Exchange Act, Making	
17		16	Findings, and Imposing	
18		17	Remedial Sanctions	
19		18	PREVIOUSLY MARKED EXHIBITS	
20		19 20	NO. DESCRIPTION PAGE Exhibit Werner 3 Notice of Errata, 339	
21			Certificate of Service	
22		21	and Exhibit 1 Corrected Opening Report on Market	
23		22	Efficiency of Dr. Adam	
24		23	Werner January 10, 2020 Exhibit Werner 7 Opinion & Order 471	
25		24 25	•	
	Page 330		Pag	re 332
1	Page 330 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Pag CONFIDENTIAL - ADAM WERNER, Ph.D.	ge 332
2	•	2	CONFIDENTIAL - ADAM WERNER, Ph.D.	ge 332
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	2 3		ge 332
2	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D.	ge 332
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D.	ge 332
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D DEPOSITION SUPPORT INDEX	ge 332
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line	ge 332
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3	ge 332
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line	ge 332
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ.	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3	ge 332
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ.	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3	ge 332
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents	ge 332
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line	ge 332
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations	ge 332
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line	ge 332
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line	ge 332
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com EEnnis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked	ge 332
2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com Eennis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ. BY: EVAN C. ENNIS, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line	ge 332
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com EEnnis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked	ge 332
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com EEnnis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ. BY: EVAN C. ENNIS, ESQ. BY: ISRAEL DAHAN, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked	ge 332
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com Eennis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ. BY: EVAN C. ENNIS, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked Page Line	ge 332
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com EEnnis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ. BY: EVAN C. ENNIS, ESQ. BY: ISRAEL DAHAN, ESQ. A L S O P R E S E N T: MARCELO RIVERA	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked Page Line Reservation	ge 332
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com EEnnis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ. BY: EVAN C. ENNIS, ESQ. BY: ISRAEL DAHAN, ESQ.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked Page Line Reservation Page Line	ge 332
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com EEnnis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ. BY: EVAN C. ENNIS, ESQ. BY: ISRAEL DAHAN, ESQ. A L S O P R E S E N T: MARCELO RIVERA	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked Page Line Reservation Page Line Motion to Strike	ge 332
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com EEnnis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ. BY: EVAN C. ENNIS, ESQ. BY: ISRAEL DAHAN, ESQ. A L S O P R E S E N T: MARCELO RIVERA	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked Page Line Reservation Page Line	ge 332
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. A P P E A R A N C E S: THE ROSEN LAW FIRM Attorneys for Plaintiffs 101 Greenwood Avenue, Suite 440 Jenkintown, Pennsylvania 19046 (215) 600-2817 Jbaker@rosenlegal.com Blapointe@rosenlegal.com BY: JOSHUA BAKER, ESQ. BY: BRENT LaPOINTE, ESQ. KING & SPALDING LLP Attorneys for Defendants 1185 Avenue of the Americas New York, New York 10036-2601 (212) 556-2262 Plsajiw@KSLAW.com EEnnis@KSLAW.com Idahan@kslaw.com BY: PETER ISAJIW, ESQ. BY: EVAN C. ENNIS, ESQ. BY: ISRAEL DAHAN, ESQ. A L S O P R E S E N T: MARCELO RIVERA	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. DEPOSITION SUPPORT INDEX Direction to Witness Not to Answer Page Line 395 3 397 3 Request for Production of Documents Page Line Stipulations Page Line Question Marked Page Line Reservation Page Line Motion to Strike	ge 332

1	Page 333	1	Page 335 CONFIDENTIAL - ADAM WERNER, Ph.D.
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	,
2 3	THE VIDEOGRAPHER: Good morning.	2 3	want to encourage at the very beginning for us to
4	We're going on the record at 11:03 a.m., on June 4th, 2021.	4	be mindful not to speak over each other because
5	•	5	it's very difficult for the Court Reporter to get it down. It's even more so on the Zoom platform.
6	This deposition is being taken remotely of Mr I mean, excuse me, Dr. Adam	6	So I just wanted to ask you to be mindful of that
7	Werner in the matter Global Brokerage Inc., f/k/a	7	and I'll do the same; is that okay?
8	FXCM Inc., securities litigation.	8	A. Sure.
9	My name is Marcelo Rivera from	9	Q. Okay. Also, any exhibits I upload
10	Veritext Legal Solutions and I am the	10	today will be introduced through the Exhibit
11	Videographer.	11	Share platform.
12	The Court Reporter is Silvia Wage in	12	Just to confirm you do have access to
13	association with Veritext Legal Solutions.	13	that; is that right?
14	I am not related to any party in this	14	A. Yes, I have that open in front of me.
15	action. Nor am I financially interested in the	15	Q. Okay. And where are you currently
16	outcome.	16	located?
17	Counsel and all present remotely will	17	A. Pismo Beach, California.
18	now state their appearances and affiliations for	18	Q. And is anyone else with you in the
19	the record. If there are any objections to	19	room?
20	proceeding, please state them at the time of your	20	A. No.
21	appearance beginning with noticing attorney.	21	Q. Okay. And do you have any materials
22	MR. ISAJIW: Peter Isajiw with King &	22	with you today that are related to this case?
23	Spalding for Defendants FXCM.	23	A. No.
24	MR. DAHAN: Israel Dahan from King &	24	Q. Okay. You were asked by Plaintiffs
25	Spalding for the Defendants as well.	25	to provide an expert opinion regarding loss
	Page 334		Page 336
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	MS. ENNIS: Evan Ennis for King &	2	causation and damages in this matter; is that
3	Spalding for the Defendants.	3	correct?
4	MR. BAKER: Josh Baker with the Rosen	4	A A(d) (T1 1' C d
		4	A. At this stage, I believe, for the
5	Law Firm for Plaintiffs and the witness.	5	A. At this stage, I believe, for the purposes of this deposition, I believe, that is
5 6	Law Firm for Plaintiffs and the witness. MR. LaPOINTE: Brent LaPointe with		A. At this stage, I believe, for the purposes of this deposition, I believe, that is correct.
		5	purposes of this deposition, I believe, that is
6	MR. LaPOINTE: Brent LaPointe with	5 6	purposes of this deposition, I believe, that is correct.
6 7	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the	5 6 7	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our
6 7 8	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness.	5 6 7 8	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner
6 7 8 9	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter	5 6 7 8 9	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your
6 7 8 9 10	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness.	5 6 7 8 9	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the
6 7 8 9 10 11	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D.,	5 6 7 8 9 10 11	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and
6 7 8 9 10 11 12	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach,	5 6 7 8 9 10 11 12	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter.
6 7 8 9 10 11 12 13	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly	5 6 7 8 9 10 11 12 13	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that
6 7 8 9 10 11 12 13 14	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as	5 6 7 8 9 10 11 12 13 14	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please.
6 7 8 9 10 11 12 13 14 15	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as follows:	5 6 7 8 9 10 11 12 13 14 15	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please. (Deposition Exhibit Werner 8, Report
6 7 8 9 10 11 12 13 14 15 16	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as follows: THE STENOGRAPHER: Thank you.	5 6 7 8 9 10 11 12 13 14 15 16	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please. (Deposition Exhibit Werner 8, Report of Loss Causation and Damages by Dr. Adam Werner
6 7 8 9 10 11 12 13 14 15 16 17	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as follows: THE STENOGRAPHER: Thank you. You may proceed.	5 6 7 8 9 10 11 12 13 14 15 16 17	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please. (Deposition Exhibit Werner 8, Report of Loss Causation and Damages by Dr. Adam Werner April 21, 2021, was marked for identification.)
6 7 8 9 10 11 12 13 14 15 16 17	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as follows: THE STENOGRAPHER: Thank you. You may proceed. MR. ISAJIW: Thank you.	5 6 7 8 9 10 11 12 13 14 15 16 17 18	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please. (Deposition Exhibit Werner 8, Report of Loss Causation and Damages by Dr. Adam Werner April 21, 2021, was marked for identification.) MS. ENNIS: It should be there.
6 7 8 9 10 11 12 13 14 15 16 17 18	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as follows: THE STENOGRAPHER: Thank you. You may proceed. MR. ISAJIW: Thank you. EXAMINATION BY MR. ISAJIW:	5 6 7 8 9 10 11 12 13 14 15 16 17 18	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please. (Deposition Exhibit Werner 8, Report of Loss Causation and Damages by Dr. Adam Werner April 21, 2021, was marked for identification.) MS. ENNIS: It should be there. Q. Can you take a look at the folder and
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as follows: THE STENOGRAPHER: Thank you. You may proceed. MR. ISAJIW: Thank you. EXAMINATION BY MR. ISAJIW: Q. Good morning, Dr. Werner. Thank you	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please. (Deposition Exhibit Werner 8, Report of Loss Causation and Damages by Dr. Adam Werner April 21, 2021, was marked for identification.) MS. ENNIS: It should be there. Q. Can you take a look at the folder and see if you can see that, Dr. Werner?
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as follows: THE STENOGRAPHER: Thank you. You may proceed. MR. ISAJIW: Thank you. EXAMINATION BY MR. ISAJIW: Q. Good morning, Dr. Werner. Thank you for joining us again today. Given that this is your second deposition in the matter, I know you're familiar	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please. (Deposition Exhibit Werner 8, Report of Loss Causation and Damages by Dr. Adam Werner April 21, 2021, was marked for identification.) MS. ENNIS: It should be there. Q. Can you take a look at the folder and see if you can see that, Dr. Werner? A. Yeah, I'm just resetting it. Okay, here we go. Q. Okay. And Werner 8, this is your
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MR. LaPOINTE: Brent LaPointe with the Rosen Law Firm for the Plaintiff and the witness. THE VIDEOGRAPHER: The Court Reporter please swear in the witness. ADAM WERNER, Ph.D., 960 Wadsworth Avenue, Pismo Beach, California 93445, after having been duly sworn, was examined and testified as follows: THE STENOGRAPHER: Thank you. You may proceed. MR. ISAJIW: Thank you. EXAMINATION BY MR. ISAJIW: Q. Good morning, Dr. Werner. Thank you for joining us again today. Given that this is your second	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	purposes of this deposition, I believe, that is correct. Q. Okay. And I want to introduce our first exhibit, which I believe will be Werner Exhibit No. 8 using sequential numbers from your prior deposition. And that would be the April 21, 2021 report on loss causation and damages that you filed in this matter. MR. ISAJIW: Evan, can you put that up on Exhibit Share please. (Deposition Exhibit Werner 8, Report of Loss Causation and Damages by Dr. Adam Werner April 21, 2021, was marked for identification.) MS. ENNIS: It should be there. Q. Can you take a look at the folder and see if you can see that, Dr. Werner? A. Yeah, I'm just resetting it. Okay, here we go.

	D 227		D 220
1	Page 337 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 339 CONFIDENTIAL - ADAM WERNER, Ph.D.
2	A. It appears to be, yes.	2	the same rate that was that appears in my
3	Q. And did you write this report?	3	original market efficiency report.
4	A. I did.	4	Q. Okay. Aside from the Crowninshield
5	Q. Anyone assist you with it?	5	employees we just talked about, did anybody else
6	A. I believe people assisted me in	6	assist with drafting this report?
7	drafting it, yes.	7	A. I don't believe so.
8	Q. Can you who assisted you, was that	8	Q. And have you done anymore work on
9	someone from Crowninshield?	9	this matter since filing the report?
10	A. Yes.	10	A. With regards to damages and loss
11	Q. And who helped with the drafting of	11	causation, no.
12	this report?	12	Q. Okay. I want to introduce a document
13	A. Nariner Walia or Valia again, if	13	that had been previously marked as Werner
14	the Court Reporter wants me to spell any of	14	Exhibit 3. This is your January 10th, 2020
15	these, just go ahead, although they're probably	15	Corrected Werner Opening Report on Market
16	those name probably appear in earlier	16	Efficiency.
17	depositions Daniel Bettencourt and Alex Huang.	17	MR. ISAJIW: Evan, can you put that
18	Q. Anyone else?	18	up please.
19	A. Not as I sit here today not that I	19	MS. ENNIS: Just give me one second.
20	can think of as I sit here today.	20	(Deposition Exhibit Werner 3, Notice
21	Q. And can you estimate how much time	21	of Errata, Certificate of Service and Exhibit 1
22	Nariner Walia spent assisting you with this	22	Corrected Opening Report on Market Efficiency of
23	report?	23	Dr. Adam Werner January 10, 2020, was previously
24	A. No.	24	marked for identification.)
25	Q. How about Daniel Bettencourt?	25	MS. ENNIS: It should be loaded.
	Page 338		Page 340
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	A. No.	2	Q. And, Dr. Werner, let me know when you
3	Q. What about Alex Huang?	3	have access to that.
4	A. No.	4	A. Okay. It just showed up.
5	Q. Do you have any idea what the		
6		5	Q. Okay. And this is your opening
		6	Q. Okay. And this is your opening report on market efficiency, correct?
7	billable rate for each of those people is? A. Not as I sit here today. I I	_	report on market efficiency, correct?
	billable rate for each of those people is? A. Not as I sit here today. I I	6	report on market efficiency, correct? A. I believe it's the corrected report
7 8 9	billable rate for each of those people is? A. Not as I sit here today. I I believe if you hold on one second. I don't	6 7	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency.
8	billable rate for each of those people is? A. Not as I sit here today. I I	6 7 8	report on market efficiency, correct? A. I believe it's the corrected report
8 9	billable rate for each of those people is? A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my	6 7 8 9	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative
8 9 10	billable rate for each of those people is? A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency	6 7 8 9 10	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct?
8 9 10 11	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the	6 7 8 9 10	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct.
8 9 10 11 12	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can	6 7 8 9 10 11 12	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there
8 9 10 11 12 13	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there.	6 7 8 9 10 11 12 13	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the
8 9 10 11 12 13 14	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those	6 7 8 9 10 11 12 13 14	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with
8 9 10 11 12 13 14 15	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those reports, as far as you know?	6 7 8 9 10 11 12 13 14 15	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with or as part of this exhibit.
8 9 10 11 12 13 14 15 16	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those reports, as far as you know? A. No.	6 7 8 9 10 11 12 13 14 15 16	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with or as part of this exhibit. Q. Okay. And behind the Notice of
8 9 10 11 12 13 14 15 16 17	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those reports, as far as you know? A. No. Q. How much time did you spend on this	6 7 8 9 10 11 12 13 14 15 16 17	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with or as part of this exhibit. Q. Okay. And behind the Notice of Errata is the corrected report.
8 9 10 11 12 13 14 15 16 17	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those reports, as far as you know? A. No. Q. How much time did you spend on this report?	6 7 8 9 10 11 12 13 14 15 16 17	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with or as part of this exhibit. Q. Okay. And behind the Notice of Errata is the corrected report. The notice is indicating that the
8 9 10 11 12 13 14 15 16 17 18	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those reports, as far as you know? A. No. Q. How much time did you spend on this report? A. As I sit here, I don't recall.	6 7 8 9 10 11 12 13 14 15 16 17 18	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with or as part of this exhibit. Q. Okay. And behind the Notice of Errata is the corrected report. The notice is indicating that the this corrected report is superseding the original
8 9 10 11 12 13 14 15 16 17 18 19 20	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those reports, as far as you know? A. No. Q. How much time did you spend on this report? A. As I sit here, I don't recall. Q. Do you have a rough approximation?	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with or as part of this exhibit. Q. Okay. And behind the Notice of Errata is the corrected report. The notice is indicating that the this corrected report is superseding the original report that was submitted in the matter; is that
8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those reports, as far as you know? A. No. Q. How much time did you spend on this report? A. As I sit here, I don't recall. Q. Do you have a rough approximation? A. Less than 50 hours, more than	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with or as part of this exhibit. Q. Okay. And behind the Notice of Errata is the corrected report. The notice is indicating that the this corrected report is superseding the original report that was submitted in the matter; is that correct?
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	billable rate for each of those people is? A. Not as I sit here today. I I believe if you hold on one second. I don't know if it's stated here or if you go to my original report, my original market efficiency report. I believe that the range of rates or the possible range of rates for those individuals can be found there. Q. And they haven't changed since those reports, as far as you know? A. No. Q. How much time did you spend on this report? A. As I sit here, I don't recall. Q. Do you have a rough approximation? A. Less than 50 hours, more than 15 hours.	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	report on market efficiency, correct? A. I believe it's the corrected report of my opening report on market efficiency. Q. So this would be the operative opening report so-to-speak; is that correct? A. That is correct. MR. BAKER: I'll just note like there seems to be another document preceding the report, Notice of Errata that was filed with or as part of this exhibit. Q. Okay. And behind the Notice of Errata is the corrected report. The notice is indicating that the this corrected report is superseding the original report that was submitted in the matter; is that correct? A. Correct.

	Page 341		Page 343
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	2020 Werner Rebuttal Report on Market Efficiency.		individual screens.
3	And I believe this will be Werner Exhibit No. 9.	3	THE WITNESS: Ah, okay. Let me do
4	(Deposition Exhibit Werner 9,	4	I think this is the right one.
5	Rebuttal Report on Market Efficiency by Dr. Adam	5	Q. And if you're going to do that, it
6	Werner July 27, 2020, was marked for	6	may make sense to download the other two as well.
7	identification.)	7	A. Okay.
8	MS. ENNIS: Loaded.	8	MR. BAKER: Peter, when you're
9	Q. Dr. Werner, let me know when you have	9	talking about the CV on Page 39, you're talking
10	access.	10	about the PDF numbers or the report page numbers
11	A. Still loading. Oh, wait. No, that's	11	
12	the wrong one. Hold on.	12	MR. ISAJIW: The report page numbers.
13	Okay, I have it in front of me now.	13	MR. BAKER: The report page numbers
14	Q. And that's your rebuttal report on	14	looks like it starts on 37, not 39.
15	market efficiency, correct?	15	MR. ISAJIW: That's correct. The
16	A. That is correct.	16	portion that I want to point him to begins on
17	Q. Okay. And so do these three reports,	17	Page 39.
18	the loss causation report, the corrected opening	18	MR. BAKER: Okay. That's fine.
19	report on market efficiency and the rebuttal	19	Q. And just let me know when you're
20	report on market efficiency embody the totality	20	ready, Dr. Werner.
21	of your opinions in this matter?	21	A. Okay. I think these are all
22	MR. BAKER: Object to the form.	22	downloaded now.
23	A. As of today, yes.	23	So let's go to Page 37 of my
24	Q. Are there any opinions that you've	24	April 21st report?
25	been asked to provide with respect to this matter	25	Q. That's fine.
	Page 342		Page 344
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	that are not included in these reports?	2	A. Okay, I'm there.
3	A. Not that I can think of.	3	Q. And 37 is the beginning of your
4	Q. Other than the materials disclosed in	4	curriculum vitae; is that correct?
5	your reports, are there any other materials that	5	A. That is correct.
6 7	you relied on to form the basis of your opinions in this matter?	6 7	Q. And if you flip to Page 39, there's a
8	A. And so when you say, "materials," I'm	8	section called, "Expert Reports and Testimony." Let me know when you're there.
9	assuming you're referring to, essentially,	9	A. Okay, I'm there.
10			A. Okay, I'll there.
	Exhibit 2 on each of these reports?	1()	O Comparing this curriculum vitae to
1	Exhibit 2 on each of these reports? Or That's correct	10	Q. Comparing this curriculum vitae to
11	Q. That's correct.	11	the ones included in your prior market efficiency
11 12	Q. That's correct.A. That is correct.	11 12	the ones included in your prior market efficiency report, it seems to me that you issued reports
11 12 13	Q. That's correct.A. That is correct.Q. Okay. Let's turn	11 12 13	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the
11 12 13 14	Q. That's correct.A. That is correct.Q. Okay. Let's turnA. You may want to re-ask the question.	11 12	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings;
11 12 13 14 15	 Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered 	11 12 13 14	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct?
11 12 13 14	 Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered any other documents outside of those listed in 	11 12 13 14 15 16	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct? MR. BAKER: You mean since his
11 12 13 14 15 16	Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered any other documents outside of those listed in Exhibit 2 of the three reports in front of me.	11 12 13 14 15	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct?
11 12 13 14 15 16 17	 Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered any other documents outside of those listed in Exhibit 2 of the three reports in front of me. Q. Okay. Thank you for that. 	11 12 13 14 15 16 17	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct? MR. BAKER: You mean since his previous report? MR. ISAJIW: That's correct.
11 12 13 14 15 16 17 18	 Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered any other documents outside of those listed in Exhibit 2 of the three reports in front of me. Q. Okay. Thank you for that. Looking at your loss causation 	11 12 13 14 15 16 17 18	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct? MR. BAKER: You mean since his previous report? MR. ISAJIW: That's correct. A. So hold on. Sorry, if you go between
11 12 13 14 15 16 17 18 19	 Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered any other documents outside of those listed in Exhibit 2 of the three reports in front of me. Q. Okay. Thank you for that. 	11 12 13 14 15 16 17 18	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct? MR. BAKER: You mean since his previous report? MR. ISAJIW: That's correct.
11 12 13 14 15 16 17 18 19 20	Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered any other documents outside of those listed in Exhibit 2 of the three reports in front of me. Q. Okay. Thank you for that. Looking at your loss causation report, can you turn to Exhibit 1, which is your	11 12 13 14 15 16 17 18 19 20	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct? MR. BAKER: You mean since his previous report? MR. ISAJIW: That's correct. A. So hold on. Sorry, if you go between documents, it takes you back to the first page
11 12 13 14 15 16 17 18 19 20 21	Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered any other documents outside of those listed in Exhibit 2 of the three reports in front of me. Q. Okay. Thank you for that. Looking at your loss causation report, can you turn to Exhibit 1, which is your CV. And it's on Page 39 of that report.	11 12 13 14 15 16 17 18 19 20 21	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct? MR. BAKER: You mean since his previous report? MR. ISAJIW: That's correct. A. So hold on. Sorry, if you go between documents, it takes you back to the first page so
11 12 13 14 15 16 17 18 19 20 21 22	Q. That's correct. A. That is correct. Q. Okay. Let's turn A. You may want to re-ask the question. I'm not sure I answered I haven't considered any other documents outside of those listed in Exhibit 2 of the three reports in front of me. Q. Okay. Thank you for that. Looking at your loss causation report, can you turn to Exhibit 1, which is your CV. And it's on Page 39 of that report. A. You may not know this. Is there a	11 12 13 14 15 16 17 18 19 20 21 22	the ones included in your prior market efficiency report, it seems to me that you issued reports and declarations in three additional cases the Nova Life, Array Biopharma and Innocoll Holdings; is that correct? MR. BAKER: You mean since his previous report? MR. ISAJIW: That's correct. A. So hold on. Sorry, if you go between documents, it takes you back to the first page so Q. Yeah.

1			
1	Page 345 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 347 CONFIDENTIAL - ADAM WERNER, Ph.D.
2	as I sit here, I believe also and this is	2	thinking of that you're unsure of?
3	there is a space missing, so I'm on Page 40 of my	3	A. No, but it's possible. I mean, it's
4	report dated in April of this year.	4	possible that I saw something. I just don't
5	It looks like there is a Michael	5	recall as I sit here today.
6	Tietz versus Crytobloc Technology Corp report.	6	Q. If you turn to Paragraph 1, Page 1 of
7	But that's a report in Canada. I don't know if	7	your loss causation report, you define "FXCM
8	you include that in your additional reports.	8	notes" as a "2.25 percent convertible senior note
9	Q. Oh, I see.	9	due in 2018," correct?
10	So, when you say, "there is a space	10	A. That is correct.
11	missing," that is combined with the paragraph for	11	Q. So, if I use the term "FXCM notes"
12	Innocoll Holdings; is that correct?	12	today, you'll understand that I'm referring to
13	A. Exactly.	13	those notes; is that okay?
14	Q. Other than those four matters, any	14	A. Yes.
15	other additional engagements or opinions	15	Q. And you define the class period as
16	regarding market efficiency since your last	16	
17	deposition?	17	March 15th, 2012 through February 6th, 2017; is that correct?
18	A. It's possible, but as I sit here	18	A. For the notes?
1	•		
19	today I can't think of any.	19	Q. For the class period.
20	Q. Were there any focusing on your	20	A. So I'm sorry. Can you repeat the
21	loss causation report in this matter, were there	21	question?
22	any materials that you requested as part of your	22	Q. Yeah. I just want to make sure that
23	engagement that you did not receive from either	23	we're on the same page getting started on defined
24	the Rosen Law Firm or Crowninshield or any other	24	terms.
25	source?	25	So you define the term in this
	Page 346		Page 348
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No.	1 2	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between
	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss		CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not	2	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct?
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report?	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity?
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report?	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity?
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case?	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes.	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here.
2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your	2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next.
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports?	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so. Q. And this report, yeah.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next. I just want to make sure when we use
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so. Q. And this report, yeah. And since you filed this particular	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next. I just want to make sure when we use the term "class period," as you define it, you're
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so. Q. And this report, yeah. And since you filed this particular loss causation report, are there any other	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next. I just want to make sure when we use the term "class period," as you define it, you're talking about March 15th, 2012 to February 6th,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so. Q. And this report, yeah. And since you filed this particular loss causation report, are there any other materials that you have reviewed relating to this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next. I just want to make sure when we use the term "class period," as you define it, you're talking about March 15th, 2012 to February 6th, 2017?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so. Q. And this report, yeah. And since you filed this particular loss causation report, are there any other materials that you have reviewed relating to this case that are relevant to your opinions?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next. I just want to make sure when we use the term "class period," as you define it, you're talking about March 15th, 2012 to February 6th, 2017? A. Okay, sure.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so. Q. And this report, yeah. And since you filed this particular loss causation report, are there any other materials that you have reviewed relating to this case that are relevant to your opinions? A. No.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next. I just want to make sure when we use the term "class period," as you define it, you're talking about March 15th, 2012 to February 6th, 2017? A. Okay, sure. Q. And when we use the term "notes
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so. Q. And this report, yeah. And since you filed this particular loss causation report, are there any other materials that you have reviewed relating to this case that are relevant to your opinions? A. No. Q. Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next. I just want to make sure when we use the term "class period," as you define it, you're talking about March 15th, 2012 to February 6th, 2017? A. Okay, sure. Q. And when we use the term "notes period," as you defined it, you're talking about
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. A. No. Q. And did you conduct any loss causation or damages analysis that's not reflected in your loss causation report? MR. BAKER: With respect to this case? MR. ISAJIW: Yes. A. No. Q. And are there any materials that you relied upon or considered in connection with your analysis of loss causation in this case that are not listed under the documents considered in Exhibit 2 of any of the other reports? A. And this report? I don't believe so. Q. And this report, yeah. And since you filed this particular loss causation report, are there any other materials that you have reviewed relating to this case that are relevant to your opinions? A. No. Q. Okay. A. Oh, wait. I don't believe so would	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. paragraph "class period" to mean the time between March 15th, 2012 and February 6th, 2017; is that correct? A. For the equity? Q. For the term "class period" as a defined term at the end. I believe it's at the second to last sentence of Paragraph 1. A. Yeah, I think we're talking semantics here. So, yes, I have defined that as the class period. But I think of the note period as a different period since it is a subset of that time period. Q. We'll get to the note period next. I just want to make sure when we use the term "class period," as you define it, you're talking about March 15th, 2012 to February 6th, 2017? A. Okay, sure. Q. And when we use the term "notes period," as you defined it, you're talking about June 24, 2014 through February 6th, 2017; is that

	Daga 240		Dog 251
1	Page 349 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 351 CONFIDENTIAL - ADAM WERNER, Ph.D.
2	Q. Okay. And so throughout today, if	2	MS. ENNIS: It's loaded.
3	we're using the terms "class period" or "notes	3	
4	period," I just want to make sure we can	4	(Deposition Exhibit Werner 10, Report and Recommendations to the Honorable Ronnie
	shorthand and use those same time definitions; is		
5		5	Abrams, was marked for identification.)
6	that okay?	6	(Deposition Exhibit Werner 11, Order
7	A. As long as we're being clear as to	7	Adopting Report & Recommendation, was marked for
8	whether or not we're talking about the equity or	8	identification.)
9	the notes, yes.	9	MS. ENNIS: That should be loaded as
10	Q. Okay. And to the extent we're not	10	well.
11	clear, please let me know if you have a question	11	A. Okay, I have them in front of me.
12	about it and I will do my best to clarify, okay?	12	Q. Okay. Did you review the Court's
13	A. Yes.	13	decision regarding Plaintiffs' motion for class
14	Q. Okay. Turning to Page 2 of your	14	certification before drafting your loss causation
15	report under "Conclusions." You conclude in	15	report?
16	Paragraph 7 that the prices of the FXCM stock and	16	A. I'm sorry. Could you repeat that
17	the FXCM notes were artificially inflated over	17	question please?
18	the course of the class period; is that correct?	18	Q. Yeah. Did you review the Court's
19	A. That is correct.	19	decision regarding Plaintiffs' motion for class
20	Q. Okay. And as you know, the Court	20	certification before drafting your loss causation
21	held an evidentiary hearing on class	21	report?
22	certification in this matter, right?	22	A. So let's go look at my documents
23	A. Correct.	23	relied upon for my April wait.
24	Q. And that hearing dealt with market	24	When did this decision come out?
25	efficiency with respect to FXCM notes; is that	25	Q. It's filed March 18, 2021.
	Page 350		Page 352
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. correct?	2	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report.
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct.	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here.
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report?
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct?	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes.	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is	2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10.
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right?	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay.
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did.	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did. Q. And I want to introduce two exhibits	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes traded in an efficient market throughout the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did. Q. And I want to introduce two exhibits related to that hearing. The first is a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes traded in an efficient market throughout the notes period. The issue size was relatively
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did. Q. And I want to introduce two exhibits related to that hearing. The first is a March 18, 2021 Report and Recommendation to the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes traded in an efficient market throughout the notes period. The issue size was relatively small, smaller than any of the cases relied on by
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did. Q. And I want to introduce two exhibits related to that hearing. The first is a March 18, 2021 Report and Recommendation to the Honorable Ronnie Abrams.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes traded in an efficient market throughout the notes period. The issue size was relatively small, smaller than any of the cases relied on by Plaintiffs in their reports and the notes were
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did. Q. And I want to introduce two exhibits related to that hearing. The first is a March 18, 2021 Report and Recommendation to the Honorable Ronnie Abrams. MR. ISAJIW: Evan, can you load that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes traded in an efficient market throughout the notes period. The issue size was relatively small, smaller than any of the cases relied on by Plaintiffs in their reports and the notes were unregistered, initially restricted and thereafter
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did. Q. And I want to introduce two exhibits related to that hearing. The first is a March 18, 2021 Report and Recommendation to the Honorable Ronnie Abrams. MR. ISAJIW: Evan, can you load that. MS. ENNIS: Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes traded in an efficient market throughout the notes period. The issue size was relatively small, smaller than any of the cases relied on by Plaintiffs in their reports and the notes were unregistered, initially restricted and thereafter traded only among a fairly small number of QIBs.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did. Q. And I want to introduce two exhibits related to that hearing. The first is a March 18, 2021 Report and Recommendation to the Honorable Ronnie Abrams. MR. ISAJIW: Evan, can you load that. MS. ENNIS: Okay. MR. ISAJIW: And the second is	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes traded in an efficient market throughout the notes period. The issue size was relatively small, smaller than any of the cases relied on by Plaintiffs in their reports and the notes were unregistered, initially restricted and thereafter traded only among a fairly small number of QIBs. No analyst followed the FXCM notes as opposed to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. correct? A. It may have touched on the on general calculation of damages. As I sit here, I don't recall. But, generally, that's correct. Q. Yeah. And so, I guess, what I'm asking is you were aware that hearing dealt with market efficiency in connection with the FXCM notes, correct? A. Among other things, yes. Q. And you testified at the hearing; is that right? A. I did. Q. And Dr. Hendershott also testified at the hearing? A. He did. Q. And I want to introduce two exhibits related to that hearing. The first is a March 18, 2021 Report and Recommendation to the Honorable Ronnie Abrams. MR. ISAJIW: Evan, can you load that. MS. ENNIS: Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. A. Okay. So, prior to the filing of this report. It's possible. I don't recall, as I sit here. Q. Is it listed in Exhibit 2 of your report? A. It is not. Q. Okay. Can you turn to Page 37 of the Report and Recommendation, which is Exhibit Werner 10. A. Okay. Q. Okay. At Page 37 the Court says, "I further find that balancing all of the Cammer and Krogman factors Plaintiffs have not met their burden of demonstrating that the FXCM notes traded in an efficient market throughout the notes period. The issue size was relatively small, smaller than any of the cases relied on by Plaintiffs in their reports and the notes were unregistered, initially restricted and thereafter traded only among a fairly small number of QIBs.

Page 353 Page 355 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 of the trading decreased over the course of the question? 3 noise period with the volume dipping below the 3 A. Well, I'm slightly confused because 4 camera benchmarks after October 2015. The only 4 we're talking about the class period versus the 5 5 direct evidence of market efficiency in the note period. So are you referring to the class 6 record offered to show a cause and effect 6 period or the note period? 7 7 relationship between the release of Q. I'm referring to your Paragraph 7 of 8 8 'company-specific news' and changes to the price your loss causation report. Take a look at that. 9 9 of the FXCM notes is Dr. Werner's event study, A. Well, I will in a second, but I'm 10 which is of limited utility due to the nature and 10 just trying to answer your question based on this 11 timing of the two events chosen. Because the 11 paragraph or the statement you just read to me. 12 12 Plaintiffs have not established that the FXCM So I'm trying to get clarification on what you 13 notes traded in an efficient market, they cannot 13 14 14 Q. I'm helping you get clarification by rely on the basic presumption of reliance as to 15 the notes meaning that each note purchaser would 15 referring to Paragraph 7 of your report. 16 be required to prove individually that it relied 16 A. Alright. We'll agree to disagree. 17 on the Defendant's allegedly false and misleading 17 So now you want me to go to 18 statements in making its purchases. This in turn 18 Paragraph 7 of my April 21st report, correct? Q. That's correct. 19 19 means that the Plaintiffs cannot satisfy the 20 predominance requirement of Rule 23(b)(3) with 20 A. Okay. 21 21 respect to the notes." Q. In the third sentence you say, "The 22 Did I read that correctly? 22 alleged representations and omissions caused the 23 A. I believe the last sentence was with 23 prices of FXCM stock and FXCM notes to be 24 respect to the FXCM notes but otherwise, yes. 24 artificially inflated over the course of the 25 25 class period." Q. Thanks. Page 354 Page 356 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 2 And if you turn to Page 40 of that Do you see that? 3 same decision. 3 A. I do see that. 4 A. Okay. 4 Q. And I'm just asking that when you 5 Q. You'll see the Court says, "For the 5 state that the FXCM notes were artificially 6 reason set forth above, I recommend respectfully inflated over the course of the class period, are 7 7 that Plaintiffs' class certification motion be you aware that the Court has already determined 8 8 granted in part as to the FXCM stock and denied that there is no class for the FXCM notes? 9 9 in part as to the FXCM notes." A. Okay. 10 Did I read that correctly? 10 MR. BAKER: Objection. 11 11 A. So let's --12 Q. Okay. So going back to your opinion 12 THE WITNESS: Oh, go ahead. Sorry, in Paragraph 7 of your loss causation report 13 13 Josh. 14 where you state that the FXCM notes were 14 MR. BAKER: It's alright. 15 "artificially inflated over the course of the 15 Objection to form. 16 But if you understand it, you can 16 class period," are you aware that the Court has 17 already determined that there is no class or 17 answer it. 18 class period for the FXCM notes in this case? 18 A. Okay. So let's separate out a couple 19 MR. BAKER: Objection to form. Just 19 of things. So it probably -- the sentence is 20 where it refers to the -- the term being as 20 somewhat inarticulate on my part. I probably defined as class period before versus -- we're 21 21 should have specified the notes period with 22 22 hopping between multiple documents here. So I regards to the notes. 23 want to be clear that which definitions of which 23 To the extent that the class for the 24 periods we're using here. 24 notes wasn't certified, that has nothing to do 25 Q. Dr. Werner, do you understand the 25 with whether or not I'm able to calculate or

Page 357 Page 359 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 estimate damages for individual plaintiffs. 2 corrected original report and possibly to my 3 3 Q. When you drafted your loss causation rebuttal report on market efficiency. 4 4 report, were you aware that the Court had Would you like me to do that? 5 determined that there was no class for note 5 Q. Sitting here today based on your work 6 holders? on this matter thus far, you don't have the 6 7 7 ability to answer that question without reference A. I believe the answer to that question 8 is, yes. 8 to your report; is that correct? 9 9 Q. And were you aware that the Court had A. No. 10 already rejected your opinion and conclusion that 10 Q. Okay. That's not correct, or you the FXCM notes traded in an efficient market? 11 11 cannot answer the question without reference to 12 MR. BAKER: Objection to form. 12 your report? 13 A. Yes. 13 A. That is not correct. 14 14 Q. Does the fact that the Court had Q. So, if you can answer the question 15 already determined that there was no class for 15 without reference to your report, I just want to 16 the FXCM notes change your conclusion on loss get your understanding sitting here today as to 16 17 causation for the notes here? what event you understood marked the beginning of 17 18 A. No. 18 the class period March 15, 2012. 19 19 O. Does the fact that the Court has MR. BAKER: He said he doesn't know 20 rejected your contention that the FXCM notes 20 sitting here today already; asked and answered. 21 21 traded in an efficient market changed your A. Like I said, I want to be as accurate 22 conclusion on loss causation for the FXCM notes 22 as possible in this deposition. So I'm happy to 23 23 refer to my previous reports to refresh my memory here? 24 24 A. I'm sorry. Could you repeat that to make sure that I'm as accurate as possible in question? 25 25 answering your question. Page 358 Page 360 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 Q. Does the fact that the Court has So it seems to me that it's -- I --3 already rejected your contention that the FXCM 3 well, I choose as I sit here today -- if you want 4 notes traded in an efficient market change your 4 me to answer that question, I'm happy to refer to 5 conclusion on loss causation for the FXCM notes 5 my other reports to make sure I'm giving you the 6 here? 6 most accurate answer that I possibly can. 7 7 A. No. Q. And can you answer the question 8 8 Q. Switching to the FXCM common stock, sitting here today without reference to the 9 you begin the class period on March 15th, 2012. 9 report? 10 What event do you contend marks the 10 MR. BAKER: Objection, asked and start of the class period? 11 11 answered. 12 A. I don't understand the question. 12 A. I refer to my previous answer to that MR. BAKER: Yeah, objection to form. 13 13 question. 14 Q. Focusing on the common stock, you 14 Q. Was that previous answer a yes or no? 15 define the class period as the period of time 15 I'm just trying to clarify the between March 15, 2012 and February 6, 2017, 16 16 record. 17 correct? 17 MR. BAKER: How many times do we need 18 A. That is correct. 18 to ask this? 19 Q. What is your understanding of the 19 MR. ISAJIW: Until he answers it. 20 event that created the beginning point of the 20 MR. BAKER: He answered it twice. 21 21 class period of March 15, 2012? A. I'm -- do you want -- let me know 22 when you guys are ready for me to answer. A. So, to answer that question 22 23 23 accurately, I'd need to -- and I have them in Q. We're ready. 24 front of me, and so I'm happy to refer to them, 24 A. Okay. I refer to -- if the Court 25 if you'd like me to -- my amended -- or my 25 Reporter wants to go back and read my previous

Page 361 Page 363 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 answer to that question, I'm more than happy to prices of FXCM securities resulted from certain 3 have her do that, if you can't remember the 3 alleged misrepresentations and omissions"; is 4 answers to my questions. But I've provided my 4 that correct? 5 answer to those questions. 5 A. So you're reading -- I'm sorry. 6 Q. Okay. So you can't answer the 6 You're reading from the first sentence in 7 question without reference to the report. We'll 7 Paragraph 7? I mean, we might as well just read 8 8 ask a second question. into the record. 9 9 A. I'm sorry, wait. Is that what I "The alleged misrepresentation and 10 stated? 10 omissions caused the price of the FXCM stock and 11 Q. I believe so. 11 FXCM notes to be artificially inflated over the A. I believe you're mischaracterizing my 12 course of the class period." 12 statement. I'll let Josh -- I'll let Josh object 13 13 And, again, you and I have had 14 14 to it, if he sees fit. disagreements in the last, I don't know, 5 or 15 MR. BAKER: Why don't we move to the 15 10 minutes about whether or not with regards to 16 next question instead of asking the same one over 16 the notes I'm talking about the class period or and over. What's the next question? 17 17 the notes period. Again, I believe I was 18 Q. What event marks the end of the class 18 probably inarticulate in the writing of that 19 19 sentence. And so, with regards to the notes, I period? 20 20 probably should have said "notes period." A. I'm just trying to give you the most 21 21 accurate answer possible. I mean, one possible Q. What were "the alleged 22 answer -- and, I mean, I can give you a more --22 misrepresentations and omissions" you're 23 comprehensive answers is the one listed in 23 referring to in Paragraph 7? 24 24 Paragraph 8 of my report. That be -- when I say, A. So, turning to Paragraph 26 of my 25 "my report," I'm referring to my loss causation 25 report -- and, again, when I say -- can we agree Page 362 Page 364 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 report of April this year. 2 when I say, "my report," unless I specify 3 "The corrected disclosure at the end 3 otherwise, we're talking about my April report 4 of the class period provided the market with the 4 with regard to loss causation and damages? 5 understanding that the company's purported lack 5 O. That's fine. 6 of conflict of interest was false and as a result 6 A. Okay. So looking at Paragraph 26 and 7 7 of the company's business model would no longer beginning with subpoint A, retail customers 8 profits or losses would have -- or maybe let me 8 be sustainable and FXCM would be subject to 9 regulatory repercussions. Following the 9 read the previous sentence. 10 corrective disclosure, analyst valuation models 10 "Plaintiffs allege that FXCM falsely reflected the reality that the company could no represented/omitted to investors and market 11 11 12 longer operate its businesses in the US and that 12 participants that, A, retail customer's profits 13 FXCM had previously misrepresented the veracity 13 or losses would have no effect on FXCM's interest 14 of its agency business model. Thus corrective 14 because FXCM's role was merely as an agent or 15 disclosures and their inextricable ramifications 15 credit intermediary. B, despite the company's 16 claims of having no conflicts of interest for its 16 dissipated the artificial inflation in the prices 17 of FXCM securities and thereby cause investor 17 retail customer's trading on the NDD platform, 18 losses." 18 FXCM, in fact, had an undisclosed financial 19 And before you jump in... 19 interest in the market maker that consistently 'won" -- and that "won" is in quotation marks --20 20 THE WITNESS: I apologize to the 21 Court Reporter if I've been going too fast. If 21 "the largest share of FXCM's NDD" -- D as in 22 22 you'd like me to slow down, please let me know. David -- "trading volume, Effex Capital (Effex). 23 Q. Let's focus on the paragraph before 23 C, Effex was essentially a front created by FXCM 24 that, on Paragraph 7. In Paragraph 7 you 24 allowing for FXCM to hold positions opposite its

customers and financially benefit at its

25

25

conclude that, "the artificial inflation in the

Page 365 Page 367 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 customers expense in direct contravention to the 2 with your understanding of the allegations of 2 3 3 company's representations to investors and to its misrepresentations and omissions in this matter. 4 4 own customers of conflict free trading on the A. Any other articles or material that 5 5 I've cited in any of my three reports when I'm NDD." Subpoint D, "FXCM manipulated its NDD dealing with the corrective disclosure and/or the platform by putting Effex" -- and now when I say 6 6 7 7 "Effex" that's the word E-F-F-E-X, as opposed to alleged misrepresentations/omissions of the 8 8 FX, the letters as in FXCM -- "in front of Defendants in this case. 9 9 Q. Okay. Turning back to Paragraph 8 of independent market makers in routing retail 10 customer orders while also permitting Effex to 10 your report, you conclude in Paragraph 8 that, 11 "The artificial inflation in the price of FXCM 11 win all 'ties' with other market makers. FXCM 12 12 provided Effex" -- again, that's the company securities was dissipated as a result of the 13 Effex -- "with the realtime view of price 13 corrective disclosures and its inextricable 14 ramifications"; is that right? 14 quotations offered by other market makers and 15 15 A. You read that correctly, yes. added smaller markups to Effex" -- again, that's 16 Q. Okay. What are the "inextricable 16 the company -- "prices then to prices provided by 17 other market makers. This way FXCM ensured that 17 ramifications" you're referring to? 18 A. I'm sorry, I don't understand the 18 the bulk of its order flow would go to Effex" --19 the company -- "and generate profits for FXCM. 19 question. 20 Q. You wrote, "Thus corrective 20 C, Effex" -- again, that's the company --21 21 disclosures and their 'inextricable "payment to FXCM were disguised as order flow 22 payments which no other market maker was making 22 ramifications' dissipated the artificial 23 23 to FXCM. FXCM's financial statements violated inflation in the prices of FXCM securities and 24 SEC regulations and Generally Accepted Accounting 24 thereby caused investor losses"; is that correct? 25 A. That is correct. 25 Principles (GAAP) for failing to disclose FXCM's Page 366 Page 368 1 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 economic interest in contractual and related 2 MR. BAKER: Objection. 3 partnership with and control over Effex" -- with 3 A. I believe so. I'm --4 an E -- "during the class period." 4 MR. BAKER: I think you added another 5 Q. And Paragraph 26 represents your sum 5 quote. 6 total understanding of "the alleged 6 A. Yeah, I'm now parsing through the 7 misrepresentations and omissions" in this case? 7 report to get to the part where I can be 8 A. No, I believe, there are other 8 responsive to your question so... 9 portions of this report, as well as my previous 9 Q. So sitting here today I'm just asking 10 reports that cover that subject matter. 10 you what are the "inextricable ramifications" you 11 Q. For Paragraph 26 for each of those 11 are referring to in Paragraph 8 of your 12 allegations, you cite the complaint that was 12 conclusions? 13 filed in this matter; is that correct? 13 A. Right. And I'm going to the portion 14 A. That appears to be correct. 14 of my report that will give you the most accurate 15 Q. Other than reference to the 15 description or answer to your question. 16 complaint, are there any other sources of 16 Okay. So beginning in Paragraph 44 17 material that you analyzed in connection with the of my report -- and I'll just read this --17 18 allegations listed in Paragraph 26? 18 "Analysts and news commentary deemed the above 19 A. Yes. 19 news as negative. Oppenheimer and Cowen and 20 O. What are those? 20 Company analyzed comment as follow: Yesterday 21 A. Well, okay. So do you want me to 21 FXCM made an announcement (see below) that led to 22 begin with my market efficiency report and going 22 a 50 percent decline in FXCM share price. One 23 through the list of documents I've reviewed? 23 component but in our view by no means the most 24 Q. I don't. I'm just asking what 24 valuable component of Luk's investment" -- oh, is 25 additional materials you relied on in connection 25 this the right one, hold on. Yes -- "investment

	Page 369		Page 371
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	in FXCM as a 49.9 percent ownership stake in FXCM	2	report dated February 7th of 2017.
3	and this has, of course, raised concerns about	3	Finally, FXCM oh, I shouldn't say
4	the valuation of the asset. To settle the	4	"finally." There's actually two more portions
5	charges, FXCM will pay \$7 million to the CFTC and	5	here.
6	no monetary damages to the NFA."	6	"FXCM plans to layoff about 150
7	I should note that I believe at one	7	workers for about 18 percent of its workforce as
8	point in this report I wrote "CFA" instead of	8	it restructures operations following two
9	what I meant to say NFA. So, if you run across	9	regulatory settlements that forced it to exit the
10	that, I don't mean certified financial analyst, I	10	US market. The foreign exchange broker, which is
11	mean NFA.	11	selling its US customer accounts to Gain expects
12	"The company will also be shutting	12	to" and that's a company name, so capital G in
13	down its US business. On February 6th, FXCM	13	Gain expects to recognize the bulk of selling
14	announced a \$7 million settlement with the CFTC,	14	its US customers oh, sorry, "expects to
15	which essentially forced them to sell their US	15	recognize the bulk of the pre-tax restructuring
16	business. The CFTC complaint said FXCM and two	16	charge in the March quarter, according to a
17	of its founding principals made false and	17	regulatory filing shares drop 54 percent to
18	misleading solicitations by concealing from	18	\$3.13." And that is from a Dow Jones
19	customers that a chief market maker was	19	institutional News article dated February 7th of
20	re-bidding, roughly, 70 percent of its revenue to	20	2017.
21	FXCM. It obviously sounds like a terrible fact	21	"Finally" and now I use that word
22	pattern." And that is from an Oppenheimer	22	properly the Commodity Futures Trading
23	report.	23	Commission hit forex capital markets parent
24	Now let me continue. "FXCM announced	24	company FXCM Holdings and two founding partners
25	late yesterday that it had reached agreement with	25	with \$7 million fine over" excuse me
		_	
	Page 370		Page 372
1	Page 370 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 372 CONFIDENTIAL - ADAM WERNER, Ph.D.
1 2		1 2	e
	CONFIDENTIAL - ADAM WERNER, Ph.D.		CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and	2	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC),	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital.
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base."
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra,
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today.
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will also be shutting down its US business. Also, as	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report. Q. Is it your opinion that there were no
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will also be shutting down its US business. Also, as a financial services company, it is certainly not	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report. Q. Is it your opinion that there were no I'm sorry, back up.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will also be shutting down its US business. Also, as a financial services company, it is certainly not a good thing for their ongoing foreign operations	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report. Q. Is it your opinion that there were no I'm sorry, back up. So those are the "inextricable
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will also be shutting down its US business. Also, as a financial services company, it is certainly not a good thing for their ongoing foreign operations that they were pretty much forced out of the US	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report. Q. Is it your opinion that there were no I'm sorry, back up. So those are the "inextricable ramifications" of the corrective disclosure in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will also be shutting down its US business. Also, as a financial services company, it is certainly not a good thing for their ongoing foreign operations that they were pretty much forced out of the US and that their debt and equity prices put parent	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report. Q. Is it your opinion that there were no I'm sorry, back up. So those are the "inextricable ramifications" of the corrective disclosure in February of 2017; is that correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will also be shutting down its US business. Also, as a financial services company, it is certainly not a good thing for their ongoing foreign operations that they were pretty much forced out of the US and that their debt and equity prices put parent level solvency into question (at least, in the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report. Q. Is it your opinion that there were no I'm sorry, back up. So those are the "inextricable ramifications" of the corrective disclosure in February of 2017; is that correct? A. I'm not sure. Let me just read this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will also be shutting down its US business. Also, as a financial services company, it is certainly not a good thing for their ongoing foreign operations that they were pretty much forced out of the US and that their debt and equity prices put parent level solvency into question (at least, in the market's mind). Solvency was, of course, always	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report. Q. Is it your opinion that there were no I'm sorry, back up. So those are the "inextricable ramifications" of the corrective disclosure in February of 2017; is that correct? A. I'm not sure. Let me just read this to make sure.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the National Futures Association (NFA) and Commodity Futures Trading Commission (CFTC), settling charges that the company did not disclose to customers that it had an interest in the market maker that traded the largest share of FXCM's trading volume. The CFTC order found that the market maker paid, roughly, 70 percent of the revenues generated from FXCM's platform back to FXCM. To be clear, this matter was not the August complaint from the CFTC. We believe this new settlement resolves this new issue and, at least, some of the issues that had been part of the original August complaint. To settle the charges, FXCM will pay \$7 million to the CFTC and no monetary damages to the NFA. The company will also be shutting down its US business. Also, as a financial services company, it is certainly not a good thing for their ongoing foreign operations that they were pretty much forced out of the US and that their debt and equity prices put parent level solvency into question (at least, in the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. "alleged trading misrepresentations. Now FXCM Incorporated as pulling out of the US in an exit that will free up almost \$52 million in capital. Gain Capital Holdings Incorporated is acquiring the US client base." And that is from S&L Financial Extra, again, dated oh, but the article is, "J.P. Morgan Gain China Interbank Bond Market Licenses." So that's what I mean when I say inextricably or let's go back to the exact language. I haven't had all my coffee yet today. That's what I mean when I say "inextricable ramifications." And, again, here I'm referring to Paragraph 7 of my report. Q. Is it your opinion that there were no I'm sorry, back up. So those are the "inextricable ramifications" of the corrective disclosure in February of 2017; is that correct? A. I'm not sure. Let me just read this

Page 373 Page 375 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 referring to, which you were just responding to, 2 Q. And you relied on that same event 3 3 I believe, you wrote, "Thus the corrective study to conclude that the dissipation of 4 disclosures and their inextricable ramifications 4 artificial inflation in the price of FXCM 5 dissipated the artificial inflation of the prices 5 securities caused investor losses; is that right? 6 of FXCM securities and thereby caused investor 6 A. Among other things, yes. 7 losses." 7 Q. In looking at Paragraph 10 of your 8 8 I believe you just gave me your best loss causation report, you say that, "These 9 as answer as to what you meant by the conclusions were based on fundamental principles 10 "inextricable ramifications." 10 of finance and valuation, company statements, 11 I'm now asking, are those 11 internal company documents, news articles, ramifications of which corrective disclosures? 12 analyst reports and event study analysis"; is 12 that correct? 13 A. I'm sorry. Are there -- are there 13 14 14 multiple corrective disclosures in this case? A. That is correct. 15 Q. That's what I'm asking you. 15 O. And I believe we discussed earlier 16 You wrote, "The corrective 16 that all of the documents you considered in 17 disclosures and their inextricable connection with your opinions in this matter are 17 18 ramifications." 18 listed in Exhibit 2 of the loss causation reports 19 and your prior report; is that right? What do you understand the corrective 19 20 disclosures to be in that -- as you used it in 20 A. I believe that is correct, yes. 21 21 Q. If you flip to Exhibit 2 of this that sentence? 22 A. Oh, I'm sorry. Now, I'm confused. 22 report. 23 So -- oh, I see what you're saying. 23 A. Okay. Yes, you should probably get rid of 24 24 Q. You do not list any documents that 25 the "S" in disclosures and make that disclosure, 25 were produced by FXCM, correct? Page 374 Page 376 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 singular, as I mention in Paragraph 9 when I'm A. In this -- in this particular -- in 3 talking about the corrective disclosure singular 3 this exhibit, it doesn't appear so. But, again, 4 on February 7th, 2017. 4 I -- it -- what -- I also have any other documents and data cited in the report. I'm 5 Q. In your opinion, are there no prior 5 6 disclosures or events that dissipated the alleged happy to go through the entire report and look at 7 7 artificial inflation in the price of FXCM every footnote and re-read it to let you know if 8 8 securities during the class period? there's anything that I referred to, 9 9 MR. BAKER: To be clear, we're specifically, with regard to the company. 10 talking about prior to February 6th, 2017? 10 Do you want me to do that or... MR. ISAJIW: Correct. Q. I don't want you to do that. We've 11 11 12 A. So, prior to February 6th, I don't 12 done that and we did not see reference to any 13 13 documents produced buy FXCM in this case. 14 Q. You conduct an event study for this 14 And if you take a look at Exhibit 2 15 loss causation report; is that right? 15 to your January 2020 Corrected Opening Report on Market Efficiency, which is Page 76 to 92 of that 16 A. I did. 16 17 Q. And was that the same event study 17 document. 18 that you used in connection with your prior 18 A. I'm sorry, which report are we 19 report on market efficiency? 19 talking about now? 20 20 Q. Your Opening Report on Market A. That is correct. 21 Q. And you relied on that event study to 21 Efficiency, which is Werner Exhibit 3. conclude that the February 2017 corrective 22 A. Right, okay. 22 23 disclosure dissipated the artificial inflation in 23 And where would you like me to go? 24 the price of FXCM securities, right? 24 Q. Exhibit 2, which begins on Page 76 25 A. Among other things, yes. 25 and goes to 92.

Page 377 Page 379 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 A. Okay. 2 will represent to you that we did not find any 3 Q. Again, there are no documents 3 documents produced by FXCM relied on in 4 produced by FXCM listed there, correct? 4 connection with your reports or listed on 5 A. Well, I don't know how to answer that 5 Exhibit 2 of any of your reports. 6 question. I don't know exactly what FXCM has 6 With that in mind, turning back to 7 produced, the company itself has produced in this 7 Paragraph 10 of your loss causation report, you 8 8 say that your conclusions are based on "amongst 9 Q. The documents that you reviewed are 9 other things internal company documents." 10 all publically available documents; isn't that 10 Which "internal company documents" 11 11 are you referring to? 12 A. It's an interesting question. I 12 A. As I sit here today, I don't know. 13 don't know. 13 Q. And none are listed in the Exhibit 2 14 Do you believe that all investment 14 of any of the reports we just went through; is 15 banking analyst articles are publically 15 that correct? 16 available? 16 A. Well, I don't -- I'm not sure that's 17 Q. Let's assume for the sake of this 17 an accurate statement. I mean, to the extent 18 question that they are. 18 that the complaint may have referred to internal 19 A. Okay. 19 company documents, the CFTC or the TFA -- no, not 20 Q. With that assumption, the list is all 20 TFA -- FTA, sorry there we go, referred to 21 publically available documents; is that correct? 21 internal client -- I mean, client documents --22 A. I mean, as I sit here today, I 22 FXCM documents. I mean, there is a whole host of 23 believe -- well, you know, hold on. Let me 23 things in here that I've listed as materials 24 finish this: no. 24 relied upon that refer to FXCM internal 25 Q. Of the documents that you are unsure 25 documents. Page 378 Page 380 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 2 whether they're publically available, were they So, as I sit here today, I don't know 3 produced by FXCM in this matter? 3 how to answer that question accurately. 4 A. I don't know one way or the other as 4 Q. To the extent --5 I sit here today. 5 A. I, certainly -- I, certainly, can't Q. And if you take a look at Exhibit 2 give you a fully inclusive answer, as I sit here 6 6 7 7 to your July 2020 rebuttal report, again -today. 8 8 A. Well, hold on. Q. In connection with your work in this 9 Q. Sure. 9 matter, did you review any documents produced by 10 A. Okay, here we go. Okay, I'm there 10 Effex Capital? A. As I sit here today, I don't recall. 11 11 now. 12 Q. Again, there are no documents 12 Q. How about Ernst & Young? 13 produced by FXCM listed in that exhibit; is that 13 A. It's certainly possible. 14 14 Q. Do you recall -- do you recall any 15 15 specific Ernst & Young-produced documents? A. Again, I don't know whether that's 16 correct or not. I don't know exactly what FXCM 16 A. Well, why don't we go -- if you would 17 has turned over in this case. 17 like to introduce some of the firm's financials 18 Q. Again, they are all publically 18 as exhibits, I'd be happy to look through those 19 available documents that you listed; is that 19 and let you know if Ernst & Young provided any 20 correct? 20 opinions in that or any of the other financial 21 21 A. Well, so, to the extent that we're documents I referred to or any of the analyst 22 talking about any other documents and data cited 22 reports that might possibly refer to Ernst & 23 23 in the report, without going through the report, Young. 24 I can't accurately answer your question. 24 Q. But sitting here today, you can't 25 Q. We have gone through the report and I 25 recall any specific documents produced by Ernst &

	D 201		D 202
1	Page 381 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 383 CONFIDENTIAL - ADAM WERNER, Ph.D.
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	Young that you relied in connection within your	2	that?
3	report, correct?	3	Q. It's not necessary.
4	A. My answer is what it is.	4	I'm just asking you to confirm that
5	Q. Did you read the deposition	5	your answer was that you listed the documents
6	transcript of Drew Niv in this matter?	6	that you relied on in connection with your report
7	A. That name sounds familiar, but I	7	in your report, correct.
8	don't recall. It's certainly possible.	8	MR. BAKER: Objection as asked and
9	Q. Is the deposition well, I'll	9	answered but
10	represent to you that the deposition transcript	10	A. I'm sorry. I'm trying to give you
11	of Drew Niv is not referenced anywhere in	11	the most precise answer that I can. So, you
12	Exhibit 2 to any of your reports. Nor is it	12	know, you guys always ask all sorts of
13	referenced in any footnotes in any of your	13	hypothetical questions like is it possible. So
14	reports.	14	rather than let's eliminate is it
15	Does that refresh your recollection	15	possible aspect of
16	as to whether or not you ever reviewed the	16	Q. Dr. Werner, my question did not have
17	deposition of Drew Niv?	17	"is it possible"
18	A. It doesn't only because I know I have	18	A. Let me finish.
19	seen, at least, one deposition at least, one	19	MR. BAKER: Counsel, let the witness
20	deposition in this case that I reviewed. I don't	20	
21	know if it was that individual's.	21	A. I'm sorry. Let me finish. Let me
22	And to the extent I haven't included	22	finish. I'm speaking.
23	it in my Exhibit 2 to any of my reports, it was	23	To the extent that I'm trying to be
24	an oversight on my part.	24	as accurate as possible, let's go back to my
25	Q. Did you review the deposition	25	original answer to that question rather than
			1
	Dogg 202		Daga 294
1	Page 382	1	Page 384
1 2	CONFIDENTIAL - ADAM WERNER, Ph.D.	1 2	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami?	2	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said.
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do.
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other.	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay.
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout?	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do.
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other.	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it.
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do	2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct?	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered that you listed all of the documents in your	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you relied on documents or information in connection
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered that you listed all of the documents in your Exhibit 2s to your report or otherwise in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you relied on documents or information in connection with your reports, you listed them in Exhibit 2
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered that you listed all of the documents in your Exhibit 2s to your report or otherwise in footnotes to the extent that you relied on them	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you relied on documents or information in connection with your reports, you listed them in Exhibit 2 to those reports or otherwise referred to them in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered that you listed all of the documents in your Exhibit 2s to your report or otherwise in footnotes to the extent that you relied on them in connection with your opinions; isn't that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you relied on documents or information in connection with your reports, you listed them in Exhibit 2 to those reports or otherwise referred to them in the footnotes of those reports; is that correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered that you listed all of the documents in your Exhibit 2s to your report or otherwise in footnotes to the extent that you relied on them in connection with your opinions; isn't that correct?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you relied on documents or information in connection with your reports, you listed them in Exhibit 2 to those reports or otherwise referred to them in the footnotes of those reports; is that correct? MR. BAKER: Asked and answered.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered that you listed all of the documents in your Exhibit 2s to your report or otherwise in footnotes to the extent that you relied on them in connection with your opinions; isn't that correct? A. That is correct. I believe so. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you relied on documents or information in connection with your reports, you listed them in Exhibit 2 to those reports or otherwise referred to them in the footnotes of those reports; is that correct? MR. BAKER: Asked and answered. A. Well, that's what your belief
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered that you listed all of the documents in your Exhibit 2s to your report or otherwise in footnotes to the extent that you relied on them in connection with your opinions; isn't that correct? A. That is correct. I believe so. I mean, I'm happy to have the Court Reporter go	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you relied on documents or information in connection with your reports, you listed them in Exhibit 2 to those reports or otherwise referred to them in the footnotes of those reports; is that correct? MR. BAKER: Asked and answered. A. Well, that's what your belief THE WITNESS: I'm sorry. Go ahead,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. transcript of John Dittami? A. As I sit here today, I don't know one way or the other. Q. Did you review the deposition transcript of William Ahdout? A. As I sit here today, I don't know one way or the other. Q. It fair to say that to the extent that these documents are not listed as documents relied upon in any of your reports that you do not base your conclusions on any of these documents; is that correct? A. I can't answer that one way or the other, as I sit here today. Q. I think earlier today you answered that you listed all of the documents in your Exhibit 2s to your report or otherwise in footnotes to the extent that you relied on them in connection with your opinions; isn't that correct? A. That is correct. I believe so. I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. asking me if I recall that that is what I said. That's what I would like to do. Q. Okay. A. And to the extent my job here is to be as accurate as possible, that's what I would like to do. Q. That is unnecessary. The original answer has been recorded. I was just asking you to confirm it. We can move along, but I In paragraph A. Okay. I'm sorry. So you have the answer? Q. I believe you testified, which is I believe you testified that to the extent you relied on documents or information in connection with your reports, you listed them in Exhibit 2 to those reports or otherwise referred to them in the footnotes of those reports; is that correct? MR. BAKER: Asked and answered. A. Well, that's what your belief

Page 385 Page 387 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 answered. And I thought we were about to move 2 get to my loss causation report and then I'll 3 3 look at that paragraph. 4 4 A. That's what your belief is. But Okay. 5 since we have the record, we don't have to rely 5 Q. In Paragraph 11, you concluded that, 6 our belief, right. We can go back to the record "The price of FXCM's common stock was inflated 6 7 and we can then know if that is the answer to my 7 by, at least, \$3.39 per share during the class 8 8 -- to the question that you're asking. period"; is that correct? 9 9 Q. I'm asking you to answer that A. That's -- you read that correctly. 10 question sitting here right now today. 10 Q. And in this paragraph, you also MR. BAKER: Objection, asked and concluded that, "The price of FXCM's notes were 11 11 answered, as he was sitting here earlier today. inflated by, at least, \$16.31 per \$100 of par 12 12 MR. ISAJIW: Josh, "objection to throughout the notes period"; is that correct? 13 13 14 14 form" is sufficient. A. That is what I wrote. 15 MR. BAKER: Asking a question once is 15 Q. And in Paragraph 12, you concluded 16 that, "The damages for investors who held FXCM's 16 sufficient. 17 A. I refer to my answer earlier today. common stock until February 7th, 2017 are up to 17 Q. Okay. In Paragraph 11 of your 18 18 \$3.39 per share"; is that right? report, you concluded that, "The price of FXCM's 19 19 A. That is what I wrote and it should --20 common stock was inflated by, at least, \$3.39 per 20 it should -- and I wrote the same thing about the 21 21 notes. It should really say "at least," as it share during the class period"; is that right? 22 A. I'm sorry. I'm looking at the wrong 22 did in Paragraph 11 for both of those -- for both 23 report. So let me get to the right report. Let 23 the notes and the equity. 24 me make sure that this is the right report. 24 Q. As we've discussed, this loss 25 You're speaking of Exhibit 8, 25 causation report and your prior market efficiency Page 386 Page 388 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 correct? 2 report represent the full extent of your opinions 3 Q. Your loss causation report. 3 in the matter regarding loss causation and 4 A. Right. And so I'm just making sure 4 damages; is that right? 5 we're talking about Exhibit 8, because it appears 5 A. I believe that's correct. 6 to me as Plaintiffs' expert report. I assume 6 Q. And they reflect the full universe of 7 7 that's my loss causation report, but I'm just documents and information you relied on in 8 8 trying to make sure that I'm at the right place. connection with forming your conclusions; is that 9 Q. Earlier today at your suggestion we 9 correct? 10 agreed when I say, "your report," you would refer 10 MR. BAKER: Objection, asked and to your loss causation report. 11 11 answered. 12 A. Well, I'm happy to have the Court 12 A. I think we --THE WITNESS: I'm sorry, Josh, were Reporter go ahead and read that back, if you're 13 13 14 asking me that. I'm just trying -- look, I've 14 you objecting? 15 got like five documents open now, right. It's 15 MR. BAKER: So you can go ahead. not like I have papers sitting in front of me. A. I think we've -- I've asked and 16 16 17 So I'm just going back and forth between the 17 answered that question multiple times now. 18 tabs. 18 MR. ISAJIW: Now is probably a good 19 So you need to be a little patient 19 time for a five-minute break. 20 when you keep going back and forth between 20 THE VIDEOGRAPHER: The time is 21 different documents. Does that seem reasonable? 21 12:12 p.m. and we're going off the record. 22 Q. Dr. Werner, I'm just asking you to 22 (Recess taken 12:12 to 12:19 p.m.) look at Paragraph 11 of your loss causation 23 THE VIDEOGRAPHER: The time is 23 24 report. 24 12:19 p.m. and we're back on the record. 25 A. Okay. So let's take a pause. Let me 25 Q. Dr. Werner, are you familiar with an

1	Page 389		Page 391
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	entity called 683 Capital? A. Am I familiar? I believe so.	2	to speculate, as I sit here today.
3 4	Q. And who is 683 Capital?	3 4	Q. Let's take another look at the
5	A. Well, if you'd like the best way	5	March 18th, 2021 Report and Recommendation to the
		6	Honorable Ronnie Abrams, which is, I believe, Exhibit 10.
6 7	for me to answer that is for you to introduce the		
8	Complaint in this matter to ensure that I give	7	A. I thought I had downloaded it, but
9	the most accurate response.	8	evidently I haven't so
10	Q. I don't think that's necessary.Do you understand that 683 Capital	9	Oh, okay. Yeah, I have it in front of me.
11	was one of the Plaintiffs in this matter?	11	
12	MR. BAKER: Object to form.	12	Q. Okay. If you look at the bottom of Page 1, the Court says, "For the reasons that
13	A. Again, I believe, that's correct.	13	
14	But I'm happy to take a look at the Complaint	14	follow, I respectfully recommend that the motion be granted as FXCM's Class A common stock."
15	was there an Amended Complaint in this case?	15	
16	Either way, I'm happy to look at	16	A. Sorry, I'm not there yet. I just
17	either those or to make sure that I'm being	17	have the document open. I haven't gotten to the part where you're reading.
18	accurate.	18	So we're talking I'm sorry, what
19		19	- · · · · · · · · · · · · · · · · · · ·
20	Q. You submitted a market efficiency report in support of Plaintiffs' motion for class	20	paragraph?
$\begin{vmatrix} 20 \\ 21 \end{vmatrix}$	certification and to be appointed as class	20	Q. The very last paragraph on the first
$\begin{vmatrix} 21\\22\end{vmatrix}$	representative in this case, correct?	22	page?
$\begin{vmatrix} 22 \\ 23 \end{vmatrix}$	A. Are you now referring to my original	23	A. Oh, okay, I'm there.Q. "For the reasons that follow, I
24	market efficiency report	24	respectfully recommend that the motion be granted
25	Q. I am.	25	as to FXCM's Class A Common Stock and denied as
23	Q. Tani.	23	as to FACIVI'S Class A Common Stock and defiled as
	Page 390		Page 392
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency	2	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report?	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018."
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am.	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes.	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there.
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay.
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says,
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right?	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so.	2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market,
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct?	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a memory test, I believe that is correct.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually relied on Defendant's misleading statements. I
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a memory test, I believe that is correct. If you want to represent to me that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually relied on Defendant's misleading statements. I agree. Therefore, even if the notes class were
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a memory test, I believe that is correct. If you want to represent to me that they're one of the Plaintiffs in this case, I'm	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually relied on Defendant's misleading statements. I agree. Therefore, even if the notes class were sufficiently numerous, I would not recommend
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a memory test, I believe that is correct. If you want to represent to me that they're one of the Plaintiffs in this case, I'm happy to agree with you.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually relied on Defendant's misleading statements. I agree. Therefore, even if the notes class were sufficiently numerous, I would not recommend certifying."
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a memory test, I believe that is correct. If you want to represent to me that they're one of the Plaintiffs in this case, I'm happy to agree with you. Q. Okay. Do you know whether or not 683	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually relied on Defendant's misleading statements. I agree. Therefore, even if the notes class were sufficiently numerous, I would not recommend certifying." Do you see that?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a memory test, I believe that is correct. If you want to represent to me that they're one of the Plaintiffs in this case, I'm happy to agree with you. Q. Okay. Do you know whether or not 683 Capital was a notes purchaser in connection with	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually relied on Defendant's misleading statements. I agree. Therefore, even if the notes class were sufficiently numerous, I would not recommend certifying." Do you see that? A. I do.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a memory test, I believe that is correct. If you want to represent to me that they're one of the Plaintiffs in this case, I'm happy to agree with you. Q. Okay. Do you know whether or not 683 Capital was a notes purchaser in connection with this case?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually relied on Defendant's misleading statements. I agree. Therefore, even if the notes class were sufficiently numerous, I would not recommend certifying." Do you see that? A. I do. Q. And then if you turn to Page 37 at
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. A or amended market efficiency report? Q. I am. A. Yes. Q. Okay. And that market efficiency report was used in support of Plaintiffs' motion for class certification and to be appointed as class representative in this matter; is that right? A. I believe so. Q. And 683 Capital was one of those Plaintiffs; is that correct? A. Again, I'm happy to verify that by looking at the Complaint. But, to the best of my recollection, which, again, this isn't really a memory test, I believe that is correct. If you want to represent to me that they're one of the Plaintiffs in this case, I'm happy to agree with you. Q. Okay. Do you know whether or not 683 Capital was a notes purchaser in connection with	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. to its 2.25 percent convertible senior notes due in 2018." And if you turn to Page 14 of this opinion let me know when you're there. A. Okay. Q. In the middle of the first full paragraph on that page the Court says, "Defendants do not contest the predominance as to the stock class but argue vigorously that the notes class cannot be certified because the FXCM notes did not trade in an efficient market, meaning, that the purchasers of those securities cannot rely on the fraud on the market hypothesis and would instead be required to establish on an individual basis that each of them actually relied on Defendant's misleading statements. I agree. Therefore, even if the notes class were sufficiently numerous, I would not recommend certifying." Do you see that? A. I do.

Page 393 Page 395 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 Q. At the bottom the paragraph says, outside knowledge of that. 3 3 "Because Plaintiffs have not established that the [INSTRUCTION] But if it's based on, 4 4 you know, communications with Counsel, I would FXCM notes traded in an efficient market, they 5 5 cannot rely on the basic presumption of reliance instruct you not to answer. 6 as to the notes, meaning, that each note 6 THE WITNESS: Okay. 7 7 A. Based on advice of Counsel I'm not purchaser would be required to prove individually 8 8 that it relied on Defendant's allegedly false or going to answer that. 9 9 Q. Just to be clear -- and I don't want misleading statements in making its purchases. 10 This in turn means that Plaintiffs cannot satisfy 10 you to reveal any information that Counsel may 11 the predominance requirement of Rule 23(b)(3) 11 have provided you in a privileged context. 12 with respect to the FXCM notes." 12 But sitting here today, you cannot 13 Do you see that? 13 answer the question of whether or not you've been 14 A. I do. 14 separately retained by 683 Capital as an 15 Q. Do you understand that 683 Capital is 15 individual plaintiff without resort to privileged 16 16 now an individual plaintiff and not a class information; is that correct? 17 representative in this matter? 17 A. Okay, so ... 18 A. Again --18 Q. I just want to be sure I'm --19 19 MR. BAKER: Objection to form. I'm A. When you say -- no, look, I 20 sorry let me -- objection to the extent that it 20 understand. I'm trying to make these as simple 21 calls for a legal conclusion. 21 as possible, because these are very vague 22 You can answer. 22 question. 23 23 So, when you say, "retained A. I'm happy to look at whatever court 24 documents that will refresh my memory on this. 24 separately," what do you mean by retained 25 If you want to stipulate to that, it's fine. 25 separately? Page 394 Page 396 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 I'll believe you. Q. As an individual plaintiff, as 3 But, you know, is it my 3 opposed to being retained to provide an opinion 4 understanding? Off the top of my head, I don't 4 on behalf of a notes class. 5 remember. But I do know that I've seen the 5 A. So how do I --6 documents about them before. I believe that they 6 MR. BAKER: Objection. 7 7 are individual Plaintiffs in this matter. THE WITNESS: I'm sorry, go ahead. 8 8 But it simply be easier when you're MR. BAKER: No. Same objection and 9 asking questions like this, if you're assuming 9 instruction. To the extent that you can answer 10 they're correct, that you just stipulate to that 10 without relying on conversations between yourself so I need to look at other documents to refresh 11 11 and Counsel, you can answer. 12 my memory. 12 A. Alright. So, if the question is, 13 Q. Have you been separately retained by 13 have I signed a separate contract with the entity 14 683 Capital as an individual Plaintiff to provide 14 you were discussing, they haven't been retained 15 a damages analysis on their behalf, as opposed to 15 me or -- and I'll be generous here. When we talk on behalf of a notes class? about me, we should also probably include 16 16 17 MR. BAKER: Objection to the form. 17 Crowninshield. 18 A. I don't know how to answer that. I 18 I don't know. 19 believe -- well, I refer to -- I defer to 19 Q. Have you calculated 683 Capital's 20 Counsel. I'm not sure if that's privileged or 20 damages on an individual basis? 21 not. If it's not privileged, I'm happy to 21 A. Again, I defer to Counsel as to 22 22 answer. whether or not I can answer that. I don't know 23 23 MR. BAKER: Yeah, to the extent you if that information is privileged or not. 24 can answer outside of any conversations you had 24 MR. BAKER: Let's say if you can answer outside of conversations with Counsel, if 25 with Counsel, you can answer, if you have any 25

Page 397 Page 399 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 2 there's something in your report, then you can please go ahead. 3 answer the question. [INSTRUCTION] But to the 3 A. I don't have anything to add. 4 extent that the question involves conversations 4 Q. I want to switch to talking, again, 5 5 about your event study conducted in connection between you and your Counsel, I would instruct you not to answer. with the loss causation report here. 6 6 7 7 You would agree that it's possible A. Alright. Based on Counsel's 8 8 representations, I cannot answer those questions for a security to over or under react to news; is 9 9 or that question. that right? 10 Q. Is it fair to say that nothing in 10 A. Oh, again --MR. BAKER: Objection to form. 11 your loss causation report expresses an opinion 11 regarding the specific damages of 683 Capital as 12 12 Go ahead. 13 an individual in connection with their purchase 13 A. You may be -- is it possible --14 of FXCM securities; is that correct? 14 look --A. No. 15 15 Q. I'm asking your opinion as an expert 16 16 Q. Where in your report do you specify is it possible. 17 683 Capital's individual damages? 17 A. Let me answer the question. 18 MR. BAKER: Objection to form. 18 You are answering extremely imprecise 19 A. Well, I have --19 questions. So, when you ask me, "is it 20 THE WITNESS: I'm sorry, Josh. I 20 possible," I believe, can you refer to my 21 don't mean to keep interrupting you. I didn't 21 previous deposition testimony when we discussed 22 hear your objection, so go ahead. 22 the possibilities of over or under reactions. 23 MR. BAKER: Objection to form. 23 Did this occur here? That is not --And you can answer, if you know the 24 24 no. I mean, obviously, it's your deposition. I 25 25 hope Josh has sent you the bill for this. We can answer. Page 398 Page 400 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 A. So, when you say, "individual 2 go as long as you want. But, look, I'm just try 3 damages," what do you mean? 3 to be as accurate as possible here. 4 Q. I mean, the damages 683 Capital 4 Q. In your opinion, is it more likely 5 allegedly suffered in connection with their 5 for a security to over or under react to news in 6 purchase of FXCM securities. an inefficient market, a market that is not 6 7 7 A. So you're -efficient, than it would be to over or under 8 8 THE WITNESS: And, Josh, if you want react in an efficient market? 9 to object, go ahead. 9 MR. BAKER: Objection, incomplete 10 A. But your question's imprecise, right. 10 hypothetical. They as note holders suffered damages per note. Answer, if you are able. 11 11 12 So, yes, to the extent that I calculated those 12 A. Yeah, I don't know how to answer your damages, I have calculated damages in this report 13 13 hypothetical question. 14 for that entity. If you're talking about 14 Q. Efficient markets incorporate news 15 aggregate damages, that is not presented here in 15 into the price of a security quickly and fully, would you agree with that statement? 16 this report. 16 17 Q. So you offer no opinion on 683 17 A. I'm happy to read the -- if you want 18 Capital's aggregate damages in connection with 18 me to point me to what you're reading off of, I'm 19 your loss causation report? 19 happy to review that statement and tell you 20 20 A. Without -whether or not I agree with you in the context of 21 MR. BAKER: Objection to form. 21 where I've written that. 22 22 Q. I'm just asking as background to your 23 Objection to the extent that his 23 opinions in this matter, as your role as an 24 prior answer answered that question. 24 economist, would you agree with the statement 25 But if you have anything to add, 25 that efficient markets incorporate news into the

1	Page 401	1	Page 403
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	price of a security quickly and fully?	2	Q. When you conducted the event study
3	A. Right. And I believe that that's a	3	here for the FXCM notes, did you assume that the
4	quote from one of my reports. And so, to the	4	market for the FXCM notes was efficient?
5	extent that you're quoting one of my reports and	5	A. Well, to the extent that I was trying
6	you would like me to review it, I'm happy to do	6	to prove efficiency, I don't think I don't
7	it.	7	believe I made it an assumption one way or the
8	Q. But I'm not quoting your report. I'm	8	other.
9	asking a general proposition question.	9	Q. Were you trying to prove efficiency
10	A. As a general proposition? So	10	in connection with your loss causation report?
11	generally, yes, I believe that's accurate.	11	A. No.
12	Q. Okay. And that's one of the reasons	12	Q. Okay. In connection with the
13	an event study can help determine investor losses	13	analysis that you did with your loss causation
14	in an efficient market; is that right?	14	report, you conducted an event study, correct?
15	A. I believe that is correct.	15	A. I mean, I had previously conducted an
16	Q. Because an efficient market the	16	event study in my original market efficiency
17	prices would quickly and fully reflect any	17	report. I relied on that analysis for this
18	alleged corrective information; is that correct?	18	report. And when I say, "this," I'm talking
19	A. It's going to depend upon the	19	about my loss causation and damages report.
20	security.	20	Q. And in connection with your analysis
21	Q. Is it more likely for the price of a	21	for your loss causation and damages report, when
22	security to quickly and fully reflect alleged	22	you relied on the event study for the FXCM notes,
23	corrective information in a market that is	23	did you assume in your loss causation analysis
24	efficient or a market that is not efficient?	24	that the market for FXCM notes was efficient?
25	MR. BAKER: Objection, incomplete	25	A. That's not anything I considered or I
	Page 402		Page 404
1	Page 402 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 404 CONFIDENTIAL - ADAM WERNER, Ph.D.
1 2		1 2	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have
	CONFIDENTIAL - ADAM WERNER, Ph.D.		CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't	2	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question.	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question.	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market?
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer.
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully?	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form.
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question.	2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes?
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical.	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form.
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question.	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question.
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then,	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please. Q. Inefficient would you agree that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is incorporated into the price of a security quickly
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please. Q. Inefficient would you agree that inefficient markets do not incorporate news into	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is incorporated into the price of a security quickly and fully; is that right? A. I think I said generally. Q. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please. Q. Inefficient would you agree that inefficient markets do not incorporate news into the price of a security quickly and fully?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is incorporated into the price of a security quickly and fully; is that right? A. I think I said generally.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please. Q. Inefficient would you agree that inefficient markets do not incorporate news into the price of a security quickly and fully? A. Not necessarily.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is incorporated into the price of a security quickly and fully; is that right? A. I think I said generally. Q. Okay. A. That is correct. Q. So, if the market is not efficient
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please. Q. Inefficient would you agree that inefficient markets do not incorporate news into the price of a security quickly and fully? A. Not necessarily. THE WITNESS: I'm sorry, Josh, were	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is incorporated into the price of a security quickly and fully; is that right? A. I think I said generally. Q. Okay. A. That is correct.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please. Q. Inefficient would you agree that inefficient markets do not incorporate news into the price of a security quickly and fully? A. Not necessarily. THE WITNESS: I'm sorry, Josh, were you going to say something? MR. BAKER: No, that's fine. I think previously he said general proposition but I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is incorporated into the price of a security quickly and fully; is that right? A. I think I said generally. Q. Okay. A. That is correct. Q. So, if the market is not efficient and therefore it is not likely that news would incorporate itself into the price of a security
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please. Q. Inefficient would you agree that inefficient markets do not incorporate news into the price of a security quickly and fully? A. Not necessarily. THE WITNESS: I'm sorry, Josh, were you going to say something? MR. BAKER: No, that's fine. I think	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is incorporated into the price of a security quickly and fully; is that right? A. I think I said generally. Q. Okay. A. That is correct. Q. So, if the market is not efficient and therefore it is not likely that news would incorporate itself into the price of a security quickly and fully, how can you be certain that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. hypothetical. But you can answer. A. Yeah, as I sit here today, I don't know how to answer your hypothetical question. Q. Would you agree as a general proposition that inefficient market do not incorporate news into the price of a security quickly and fully? A. Again, I don't know how to answer your hypothetical question. Q. I don't believe it's a hypothetical. I think it's a general proposition question. A. Okay. Repeat the question then, please. Q. Inefficient would you agree that inefficient markets do not incorporate news into the price of a security quickly and fully? A. Not necessarily. THE WITNESS: I'm sorry, Josh, were you going to say something? MR. BAKER: No, that's fine. I think previously he said general proposition but I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. considered in submitting this report. So I have to think about that. Q. So sitting here today, you can't tell me whether or not your loss causation analysis for the FXCM notes assumed an efficient market? A. I defer to my previous answer. Q. If you did not assume that the notes market was efficient, how can you be certain that the alleged corrective disclosure caused a price drop in the FXCM notes? MR. BAKER: Object to the form. A. I don't understand the question. Q. We just discussed and, I believe, you agreed that an efficient market news is incorporated into the price of a security quickly and fully; is that right? A. I think I said generally. Q. Okay. A. That is correct. Q. So, if the market is not efficient and therefore it is not likely that news would incorporate itself into the price of a security

,	Page 405		Page 407
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	drop?	2	between the two and
3	MR. BAKER: Objection to form. There	3	THE STENOGRAPHER: I'm sorry, Josh.
4	is a bunch of assumptions in there that are not	4	You're going to have to get closer to the
5	what we talked about before.	5	microphone. I'm getting like every other word.
6	The Witness: You're right. So	6	Sorry about that.
7	I'm sorry, Josh.	7	MR. BAKER: Sorry.
8	MR. BAKER: If you understand the	8	I believe in Dr. Werner's previous
9	question, you can answer.	9	answer, he described that there would be sort
10	THE WITNESS: No, no, Josh. I	10	of mentioned that there would be a difference
11	actually was going to say that.	11	between inefficient and not efficient in various
12	A. You've made a ton of assumptions in	12	context and so that's what I'm trying to clarify
13	that question. And so, without exploring those	13	to make sure we are all understanding and
14	assumptions more, I can't answer that question.	14	answering the same question.
15	It's only I only laugh because Josh as he	15	Q. If the market for a security is
16	was making that objection, I was like, no,	16	inefficient, are there any modifications to your
17	there's a lot of assumption in there, so I can't	17	event study methodology that would be required to
18	answer that question.	18	accommodate for the fact that the market is
19	Q. Generally speaking, as an economist,	19	inefficient?
20	do you believe that an event study can properly	20	A. That's not something I've thought
21	form the basis of a loss causation analysis if	21	about as of today. I would need to think about
22	the market for a security is not efficient?	22	that more.
23	A. That's that's not anything that I	23	Q. Did you make any accommodations to
24	ever thought about. Sure, it's certainly	24	your event study methodology in this case to
25	possible that an event study can form the	25	accommodate for an inefficient market for the
	Page 406		Page 408
1	Page 406 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 408 CONFIDENTIAL - ADAM WERNER, Ph.D.
1 2		1 2	
1	CONFIDENTIAL - ADAM WERNER, Ph.D.		CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a	2	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes?
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say.	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts.
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record.
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market?	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form.	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing.	2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking.	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question?
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think objection to form is generally sufficient. But what I was trying to do was clarify for the Court Reporter the difference	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to the event study between the in connection with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think objection to form is generally sufficient. But what I was trying to do was	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to the event study between the in connection with the FXCM common stock versus the FXCM notes?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think objection to form is generally sufficient. But what I was trying to do was clarify for the Court Reporter the difference	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to the event study between the in connection with the FXCM common stock versus the FXCM notes? A. Again, without a definition of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think objection to form is generally sufficient. But what I was trying to do was clarify for the Court Reporter the difference between efficient and inefficient by saying "not"	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to the event study between the in connection with the FXCM common stock versus the FXCM notes? A. Again, without a definition of "modifications" or some notion of what you're
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think objection to form is generally sufficient. But what I was trying to do was clarify for the Court Reporter the difference between efficient and inefficient by saying "not efficient."	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to the event study between the in connection with the FXCM common stock versus the FXCM notes? A. Again, without a definition of "modifications" or some notion of what you're talking about, I can't answer those questions or
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think objection to form is generally sufficient. But what I was trying to do was clarify for the Court Reporter the difference between efficient and inefficient by saying "not efficient." Q. So, to ask the question again A. Well, go ahead. MR. BAKER: Just, you know, Mr.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to the event study between the in connection with the FXCM common stock versus the FXCM notes? A. Again, without a definition of "modifications" or some notion of what you're talking about, I can't answer those questions or that individual question or the series of questions. Q. Again, we discussed it earlier, but
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. foundation of a damage analysis if a market for a stock is inefficient or not efficient, I should say. Q. Would you need to make any modifications to your event study methodology to accommodate for an inefficient, not efficient market? MR. BAKER: Objection to the form. So we're clear inefficient and not efficient are not necessarily the same thing. So are you asking and I just want to make sure I understand what you're asking. Are you asking in either situation, or are you saying that they're the same one? MR. ISAJIW: Again, Josh, I think objection to form is generally sufficient. But what I was trying to do was clarify for the Court Reporter the difference between efficient and inefficient by saying "not efficient." Q. So, to ask the question again A. Well, go ahead.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM notes? MR. BAKER: Object to form, assumes facts. A. Well, I MR. BAKER: Assumes facts not in the record. Go ahead. A. I don't know what you mean by "modifications." Could you define those "modifications" that you're thinking of and maybe I would be able to give you an answer to that question? Q. When analyzing the event study in connection with your loss causation and damages conclusions, did you make any modifications as to the event study between the in connection with the FXCM common stock versus the FXCM notes? A. Again, without a definition of "modifications" or some notion of what you're talking about, I can't answer those questions or that individual question or the series of questions.

Page 409 Page 411 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 FXCM notes traded in an in -- an efficient 2 using the same term that the witness has 3 3 market, correct? repeatedly asked you to clarify without 4 A. Do you want to repeat that question? 4 clarifying that term. 5 I heard an in and efficient and inefficient. So 5 MR. ISAJIW: Josh, your speaking I don't understand the question. objections are getting a little extreme. 6 6 7 Q. The Court rejected your conclusion 7 Q. If we -- did you -- is there anything that the market for the FXCM notes was efficient, 8 8 in your loss causation report describing any type 9 of change to your loss causation analysis to correct? 10 A. I believe I've answered that question 10 accommodate for the fact that the Court has made a ruling on market efficiency in connection with 11 previously. So I defer to my earlier answer. 11 Q. Did you modify your loss causation the notes in this matter? 12 12 13 and damages analysis in connection with the notes 13 MR. BAKER: Objection to form. 14 14 in any way to accommodate for the Court's You can answer. 15 conclusion that the FXCM notes market was not 15 A. I don't know how to answer that 16 efficient? 16 question. 17 MR. BAKER: Object to form. 17 Q. Did the Court's ruling on market 18 You can answer. 18 efficiency for the notes in this matter factor into your loss causation and damages analysis in 19 A. Again, I don't know what you mean by 19 20 "modify" and there was jumbling of inefficient 20 connection with the notes? 21 21 and not efficient. A. Did it factor in? I mean, I suppose 22 If you want to repeat the question 22 to the extent that I knew about it, it may have 23 and explain what you mean by "modify," I'll make 23 factored in but, no, in general, no. 24 24 an attempt to answer the question. Q. Okay. Let's take a look at Page 32 25 Q. I'm just asking if your analysis 25 of your report and the section entitled, Page 410 Page 412 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 2 required any modification to accommodate for the "Artificial Inflation Ribbon." 3 Court's ruling on market efficiency in connection 3 A. Hold on. Let me get there. 4 with the notes in this matter? 4 Okay. I'm sorry what page? 5 MR. BAKER: Object to form. 5 O. 32. 6 And, Counsel, he said numerous times 6 A. 32. Okay, I'm there. 7 7 that he needs clarification of what Q. Paragraph 88 of this report you 8 "modifications" you're talking about. So, if you 8 define "artificial inflation" as "the difference 9 want to clarify something, he's asked that 9 between what a securities price actually was at a 10 multiple times and you keep on using the same 10 point of time and what the price would have been words. So it's understandably confusing. absent the alleged fraud"; is that correct? 11 11 12 A. I refer to my previous answer on this 12 A. You read that correctly. 13 13 Q. Would you agree that the price of a question or on this topic. 14 Q. Is there anything in your report 14 security absent the artificial inflation impact 15 describing a modification to your loss causation 15 of any alleged fraud is referred to generally as analysis in connection with the notes to 16 the "but for price"? 16 17 accommodate for the Court's ruling on market 17 A. I believe that's correct. 18 efficiency for the notes in this matter? 18 Q. And in order to determine the but for 19 MR. BAKER: Same objection. 19 price of a company's security, you need to 20 determine what price would -- the security would A. Same answer. 20 21 21 Q. I don't understand what the "same have been had the company made the allegedly answer" is. This is a different question and 22 corrective disclosure at an earlier point in 22 23 23 it's yes or no. time: is that correct? 24 A. Same --24 A. I believe that statement is correct. 25 MR. BAKER: Same objection. You're 25 Q. And assuming there is no confounding

Page 413 Page 415 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 information, the residual price decline following itself indicate that the inflation amount 3 an allegedly corrective disclosure demonstrates 3 reflected in that price decline was constant 4 the level of artificial inflation in a security 4 throughout the whole class period, does it? 5 immediately before that corrective disclosure; is 5 A. So, I mean, there's all sorts of 6 that right? 6 assumptions that would go into giving you an 7 7 A. I'm sorry, could you repeat that accurate answer to that statement. 8 8 question please? But I think -- I mean, if you want --9 9 Q. Assuming there is no confounding if you want to repeat the question, I can give 10 information, the residual price decline following 10 you a general answer to an extremely complex 11 an allegedly corrective disclosure demonstrates 11 question. But this won't -- as to the facts of the level of artificial inflation in a security 12 this case, I'm not sure if the answer would apply 12 13 immediately before that corrective disclosure; is 13 one way or the other. 14 14 that correct? Q. Just -- I'm looking for just general 15 A. At least. 15 -- we'll get to the facts of this case in a 16 Q. Would you agree that the level of 16 minute. inflation in a security can change over time 17 17 I'm just looking for a general answer 18 during a class period? 18 to the question of just because the price 19 A. As a general statement -- as a 19 declines at the end of multi-year class period 20 20 does not by itself indicate that the inflation general premise, that statement is correct. 21 21 Q. And, generally speaking, what are the amount reflected in that price decline was 22 circumstances that could create a situation where 22 constant throughout that class period, would you 23 23 the level of inflation could change over time? agree with that statement? 24 24 A. I mean, there's an expansive number A. I think as a general statement, that 25 of answers. I mean, I could give you some 25 is correct. Page 414 Page 416 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 examples. One would be an additional corrective Q. Is it possible that the substance of 3 disclosure. One could be a statement -- an 3 information a company could or should have 4 allegedly fraudulent statement that may serve to 4 disclosed to correct an allegedly fraudulent 5 increase the stock price or the inflation. I 5 misstatement could change during the class 6 mean, it's an extremely large question. But I 6 period? 7 7 think those two are two examples of situations A. I'm sorry, so the question -- could 8 where inflation might change during the class 8 you re-read the question please? Because, I 9 period. 9 think, it -- it either started with, could it --10 Q. And would you agree that any analysis 10 and, again, now we're -- when you ask questions of inflation would need to explore those like "could," are we talking about likelihoods or 11 11 12 potential circumstances to determine whether 12 a tale possibility? 13 13 inflation did, in fact, change over a class So go ahead and re-read the question. 14 period? 14 I'll try to answer it, as you've stated it. 15 15 Q. It possible that the substance of A. I think that statement's accurate. information a company could or should disclose to 16 Q. And would you agree that you can't 16 17 use a residual price decline on one day alone 17 correct an allegedly fraudulent misstatement 18 without more information to measure artificial 18 could change during the class period? 19 inflation in the price of a security over a 19 MR. BAKER: I'm going to object to 20 20 multi-year period? form. 21 21 A. I don't know how to answer that But you can answer. 22 question. 22 A. To the extent that anything is 23 Q. Let me ask it another way. 23 possible, in the same sense that -- I mean, I 24 Just because the price declines at 24 don't know -- I don't know what percentage to put

25

on this.

the end of a multi-year class period, does not by

25

Page 417 Page 419 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 I mean, is it possible Trump actually 2 MR. BAKER: Objection to form. 3 3 won the 2020 election? I suppose it's possible. You can answer again. 4 4 Is it probable? No. A. I don't know how to answer that 5 5 So, again, it's an overly broad question. Yeah, I don't know how to answer that 6 question. I mean, if you ask me if something is 6 question. 7 7 possible, anything is possible, right. Q. Is there any section in your loss 8 8 Is it possible that my ceiling has a causation report where you detail but for 9 crack in it and there's about to be water flowing disclosures that you believe FXCM should have 10 in on my head? It's possible. Probable, no. 10 made during the class period? 11 So I don't know how to answer these 11 A. Well, so, ultimately, it's not up to 12 me to decide what FXCM should have disclosed 12 questions about -- that are vaguely asked. So, 13 because if I -- when you ask questions like is it 13 during the class period. The court will decide 14 possible, if I say, ah, yes, it is possible, then 14 what FXCM should have disclosed during the class 15 all of the sudden it's like, oh, Dr. Werner said 15 period and when they should have disclosed it. 16 it's possible, right. But possible and probable 16 It seems to me, though, that the are two different things. 17 17 information contained in the corrective 18 So, I mean, generally, anything is 18 disclosure at the end of the class period as a 19 possible. 19 general principle to the extent that FXCM was 20 Q. Would you agree that in conducting a 20 aware of any information associated with it 21 loss causation analysis and damages analysis, you 21 should have been announced earlier. 22 would need to explore the possibility that the 22 Q. And what information contained in the 23 substance of a potential corrective disclosure 23 corrective disclosure do you believe FXCM should 24 could change during the class period? 24 have made earlier? 25 A. As a general principle, yes. 25 A. Well, again -- well, alright. Let's Page 418 Page 420 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 Q. Would you agree that you would also 2 go to their corrective disclosure. 3 need to explore the possibility that the impact 3 So -- and I'm referring now to 4 of any potential corrective disclosure would 4 Paragraph 26 of my report. "I believe Plaintiffs 5 change over the course of a class period? 5 are saying that FXCM should have disclosed that 6 A. Okay. Could you re-read that 6 retail customer's profits or losses would have an 7 7 sentence please? effect on FXCM interest because FXCM's role was 8 8 Q. Would you agree that you would also merely as an agent or a credit intermediary." 9 need to explore the possibility that the impact 9 "They should have disclosed that they 10 of any potential corrective disclosure on the 10 had a financial interest in the market maker that price of a security could change over the course consistently won the largest share of FXCM's NDD 11 11 12 of a class period? 12 trading volume." 13 13 A. So, to quote you, possibly. "Plaintiffs allege that they should 14 Q. Okay. I want to focus on the 14 have stated that Effex" -- that's, again, with 15 disclosure assumptions in your analysis today. 15 capital E so we're talking about the company --In your report, you do not list was, "essentially, a front created by FXCM 16 16 17 specific but for disclosures that FXCM should 17 allowing for FXCM to hold positions opposite its 18 have made or when they should have made them; is 18 customers and financially benefit at its 19 that correct? 19 customers expense in direct contravention to the 20 20 A. Could you re-read the question company's representations to investors and its 21 21 own customers of" conflict trading -- or please? 22 22 Q. In your report, you do not list "conflict-free trading on the NDD." 23 specific but for disclosures that FXCM should 23 "Plaintiffs allege that or suggest 24 have made or when they could have made them; is 24 that FXCM should have announced or told the 25 that correct? 25 market that it had manipulated its NDD platform

Page 421 Page 423 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 by putting Effex" -- again, that's with a capital 2 expert opinion on whether FXCM should have 3 E -- "in front of independent market makers and 3 disclosed Effex by name as a liquidity provider 4 routing retail customer orders while also 4 from which it received pay for flow payments? 5 permitting Effex to win all ties with other 5 A. Well, okay, so couple questions; by 6 market makers." 6 name as opposed to what? 7 "FXCM provided Effex" -- again, with 7 Q. As opposed to, I guess, a general 8 8 a capital E -- "with a realtime view of price description of receiving pay for flow payments. 9 quotations offered by other market makers and 9 A. You mean alleged pay for flow 10 added smaller markups to Effex" -- capital E --10 statements? 11 "prices than the prices provided by other market 11 Q. I'm asking if you have formed an makers. This way FXCM ensured that the bulk of opinion as to whether FXCM should have disclosed 12 12 its order flow would go to Effex -- capital E --Effex by name as a liquidity provider from which 13 13 14 and generate profits for FXCM." 14 it received pay for flow payments? 15 I believe that they believed --15 A. I don't have an opinion about that 16 "Plaintiffs believe that Effex should not have 16 one way or another. It's an extremely -- I'll 17 disguised its order flow payments, which no other 17 leave it at that. 18 market maker was making to FXCM." 18 Q. Do you have an opinion as to whether 19 19 And I believe that it's alleged that or not FXCM should have disclosed that its 20 they should have corrected their financial 20 relationship with Effex was being investigated by 21 21 statements so they did not violate SEC regulators? 22 regulations and Generally Accepted Accounting 22 A. So, again, to the extent you're 23 Principles for failing to disclose FXCM economic 23 asking me should they have done that, that's not 24 24 interest in contractual and related-party in my purview. 25 relationship with and control over Effex --25 Q. Do you have any opinion as to whether Page 422 Page 424 1 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 capital E -- during the class period. 2 or not FXCM should have issued a different set of 3 Q. So those are Plaintiffs' allegations 3 financial statements consolidating Effex as a 4 in the Complaint. 4 variable interest entity? 5 And I'm just asking in connection 5 A. Same answer to the previous question. 6 with your expert opinion in this matter, is there 6 Q. Have you done any analysis as to 7 7 any place in this report where you independently whether consolidating Effex into FXCM's financial 8 8 opine what FXCM should have disclosed in reporting would negatively affect FXCM's 9 connection with each of those allegations or when 9 financials? 10 it could have disclosed them? 10 A. As a GAAP principle? 11 A. Do I independently do it? 11 Q. In any way. 12 I'm not sure how to answer that 12 Have you done any analysis? 13 A. I don't understand the question. question. 13 14 Q. In connection with your loss 14 Q. Did you analyze in connection with 15 causation and damages analysis, did you assume 15 the scope of work for your retention as an expert that FXCM should have disclosed Effex by name as 16 in this matter whether consolidating Effex into 16 17 a liquidity provider from which it received pay 17 FXCM's financial reporting would negatively 18 for flow payments? 18 affect FXCM's financials? 19 MR. BAKER: Objection to form. 19 A. Same answer. 20 A. Yeah, I -- I'm not sure how to answer 20 Q. And, to be clear, the "same answer" 21 21 that you're referring to was, "that's not in my that question. I mean, ultimately, I think, 22 22 purview"; is that correct? Plaintiffs will have to prove one way or another 23 23 what should have been disclosed and what period A. I believe that's what I stated. But 24 of time it should have been disclosed. 24 if you would like the Court Reporter to read back 25 Q. Sitting here today do you have an 25 exactly what I state, I'm happy to have them do

1	D 405		D 407
1	Page 425 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 427 CONFIDENTIAL - ADAM WERNER, Ph.D.
1 2	that. Or if you want to stipulate that's what I	2	
3	said, I won't disagree with you.	3	this. And I'm happy to accommodate you. Just let us know give us five minutes in advance.
4	Q. I believe that's what you said. And	4	As long as there is no question pending, it
5	I just want to make sure, because we had a	5	should be fine.
6	colloquy between your end.	6	A. Okay. Well, when I hear the dogs
7	A. Well, okay. So now to the extent you	7	barking, I'll know that he's about to leave.
8	"believe" that's what I said, you might as well	8	THE STENOGRAPHER: Okay. Every time
9	just refer to what the Court Reporter wrote.	9	you guys talk, I can't look at the transcript.
10	Q. I am happy to do that.	10	So just pause for one second. I'm sorry.
11	MR. ISAJIW: Ms. Wage, are you able	11	A. Well, okay, why don't we take a break
12	to read back the previous answer to his	12	while she's tracking down the answer, if that's
13	questions?	13	okay.
14	MR. BAKER: Which question?	14	Q. I'm happy to go off the record.
15	MR. ISAJIW: The one that he's	15	A. I would I'd like to take a break
16	referring to when he says, "same answer."	16	for a minute.
17	THE STENOGRAPHER: Just give me a	17	Q. I'm happy to go off the record.
18	moment, so I can find it.	18	A. Okay.
19	MR. ISAJIW: Sure.	19	THE VIDEOGRAPHER: The time is
20	MR. BAKER: He said the "same answer"	20	1:10 p.m. We're going off the record.
21	a couple of times. Is he referring to the same	21	(Recess taken 1:10 to 1:19 p.m.)
22	one. But just, Silvia for the clear record,	22	(Whereupon, the questions and answers
23	Peter, if there's a certain part of the draft	23	are read back as follows off he record:
24	like lines or pages that you can refer to, maybe	24	"Question: Do you have an opinion
25	that would help clear things up just as a	25	whether or not FXCM should have disclosed that
	Page 426		Page 428
			F49E 420
1		1	-
1 2	CONFIDENTIAL - ADAM WERNER, Ph.D.	1 2	CONFIDENTIAL - ADAM WERNER, Ph.D.
			-
2	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking	2	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay.	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators?
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well.	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that,
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview.
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay?	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break?	2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity?
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know.	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know. So, again, sometime in the next hour	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect FXCM's financials?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know. So, again, sometime in the next hour or, I guess, now 45 minutes	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect FXCM's financials? Answer: As a GAAP principle?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know. So, again, sometime in the next hour or, I guess, now 45 minutes Q. I'm happy to accommodate	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect FXCM's financials? Answer: As a GAAP principle? Question: In any way.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know. So, again, sometime in the next hour or, I guess, now 45 minutes Q. I'm happy to accommodate A. I'm sorry. You asked me a question	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect FXCM's financials? Answer: As a GAAP principle? Question: In any way. Have you done any analysis?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know. So, again, sometime in the next hour or, I guess, now 45 minutes Q. I'm happy to accommodate A. I'm sorry. You asked me a question and I'm explaining the answer.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect FXCM's financials? Answer: As a GAAP principle? Question: In any way. Have you done any analysis? Answer: I don't understand the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know. So, again, sometime in the next hour or, I guess, now 45 minutes Q. I'm happy to accommodate A. I'm sorry. You asked me a question and I'm explaining the answer. Within the next 51 minutes, I would	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect FXCM's financials? Answer: As a GAAP principle? Question: In any way. Have you done any analysis? Answer: I don't understand the question.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know. So, again, sometime in the next hour or, I guess, now 45 minutes Q. I'm happy to accommodate A. I'm sorry. You asked me a question and I'm explaining the answer. Within the next 51 minutes, I would like to take a break to wish my son well in his	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect FXCM's financials? Answer: As a GAAP principle? Question: In any way. Have you done any analysis? Answer: I don't understand the question. Question: Did you analyze in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. ISAJIW: I'm literally looking for clarity as well. MR. BAKER: Okay. A. Just if I may ask, at some point in the next hour, my sixth grade son is going to his graduation. I would like to pause the proceedings because it looks like I won't be making that graduation and, at least, wish him good luck; is that okay? Q. What time are you asking for a break? A. Well, I don't know what time he's leaving. The graduation starts at 11. So I don't know. We live ten minutes from the school. I don't know what his mom is thinking in regards to traffic, et cetera. I don't know. So, again, sometime in the next hour or, I guess, now 45 minutes Q. I'm happy to accommodate A. I'm sorry. You asked me a question and I'm explaining the answer. Within the next 51 minutes, I would	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. its relationship with Effex was being investigated by regulators? Answer: So, again, to the extent you're asking me should they have done that, that's not in my purview. Question: Do you have any opinion as to whether or not FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity? Answer: Same answer to the previous question. Question: Have you done any analysis as to whether consolidating Effex into FXCM's financial reporting would negatively affect FXCM's financials? Answer: As a GAAP principle? Question: In any way. Have you done any analysis? Answer: I don't understand the question.

	D 420		P. 421
1	Page 429 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 431 CONFIDENTIAL - ADAM WERNER, Ph.D.
2	consolidating Effex into FXCM's financial	2	A. Again, I don't understand the
3	reporting would negatively affect FXCM's	3	question. So, to the extent that I don't
4	financials?	4	understand the question, I don't know I don't
5	Answer: Same answer.	5	know how to give you an accurate answer one way
6	Question: And, to be clear, the	6	or other. It's possible, in using that word that
7	'same answer' that you're referring to was,	7	everyone loves to use in litigation. But as I
8	'that's not in my purview'; is that correct?	8	sit here today, I don't know.
9	Answer: I believe that's what I	9	Q. Do you understand what a variable
10	stated.")	10	interest entity is?
11	THE VIDEOGRAPHER: The time is	11	A. Do I understand what a variable
12	1:19 p.m. We're going back on the record.	12	interest entity? You know, as I sit here today,
13	Q. Dr. Werner, before we went off the	13	I'm not sure.
14	record, I asked, did you analyze in connection	14	Q. Do you have any opinion as to whether
15	with the scope of work for your retention as an	15	FXCM should have issued a different set of
16	expert in this matter whether consolidating Effex	16	financials consolidating Effex as a variable
17	into FXCM's financial reporting would negatively	17	interest entity?
18	affect FXCM's financials.	18	MR. BAKER: Objection to form.
19	A. Okay. And I don't understand the	19	A. Again, I don't understand the
20	question.	20	question. So I don't know how to give you an
21	Q. Did you do any analysis in connection	21	accurate answer.
22	with the scope of work in this matter to	22	Q. In connection with your scope of work
23	determine in your expert opinion as to whether	23	for the loss causation and damages report in this
24	FXCM consolidating Effex into FXCM's financial	24	matter, did you analyze whether FXCM should have
25	reporting would negatively affect FXCM's	25	issued financial statements disclosing
23		23	
	Page 430		Page 432
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
		_	
2	financials?	2	transactions with Effex as related-party
3	A. To the extent that I don't understand	3	transactions with Effex as related-party transactions?
3 4	A. To the extent that I don't understand the question, I can't answer it.	3 4	transactions with Effex as related-party transactions? A. Again, I don't understand the
3 4 5	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did	3 4 5	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't
3 4 5 6	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis?	3 4 5 6	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it.
3 4 5 6 7	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your	3 4 5 6 7	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not
3 4 5 6 7 8	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're	3 4 5 6 7 8	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed.
3 4 5 6 7 8 9	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other	3 4 5 6 7 8 9	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any
3 4 5 6 7 8 9	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your	3 4 5 6 7 8 9 10	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done
3 4 5 6 7 8 9 10	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question.	3 4 5 6 7 8 9 10 11	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses.
3 4 5 6 7 8 9 10 11 12	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an	3 4 5 6 7 8 9 10 11 12	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent
3 4 5 6 7 8 9 10 11 12 13	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in	3 4 5 6 7 8 9 10 11 12 13	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't
3 4 5 6 7 8 9 10 11 12 13 14	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have	3 4 5 6 7 8 9 10 11 12 13 14	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to
3 4 5 6 7 8 9 10 11 12 13 14 15	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting?	3 4 5 6 7 8 9 10 11 12 13 14 15	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them.
3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't	3 4 5 6 7 8 9 10 11 12 13 14 15 16	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses?
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't understand the question, I don't know how to	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses? Possible. But I don't understand the question
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't understand the question, I don't know how to answer it.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses? Possible. But I don't understand the question so
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't understand the question, I don't know how to answer it. Q. Did in connection with your scope	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses? Possible. But I don't understand the question so I've given you the best answer I can.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't understand the question, I don't know how to answer it. Q. Did in connection with your scope of work in this matter, did you do any analysis	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses? Possible. But I don't understand the question so I've given you the best answer I can. Q. Okay. Let's look at Paragraph 7 of
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't understand the question, I don't know how to answer it. Q. Did in connection with your scope of work in this matter, did you do any analysis as to whether FXCM should have issued a different	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses? Possible. But I don't understand the question so I've given you the best answer I can. Q. Okay. Let's look at Paragraph 7 of your loss causation report again. Please let me
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't understand the question, I don't know how to answer it. Q. Did in connection with your scope of work in this matter, did you do any analysis as to whether FXCM should have issued a different set of financial statements consolidating Effex	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses? Possible. But I don't understand the question so I've given you the best answer I can. Q. Okay. Let's look at Paragraph 7 of your loss causation report again. Please let me know when you're there.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't understand the question, I don't know how to answer it. Q. Did in connection with your scope of work in this matter, did you do any analysis as to whether FXCM should have issued a different set of financial statements consolidating Effex as a variable interest entity?	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses? Possible. But I don't understand the question so I've given you the best answer I can. Q. Okay. Let's look at Paragraph 7 of your loss causation report again. Please let me know when you're there. A. I'm in the wrong report.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. To the extent that I don't understand the question, I can't answer it. Q. You don't understand whether you did that analysis? A. Well, I don't understand your question. So, if I don't know what you're talking about, I can't say one way or the other whether I did the analysis associated with your question. Q. Was it within your purview as an expert retained for loss causation and damages in this matter to analyze whether FXCM should have consolidated Effex in its financial reporting? A. So, again, to the extent that I don't understand the question, I don't know how to answer it. Q. Did in connection with your scope of work in this matter, did you do any analysis as to whether FXCM should have issued a different set of financial statements consolidating Effex	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	transactions with Effex as related-party transactions? A. Again, I don't understand the question. So, to the extent that I don't understand the question, I can't answer it. Q. And I'm just asking whether or not these are analyses you performed. So I'm not asking for any conclusions. I'm just asking if you have done these analyses. A. Right. And so, again, to the extent that I don't understand your questions, I don't know how to answer the I don't know how to answer them. Did I perform some analyses? Possible. But I don't understand the question so I've given you the best answer I can. Q. Okay. Let's look at Paragraph 7 of your loss causation report again. Please let me know when you're there.

	Page 433	1	Page 435
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	the market about the company's purported lack of	2	period than a principal or dealing desk model?")
3	conflict of interest with customer transactions	3	A. And I don't really understand the
4	on FXCM's NDD platform."	4	question, but I'll ask some clarifying questions
5	Did I read that correctly?	5	in an attempt to answer that.
6	A. You did.	6	So from whose perspective?
7	Q. Are you offering an opinion that	7	Q. From anyone's perspective, were you
8	receiving payment for order flow created a	8	asked to analyze that issue?
9	conflict of interest with customer transactions	9	A. Yeah, I don't know one way or the
10	on FXCM's NDD platform?	10	other, as I sit here today.
11	A. I don't know how to answer that	11	Q. You go on to say in that paragraph
12	question. I mean, look, companies pay for order	12	that, "FXCM misled market participants about the
13	flow all the time. It's not just the question of	13	extent of FXCM's exposure to regulatory
14	paying for order flow. There's a whole miasma of	14	scrutiny."
15	things going on here.	15	Did I read that correctly?
16	So I'm not quite sure how to answer	16	A. I'm sorry. We're back at Paragraph 7
17	that question without going into the entirety of	17	or 8?
18	this question.	18	Q. Seven.
19	Q. Have you analyzed in connection with	19	A. (The witness reads to himself out
20	your work as an expert on this matter whether	20	loud.)
21	FXCM's relationship with Effex was detrimental or	21	Okay. So you stopped after
22	beneficial to its customers during the class	22	"regulatory scrutiny"?
23	period?	23	Q. I did.
24	A. Well, I mean, to the extent that I've	24	A. Okay. Yeah, you read that correctly.
25	previously during this deposition read analyst	25	Q. Are you offering an opinion regarding
	Page 434		Page 436
1	Page 434 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 436 CONFIDENTIAL - ADAM WERNER, Ph.D.
1 2		1 2	_
	CONFIDENTIAL - ADAM WERNER, Ph.D.		CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I	2	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be.	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter?
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know.
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period?	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM?
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that.	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form.
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze	2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise."
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic?
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to financial firms and the impact that those
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model? A. Could you re-read the question	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model? A. Could you re-read the question please?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to financial firms and the impact that those regulators sometimes have on those financial
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model? A. Could you re-read the question please? MR. ISAJIW: Ms. Wage, can you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to financial firms and the impact that those regulators sometimes have on those financial firms. So I don't know exactly what you're
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model? A. Could you re-read the question please? MR. ISAJIW: Ms. Wage, can you re-read the question please.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to financial firms and the impact that those regulators sometimes have on those financial firms. So I don't know exactly what you're asking here or how you're defining expert. Q. In the manner in which you define
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model? A. Could you re-read the question please? MR. ISAJIW: Ms. Wage, can you re-read the question please. (Whereupon, the question is read back as follows:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to financial firms and the impact that those regulators sometimes have on those financial firms. So I don't know exactly what you're asking here or how you're defining expert. Q. In the manner in which you define "expertise," are you offering an opinion as to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model? A. Could you re-read the question please? MR. ISAJIW: Ms. Wage, can you re-read the question please. (Whereupon, the question is read back	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to financial firms and the impact that those regulators sometimes have on those financial firms. So I don't know exactly what you're asking here or how you're defining expert. Q. In the manner in which you define
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model? A. Could you re-read the question please? MR. ISAJIW: Ms. Wage, can you re-read the question please. (Whereupon, the question is read back as follows: "Question: Was it within your	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to financial firms and the impact that those regulators sometimes have on those financial firms. So I don't know exactly what you're asking here or how you're defining expert. Q. In the manner in which you define "expertise," are you offering an opinion as to the exposure to regulatory scrutiny of FXCM in this matter?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. quotes that suggest that it was detrimental, I suppose it could certainly could be. Q. Was it within your purview as an expert to opine on whether FXCM's relationship with Effex was detrimental or beneficial to its customers during the class period? A. That's an interesting question. I'm not sure whether or not I've been asked to opine on that. Q. Was it within your purview to analyze whether an agency or no dealing desk model would be more beneficial to FXCM's business operations during the class period than a principal or dealing desk model? A. Could you re-read the question please? MR. ISAJIW: Ms. Wage, can you re-read the question please. (Whereupon, the question is read back as follows: "Question: Was it within your purview to analyze whether an agency or no	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. FXCM's exposure to regulatory scrutiny in this matter? A. I don't understand the question. My opinions are laid out here in my report. I so I don't know. Q. Do you have any expertise that would allow you to opine on the potential exposure to regulatory scrutiny for FXCM? MR. BAKER: Objection to form. A. Define "expertise." Am I familiar with it, the topic? Yeah, I'm familiar with the topic. I don't know if that makes me an expert. I mean, just in general I understand what regulators do to financial firms and the impact that those regulators sometimes have on those financial firms. So I don't know exactly what you're asking here or how you're defining expert. Q. In the manner in which you define "expertise," are you offering an opinion as to the exposure to regulatory scrutiny of FXCM in

Page 437 Page 439 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 2 question. Q. Are you offering an opinion about the 3 3 Q. Later in that paragraph you state "viability and sustainability" of FXCM's overall 4 that "market participants were misled about the 4 operations in forex trading generally? 5 viability and sustainability of FXCM's business 5 MR. BAKER: Objection to form. 6 model." 6 A. No. I mean, again, I refer back to 7 What "business model," specifically, 7 those investment analysts quotes that I referred 8 8 are you referring to there? to earlier. I'm happy to read them again. 9 9 A. FXCM's business model. That's my understanding of the firm's "viability 10 Q. Are you referring to, for instance, 10 and sustainability." Or that, certainly, represents my understanding of their "viability 11 the no dealing desk, forex trading generally, 11 their operations in the United States, their and sustainability." 12 12 13 operations globally? Which specific "business 13 Q. Other than by reference to the 14 model" are you referring to? 14 analyst quotes, do you have any personal 15 A. Well, those are all part of its 15 expertise in forex trading sufficient for you to 16 16 business model, correct? determine independently the sustainability of 17 Q. So you are referring to all of those FXCM's business model, generally? 17 18 when you say that "market participants were 18 MR. BAKER: Objection to form. misled about the viability and sustainability of 19 19 A. Again, I don't know what you mean by 20 FXCM's business model"? 20 "expertise." I mean, I TA'ed a course on 21 A. I believe "business model" -- I mean, 21 international finance in graduate schools by one 22 I'm using that in the general sense of "business 22 of the foremost international finance experts 23 model." I mean, does that include FXCM's claim 23 where we dealt with foreign exchange markets. I 24 that they were -- that they had an NDD platform? 24 don't know if that makes me an expert. I 25 That certainly would be one of them. That's 25 certainly, teach about foreign exchange or FX Page 438 Page 440 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 certainly part -- my understanding is that's part 2 trading in my macroeconomics class. I don't know 3 of their "business model" among other things. 3 if that makes me an expert. 4 Q. Are you offering an opinion about the 4 I mean, I suppose if I'm asked, 5 viability of FXCM's no dealing desk in connection 5 ultimately, it will be up to the Court to decide 6 with your scope of engagement in this matter? whether or not I'm an expert, if I am, in fact, 7 7 A. I don't understand the question. I asked that question by the Court. 8 8 mean, they didn't have -- what do you mean "the Q. In connection with your loss 9 viability"? 9 causation and damages report, do you believe that 10 My understanding is they didn't have 10 you've been retained as an expert concerning forex trading and the sustainability of FXCM's 11 a no dealing desk. 11 12 Q. I'm just trying to get a sense of 12 business model? which "business model" and what specific 13 13 A. I believe that in this matter -- and 14 "business model" you're discussing in your 14 I'm now reading from Paragraph 4 of my report. 15 15 "I was asked by lead Counsel for the Plaintiffs report. to determine whether the losses of the Plaintiffs 16 A. I mean, I gave you certainly an 16 17 example of what I mean by their "business model." 17 and the class were caused by Defendant's alleged 18 That was one part of it. 18 misrepresentations and omissions (i.e., loss 19 Q. Are you --19 causation) as described in the third amended 20 A. I don't know -- I don't know if their 20 consolidated securities class action complaint 21 "business model" is to spinoff a company that, 21 dated April 17, 2020 (Complaint). 22 22 basically, appeared to be kicking back profits to Furthermore, I was asked to quantify 23 them. I'm not sure if I meant that that was part 23 the loss, if any, due to the Defendant's alleged 24 of their "business model" or not, as I sit here 24 misrepresentations and omission of both a per

share and per note basis (i.e., damages)."

25

today among other things.

25

1	Page 441	1	Page 443
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2 3	That's what I was retained to do in this matter.	2 3	Q. What corrective information do you believe could have been disclosed on March 15th,
	Q. Okay. Further in Paragraph 7 you	3	2012?
5	say, "The alleged fraud also concealed from the market the inextricable ramifications that would	5	A. Well, I believe that Plaintiffs are
6	manifest upon corrective disclosure."	6	contending that whatever information was
7	Earlier we discussed your view of	7	disclosed on the February 7th, '17 2017 could
8	"the inextricable ramifications."	8	have been disclosed at the beginning of the class
9	What I want to know what is your	9	period.
10	basis for contending those ramifications were	10	Q. And have you independently analyzed
11	"inextricable"?	11	that contention and formed a belief as to whether
12	A. All the material that I reviewed in	12	or not that is accurate?
13	forming my opinions, all of my opinions in this	13	A. Well, I have not seen any evidence to
14	matter.	14	indicate that that assumption is inaccurate.
15	Q. And which "ramifications,"	15	Q. Do you have an opinion as to what
16	specifically, are you referring to as the	16	specific corrective information could have been
17	"inextricable ramifications"?	17	disclosed to the market on March 15th, 2012?
18	A. The same ones I referred to when you	18	A. I believe Plaintiffs are maintaining
19	asked me this question earlier.	19	that all information the corrective
20	Q. So the myriad of things defined	20	disclosures that occurred at the end of the class
21	explained, sorry, in the analyst report quotes	21	period could have occurred at the beginning of
22	that you read earlier; is that correct?	22	the class period.
23	MR. BAKER: Objection.	23	Q. Is it your opinion that had that
24	A. Well, I'm not sure that I would use	24	information been disclosed on March 15th, 2012
25	the word "myriad." That's your qualification of	25	that the stock would have reacted in the same way
	Page 442.		Page 444
1	Page 442 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 444 CONFIDENTIAL - ADAM WERNER, Ph.D.
	CONFIDENTIAL - ADAM WERNER, Ph.D.		CONFIDENTIAL - ADAM WERNER, Ph.D.
1 2 3		1 2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017?
2	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier.	2	CONFIDENTIAL - ADAM WERNER, Ph.D.
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"?
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012?
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that.	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least,
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount.
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th,	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period?	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period? MR. BAKER: Objection to form. A. Could have a corrective disclosure have been made?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if the corrective disclosure was made on March 15th, 2012? A. Well, okay. So, again, let's first
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period? MR. BAKER: Objection to form. A. Could have a corrective disclosure have been made? THE WITNESS: I'm sorry, Josh.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if the corrective disclosure was made on March 15th, 2012? A. Well, okay. So, again, let's first I just said "at least," correct? Did you miss
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period? MR. BAKER: Objection to form. A. Could have a corrective disclosure have been made? THE WITNESS: I'm sorry, Josh. MR. BAKER: It assumes facts not in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if the corrective disclosure was made on March 15th, 2012? A. Well, okay. So, again, let's first I just said "at least," correct? Did you miss that part of my answer?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period? MR. BAKER: Objection to form. A. Could have a corrective disclosure have been made? THE WITNESS: I'm sorry, Josh. MR. BAKER: It assumes facts not in the record.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if the corrective disclosure was made on March 15th, 2012? A. Well, okay. So, again, let's first I just said "at least," correct? Did you miss that part of my answer? Because I want to make sure that it's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period? MR. BAKER: Objection to form. A. Could have a corrective disclosure have been made? THE WITNESS: I'm sorry, Josh. MR. BAKER: It assumes facts not in the record. You can answer.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if the corrective disclosure was made on March 15th, 2012? A. Well, okay. So, again, let's first I just said "at least," correct? Did you miss that part of my answer? Because I want to make sure that it's understood that I said it would, "at least," fall
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period? MR. BAKER: Objection to form. A. Could have a corrective disclosure have been made? THE WITNESS: I'm sorry, Josh. MR. BAKER: It assumes facts not in the record. You can answer. A. Yeah. Could it have happened? I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if the corrective disclosure was made on March 15th, 2012? A. Well, okay. So, again, let's first I just said "at least," correct? Did you miss that part of my answer? Because I want to make sure that it's understood that I said it would, "at least," fall to that amount at the beginning of the class
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period? MR. BAKER: Objection to form. A. Could have a corrective disclosure have been made? THE WITNESS: I'm sorry, Josh. MR. BAKER: It assumes facts not in the record. You can answer. A. Yeah. Could it have happened? I don't know. I mean, it's another really broad	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if the corrective disclosure was made on March 15th, 2012? A. Well, okay. So, again, let's first I just said "at least," correct? Did you miss that part of my answer? Because I want to make sure that it's understood that I said it would, "at least," fall to that amount at the beginning of the class period.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. what I read to you earlier. So, to the extent that I'm not sure I agree with your representation or the way you structured your sentence, I'm not sure I can answer that question. But I believe to the extent that you've asked this question previously, without injecting additional adjectives or nouns, maybe a noun, I've answered the question. So I can refer to that. Q. In your view in this case, could the same corrective disclosure that was made on February 7th, 2017 have been made on March 15th, 2012, which is the first day of the class period? MR. BAKER: Objection to form. A. Could have a corrective disclosure have been made? THE WITNESS: I'm sorry, Josh. MR. BAKER: It assumes facts not in the record. You can answer. A. Yeah. Could it have happened? I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. as it did in February of 2017? A. What do you mean by "the same way"? Q. Would the stock have had the same price reaction as it did upon revelation of the alleged corrective disclosure in February of 2017 if that alleged corrective disclosure was disclosed on March 15th, 2012? MR. BAKER: Objection to form. A. I mean, to all based on all the evidence I reviewed, it would have, at least, fallen by that amount. Q. And what information do you believe would have caused it to fall by that amount if the corrective disclosure was made on March 15th, 2012? A. Well, okay. So, again, let's first I just said "at least," correct? Did you miss that part of my answer? Because I want to make sure that it's understood that I said it would, "at least," fall to that amount at the beginning of the class

Page 445 Page 447 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 this case. 2 I'm not sure you can disaggregate that, that 3 Q. Do you believe that if FXCM disclosed 3 particular statement, because all of these things its relationship with Effex on March 15th, 2012 4 4 are woven together. Look, if they hadn't lied 5 that the stock would have had the same price about it, you know, it's not -- presumably, the 6 reaction as it did upon the corrective regulators may not have come down on them that 7 7 disclosures in February of 2017? hard and market participants wouldn't have said, 8 A. Well, I refer to my definition or my 8 oh, these guys are teetering on the edge of 9 discussion of these things as being -- as having 9 bankruptcy or they may not be solvent. 10 "inextricable ramification." So, if that 10 So I'm not -- as I sit here today, 11 specific component had been told to the market on 11 I'm not quite sure how to parse that out. 12 that date without the regulators going ahead and 12 O. Let's look at the CFTC and NFA 13 saying, you can no longer operate in the US -- is 13 settlement for a minute. 14 that the hypothetical question you want me to 14 And correct me if I'm wrong, but 15 answer? 15 these settlements are the basis in your view of 16 Q. Yes. 16 the corrective disclosure, which occurred on 17 A. Okay. And nothing about their 17 February 6th, 2017; is that correct? 18 reputation or what the analyst thought about what 18 A. I don't understand. What do you mean 19 it would do to their business? 19 by "the basis"? 20 Q. I'm asking you for your opinion as to 20 Q. You identified the public disclosure 21 what the effect of that disclosure would have 21 contained in FXCM's settlements with the CFTC and 22 been made on March 15th, 2012. 22 the NFA on February 6th, 2017 as the corrective 23 A. And, again, I -- if you're talking 23 disclosure in this case; isn't that right? 24 about the corrective disclosure and the -- as 24 A. Where are you looking at? 25 well as the response by market analysts, as well Q. I'm not looking at anything in 25 Page 446 Page 448 1 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 as the government saying or the CFTC saying, you 2 particular. 3 can no longer operate in the US, it would have --3 I'm just -- do you disagree with 4 I believe it would have, at least, caused that 4 that? 5 amount of price decline. But hence, again, the 5 A. I don't disagree or agree one way or 6 word "inextricable." 6 the other. As I sit here, I don't recall exactly 7 7 Oh, I left out FXCM lying about the that that's exactly verbatim what I said. 8 8 fact that they had a no deal desk. Because I Q. I'm not asking for --9 think the lying actually played a part in the 9 A. So if you want to point me to the 10 analyst -- I'm sorry, in the regulatory body's 10 part in the report or I can go to the part in the 11 report where I talk about the corrective decisions. 11 12 Q. Did you analyze whether the 12 disclosure. 13 revelation of the relationship between Effex and 13 Q. As a general -- as a general matter, 14 FXCM by itself, if that was the disclosed in 14 do you disagree that the information that your 15 March 15th, 2012, did you analyze whether the 15 analysis assumes is the corrective disclosure is 16 16 price reaction to the stock would have been the taken from the information contained in the CFTC 17 same as it was in February 2017, just that one 17 and NFA settlements in February of 2017? 18 piece of information? 18 MR. BAKER: Objection. 19 A. So, again, so just that they had a 19 A. Again, I refer to Paragraph 7 of my 20 relationship, not that they were possibly trading 20 report. "The alleged misrepresentations and 21 21 omissions caused the price of the Effex FXCM in front of their clients and that regulators 22 22 would -- because they had been lying to the stock and FXCM notes to be artificially inflated 23 market would shut them down or not allow them to 23 over the course of the class period. FXCM misled 24 operate in the US? 24 the market about the company's purported lack of

conflict of interest with customer transactions

25

I'm not sure that as a standalone --

25

	Page 449		Dog 451
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 451 CONFIDENTIAL - ADAM WERNER, Ph.D.
2	on FXCM's NDD platform. This in turn misled	2	A. I believe so.
3	market participants about the extent of FXCM's	3	Q. Have you heard the term "no admit no
4	exposure to regulatory scrutiny, the viability	4	deny settlement" before?
5	and sustainability of its business model and	5	A. As a general principle, yes.
6	FXCM's future profitability. The alleged fraud	6	Q. And what does that mean to you?
7	also concealed from the market the inextricable	7	A. It means that you don't admit to any
8	ramifications that would manifest upon corrective	8	wrongdoings. Nor do you deny any wrongdoing.
9	disclosures all of which in turn" excuse me	9	Q. Are you aware that FXCM settlements
10	"caused the price of FXCM securities to be	10	with the CFTC and the NFA were "no admit no deny
11	artificially inflated."	11	settlements"?
12	Q. And, again, do you disagree that the	12	A. Again, I'm happy to look at them. I
13	alleged corrective disclosure, the information	13	mean, most of these settlements are that way. It
14	that was allegedly corrective disclosure, came	14	doesn't mean you didn't do anything wrong.
15	from the CFTC and NFA settlements in February of	15	Q. Sitting here today are you aware that
16	2017?	16	these particular settlements on which you base
17	MR. BAKER: Objection to form.	17	your analysis were "no admit no deny
18	A. Well, let's go to Paragraph 17 and	18	settlements"?
19	read exactly what I say.	19	A. Well, let's look at the settlement
20	"On February 6, 2017, the US	20	agreement.
21	Commodities Future Trades Commission (CFTC) found	21	MR. BAKER: Objection.
22	that FXCM, 'engaged in false and misleading	22	A. So, I guess, my son left without me.
23	solicitations of FXCM retail foreign exchange	23	MR. ISAJIW: Evan, can you introduce
24	(forex) customers.' While FXCM told its retailer	24	the February 6th, 2017 CFTC order and let me know
25	customers that it had no conflict of interest and	25	what number that would be.
	D 450		
1	Page 450		Page 452
1 2	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on	1 2	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an	1 2 3	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c)
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that	1 2 3 4	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's	1 2 3 4 5	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume,'" end quote.	1 2 3 4 5 6	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.)
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume,'" end quote. "The market makers 'shared most of	1 2 3 4 5 6 7	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume,'" end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and	1 2 3 4 5 6 7 8	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately,	1 2 3 4 5 6 7 8 9	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did	1 2 3 4 5 6 7 8 9	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12.
2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume,'" end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order	1 2 3 4 5 6 7 8 9 10	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it.
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of	1 2 3 4 5 6 7 8 9 10 11 12	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further	1 2 3 4 5 6 7 8 9 10 11 12 13	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record,
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC	1 2 3 4 5 6 7 8 9 10 11 12 13	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume,'" end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged."	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement with the CFTC that you just referred to, are you	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to Section 60 and 60 of the Commodity Exchange Act
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement with the CFTC that you just referred to, are you aware that that settlement was a negotiated	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to Section 60 and 60 of the Commodity Exchange Act Making Findings and Imposing Remedial Sanctions.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume,'" end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement with the CFTC that you just referred to, are you aware that that settlement was a negotiated agreement between FXCM and the CFTC?	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to Section 60 and 60 of the Commodity Exchange Act Making Findings and Imposing Remedial Sanctions. Under Roman Numeral II, first
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement with the CFTC that you just referred to, are you aware that that settlement was a negotiated agreement between FXCM and the CFTC? A. I don't know if I knew that one way	1 2 3 4 4 5 6 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to Section 60 and 60 of the Commodity Exchange Act Making Findings and Imposing Remedial Sanctions. Under Roman Numeral II, first paragraph it says, "In anticipation of the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement with the CFTC that you just referred to, are you aware that that settlement was a negotiated agreement between FXCM and the CFTC? A. I don't know if I knew that one way or the other as I sit here. But I'm happy do	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to Section 60 and 60 of the Commodity Exchange Act Making Findings and Imposing Remedial Sanctions. Under Roman Numeral II, first paragraph it says, "In anticipation of the institution of administrative proceedings,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement with the CFTC that you just referred to, are you aware that that settlement was a negotiated agreement between FXCM and the CFTC? A. I don't know if I knew that one way or the other as I sit here. But I'm happy do you just want to introduce those agreements as	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to Section 60 and 60 of the Commodity Exchange Act Making Findings and Imposing Remedial Sanctions. Under Roman Numeral II, first paragraph it says, "In anticipation of the institution of administrative proceedings, Respondents have submitted an offer of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement with the CFTC that you just referred to, are you aware that that settlement was a negotiated agreement between FXCM and the CFTC? A. I don't know if I knew that one way or the other as I sit here. But I'm happy do you just want to introduce those agreements as evidence and we can review them?	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to Section 60 and 60 of the Commodity Exchange Act Making Findings and Imposing Remedial Sanctions. Under Roman Numeral II, first paragraph it says, "In anticipation of the institution of administrative proceedings, Respondents have submitted an offer of settlement, which the Commission has determined
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	that it acted only as a credit intermediary on its 'no dealing desk' platform, FXCM 'had an undisclosed interest' in the market maker that consistently 'won' the largest share of FXCM's trading volume," end quote. "The market makers 'shared most of its trading profits with FXCM." From 2010 and through 2014, FXCM received, approximately, \$77 million from the market maker, which FXCM did not disclose to its customers. The CFTC order required FXCM to pay a civil monetary penalty of \$7 million and to cease and desist from further violations of the Commodity Exchange Act and CFTC regulations as charged." Q. So, the February 6th, 2017 settlement with the CFTC that you just referred to, are you aware that that settlement was a negotiated agreement between FXCM and the CFTC? A. I don't know if I knew that one way or the other as I sit here. But I'm happy do you just want to introduce those agreements as	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Page 452 CONFIDENTIAL - ADAM WERNER, Ph.D. (Deposition Exhibit Werner 12, Order Instituting Proceedings Pursuant to Sections 6(c) and 6(d) of the Commodity Exchange Act, Making Findings, and Imposing Remedial Sanctions, was marked for identification.) MS. ENNIS: It's loaded as Exhibit 12. Q. Dr. Werner, let me know when you have access to Exhibit 12. A. Okay, I've got it. Q. On Page 1 under paragraph numbered Roman Numeral II first of all, for the record, Exhibit 12 is the Forex Capital Markets LLC, FXCM Holdings LLC, Dror Niv and William Ahdout, CFTC Order Instituting Proceedings Pursuant to Section 60 and 60 of the Commodity Exchange Act Making Findings and Imposing Remedial Sanctions. Under Roman Numeral II, first paragraph it says, "In anticipation of the institution of administrative proceedings, Respondents have submitted an offer of

Page 453 Page 455 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 2 Q. Are you aware of any other court that consent to the entry and acknowledge service of 3 this order instituting proceedings pursuant to 60 3 has already determined that the allegations in 4 and 6D of the Commodity Exchange Act, making 4 the CFTC and NFA settlements are true? 5 5 findings and imposing remedial sanctions." A. I don't believe so. 6 It says, "without admitting or 6 O. Are you aware that the CFTC itself 7 7 denying the findings or conclusions herein." has taken the position that allegations in "no 8 8 Were you aware of that condition -admit no deny" settlements are not evidence of 9 9 A. Yeah, I mean, that's pretty fraud? 10 boilerplate language. 10 A. Am I familiar with that type of 11 Q. Let me ask the question. 11 boilerplate language? A. Oh, I'm sorry. Well, you just asked 12 Q. No. I'm asking you if you're --12 me if I was aware of it, right, so I answered A. At the same time -- whoa, whoa, whoa, 13 13 14 that question. But if I interrupted you, I 14 whoa, whoa. 15 apologize. Go ahead. 15 At the same time if you're going to 16 Q. In connection with -- prior to 16 go ahead and do that, I don't understand why you 17 drafting your loss causation report, were you would agree to close down your US trading 17 18 aware that these were "no admit no deny 18 operations. 19 settlements"? 19 Q. But you do understand that you would 20 A. I don't know one way or the other, as 20 agree to do that, it was a negotiated resolution 21 21 to a regulatory inquiry, correct? I sit here today. 22 Q. Are you aware --22 A. Right. And I'm saying that me as a 23 A. But that having been said -- whoa, 23 normal person, if I hadn't done anything wrong, 24 whoa, whoa, whoa, whoa. 24 it occurs to me that I probably wouldn't have 25 That having been said, right, that 25 agreed to shut down my business. Page 454 Page 456 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 2 type of language is boilerplate. So let's go Q. In your experience, do you believe a 3 back to the -- let's go to the section of this 3 company could enter a settlement with its 4 proceeding where they talk about what they're 4 regulator for business reasons? 5 going to do in response to neither admitting or 5 A. Is it possible? Certainly, it's 6 denying any wrongdoing. 6 possible. 7 7 "Respondents and their successors and Q. And would you agree that regulatory 8 assigns shall comply with the following 8 penlites for any alleged violations could vary 9 conditions and undertaking set forth in the 9 depending on several factors in connection with a 10 offering." 10 negotiation with regulators? 11 You know what, I'm just going to 11 A. As a general principle, yeah. 12 refer to Subsection C as well as Point 4 in what 12 Q. Okay. Do you know what portion of is referred to as Werner Exhibit 12 as to what FXCM's gross revenue was generated by its US 13 13 14 informs my opinion about the language of "no deny 14 business in 2016 and early 2017? 15 no admit" and whether it's industry practice to 15 A. I believe it was somewhere between 20 include that type of boilerplate language in 16 and 30 percent. I might be off on those numbers. 16 17 these types of agreements. 17 Q. And do you know whether FXCM's net 18 Q. Are you aware that no court has 18 revenue benefitted from the closure of its US 19 determined that the CFTC and NFA allegations are 19 business? 20 true? 20 MR. BAKER: Objection to form. 21 21 A. "Benefitted" as in increased? A. I'm not sure whether or not -- I 22 don't know whether or not the courts have 22 Q. Improved. 23 A. I'm sorry, "improved"? 23 determined that or not. I mean, presumably, that 24 would be something that the Court would determine 24 Q. Yes. 25 here in this matter. 25 A. Hmm interesting question; not as I

Page 457 Page 459 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 2 sit here today. Q. In your opinion, at what point in 3 Q. Are you aware that FXCM continues to 3 time between March 15th, 2012 and February 16th, 4 operate as an online forex broker outside of the 4 2017 was it foreseeable that FXCM would settle 5 **United States?** 5 the CFTC investigation by agreeing to pay a fine 6 A. Yeah, I believe, after it declared and withdraw from the US market? 6 7 bankruptcy, it may have restructured. And so, to 7 MR. BAKER: Objection to form. 8 8 the best of my knowledge, it's still operational. A. Right. So, to the extent that you're 9 I know I looked for financials, its 9 talking about something that hypothetically would 10 current financial and because it's private 10 have occurred in 2012, I haven't seen any 11 entity, I was unable to find them, which is a 11 evidence that indicates to me that that would not long way of saying, yes, to your -- or answering have been their price reaction or, at least, the 12 12 13 yes to your question but giving it a little 13 price reaction throughout the entire class 14 14 context. period, if that statement -- if these statements 15 O. So the current financials were not a 15 or these clarifications had become known at the 16 component of your loss causation and damages 16 beginning of the class period. Q. That's not --17 analysis as expressed in your report? 17 18 MR. BAKER: Objection. 18 A. And I have reviewed all the -- well, 19 A. To the extent that I haven't seen 19 I have reviewed all the data or all of the 20 them, the current financials -- I don't believe 20 documents associated with this case, at least, to 21 21 the extent that they're reflected in my three I've seen any of their current financials. And 22 so, to the extent I haven't seen them, I don't 22 reports. 23 believe that they played any part in the 23 Q. That's not the question I asked. 24 24 formation of my opinions in this report. I asked, in your opinion, at what 25 Q. Let's take a look at Paragraph 91 of 25 point between March 15th, 2012 and February 6th, Page 458 Page 460 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 your report. Let me know when you're there. 2 27 [sic] was it foreseeable that FXCM would 3 A. Okay, I'm there. 3 settle the CFTC investigation by agreeing to pay 4 Q. In Paragraph 91 you state, "The 4 a fine and withdraw from the US market? 5 residual decline following the corrective 5 MR. BAKER: Objection to form. 6 disclosure through which the" --6 A. Yeah, I mean, I refer to my previous 7 7 A. Okay. We're in the middle. Okay, go answer. 8 8 Q. Did you analyze -ahead. 9 9 Q. Yes. A. I don't understand -- I believe 10 (Continuing.) "Through which the 10 that's responsive to your question. market learned the truth about the company's 11 11 Q. Did you analyze at what date in 12 purportedly conflict free agency model and the 12 between the start of the class period and the end 13 ramifications associated therewith, including the of the class period it would have been 13 14 company's business model would no longer be 14 foreseeable for FXCM to settle the investigations 15 sustainable and FXCM would be subject to 15 by agreeing to pay a fine and withdraw from the regulatory repercussions equals the diminution of 16 US market? 16 17 value stemming from the market's new 17 MR. BAKER: Objection to form. 18 understanding of the truth of the company's 18 A. I believe Plaintiffs contended it 19 exposure to regulatory scrutiny, systemic shocks 19 would have been foreseeable as of the date of the 20 to its business model, its future profitability 20 beginning of the class period. And I see no 21 and the market's prior underestimation of the 21 evidence to suggest otherwise. 22 risks of foreseeable ramifications had the truth 22 Q. So the class period began March 15th, 23 been disclosed." 23 2012, correct? 24 Did I read that correctly? 24 A. That is correct. 25 A. You did. 25 Q. And according to your report,

1	D 461		Page 462
1	Page 461 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 463 CONFIDENTIAL - ADAM WERNER, Ph.D.
2	Paragraph 35E	2	October 15, 2014.
3	A. Hold on; 35E. Ah, yes.	3	Q. Okay. So assuming that the NFA
4	Q. The NFA investigation started, at	4	investigation started in the beginning of
5	least, by the beginning of April 2014; is that	5	April 2014 and the CFTC investigation began at
6	correct?	6	the end of 2014 let me break that up.
7	A. "At least," yeah, certainly, "at	7	The NFA investigation started at the
8	least."	8	beginning of April 2014.
9	Q. And if you look at your report	9	So that investigation was going on
10	A. Oh, wait, I'm sorry. Wait. Whoa,	10	for nearly three years before the end of the
11	whoa, whoa, whoa.	11	class period in February 2017; is that correct?
12	I mean, "at least," yeah, it	12	MR. BAKER: Objection to form,
13	certainly could have happened prior to that.	13	assumes facts not in the record.
14	Q. What is your understanding of the	14	A. Yeah, I mean, based on your
15	date of when the NFA investigation began? Was it	15	representation, I I mean, I'll assume it's
16	on or about April of 2014?	16	correct but
17		17	
18	A. I don't I don't know one way or the other. I just know that FXCM was receiving	18	Q. And assuming the CFTC investigation
19	payment for order flow with an entity that was	19	began at the end of 2014, that would have been ongoing for more than two years before the
20		20	completion of the class period in February 2017;
20	directly related to it as of 2010. So, I mean,	20	is that correct?
$\begin{vmatrix} 21\\22\end{vmatrix}$	as to when the violation or the alleged violation	22	
23	began occurring as early as 2010. Q. And I'm asking as to when the	23	MR. BAKER: Same objection. A. I mean, again I'd use the same
24	_	24	_
25	investigations began. A. Yeah, as I sit here today, I don't	25	answer as the other question just changing the date in the entity.
23	•	23	·
	Page 462		
1	-	1	Page 464
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. know.	2	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that,	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began?
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct?	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer.
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly.	2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on.
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014,	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct?	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record. A. Yeah, I don't think that's my	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not THE WITNESS: Oh, sorry. Go ahead.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record. A. Yeah, I don't think that's my understanding one way or the other.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not THE WITNESS: Oh, sorry. Go ahead. MR. BAKER: That's it.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record. A. Yeah, I don't think that's my understanding one way or the other. Q. Do you have an understanding one way	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not THE WITNESS: Oh, sorry. Go ahead. MR. BAKER: That's it. A. I have not seen any evidence to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record. A. Yeah, I don't think that's my understanding one way or the other. Q. Do you have an understanding one way or the other as to whether or when the CFTC	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not THE WITNESS: Oh, sorry. Go ahead. MR. BAKER: That's it. A. I have not seen any evidence to suggest that that opinion is incorrect.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record. A. Yeah, I don't think that's my understanding one way or the other. Q. Do you have an understanding one way or the other as to whether or when the CFTC investigation began?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not THE WITNESS: Oh, sorry. Go ahead. MR. BAKER: That's it. A. I have not seen any evidence to suggest that that opinion is incorrect. Q. Have you done any analysis to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record. A. Yeah, I don't think that's my understanding one way or the other. Q. Do you have an understanding one way or the other as to whether or when the CFTC investigation began? A. The exact date, no, not as I sit here	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not THE WITNESS: Oh, sorry. Go ahead. MR. BAKER: That's it. A. I have not seen any evidence to suggest that that opinion is incorrect. Q. Have you done any analysis to affirmatively confirm that that opinion is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record. A. Yeah, I don't think that's my understanding one way or the other. Q. Do you have an understanding one way or the other as to whether or when the CFTC investigation began? A. The exact date, no, not as I sit here today.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not THE WITNESS: Oh, sorry. Go ahead. MR. BAKER: That's it. A. I have not seen any evidence to suggest that that opinion is incorrect. Q. Have you done any analysis to affirmatively confirm that that opinion is correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	know. Q. Okay. And if you look at Paragraph 36 of your report, it indicates that, "On or about October 15th, 2014 the CFTC sent a request to accept FXCM for production of documents and information relating to Effex's business and/or financial relationship with FXCM including but not limited to Effex's relationship as a liquidity provider to FXCM," correct? A. Yeah, you read that correctly. Q. So it's your understanding that the CFTC investigation began at the end of 2014, correct? MR. BAKER: Objection. That misstates the record. A. Yeah, I don't think that's my understanding one way or the other. Q. Do you have an understanding one way or the other as to whether or when the CFTC investigation began? A. The exact date, no, not as I sit here	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. Q. Okay. So is it your position that FXCM should have anticipated the outcome of those multi-year investigations at the start of the class period in March of 2012, two years before the investigations began? MR. BAKER: Objection, assumes facts not in the record. If you understand the question, you can answer. A. Well, I believe, that's the theory that Plaintiffs' lawsuit is based on. Q. And is that a theory you are putting forth as your opinion in this matter? MR. BAKER: Objection to form. A. I have not THE WITNESS: Oh, sorry. Go ahead. MR. BAKER: That's it. A. I have not seen any evidence to suggest that that opinion is incorrect. Q. Have you done any analysis to affirmatively confirm that that opinion is

Page 465 Page 467 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 Is it foreseeable that when they were Q. So you don't know other than what's 3 breaking CFTC regulations and lying about what 3 in your report? 4 they were doing that it was foreseeable that the 4 A. I mean, I think, my answer speaks for 5 CFTC would go ahead and fine them and tell them 5 itself. that they could not operate in the US? It's 6 6 If it's besides what's in my report? 7 certainly possible. And I, certainly, haven't 7 Are we talking about things that are besides 8 seen anything to suggest that that is not the 8 what's in my report? 9 case. 9 Q. I'm talking about whether or not 10 I mean, it's like if you ask me 10 you're offering an expert opinion as to when FXCM 11 today, okay, so, if I murdered someone today and management became aware of the NFA investigations 11 12 five years before I knew I was going to murder 12 regarding its relationship with Effex. 13 someone, is it foreseeable that I would go to 13 A. I believe I've asked and answered 14 jail five years ago? Yeah, it's foreseeable I 14 that questions multiple times now. 15 would go to jail five years ago, if I knew I was 15 Is now -- can I take a five-minute 16 going to murder someone today. 16 break? I just need to go get some water, if 17 Q. So you're talking about CFTC 17 that's okay. It doesn't even have to be five 18 regulations. 18 minutes. It can be two minutes. I'm just going 19 Do you have -- are you familiar with 19 to the kitchen. 20 the rules and regulations governing foreign 20 Q. That's fine. We can take a break. 21 exchange brokers? 21 A. Alright. I haven't heard anything. 22 A. Am I familiar with them? "Familiar," So I'm going to assume that -- -22 23 23 THE VIDEOGRAPHER: The time is yes. 24 Q. Are you offering any expert opinions 24 2:09 p.m. We're going off the record. 25 as to what rules and regulations govern foreign 25 (Recess taken 2:09 to 2:23 p.m.) Page 466 Page 468 1 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 2 exchange brokers in this matter? THE VIDEOGRAPHER: The time is 3 A. I mean, I think, we've already gone 3 2:23 p.m. and we're back on the record. 4 over what I've been asked to opine upon. I'm not 4 Q. Dr. Werner, in connection with your 5 sure that that was in that -- that would fall 5 analysis for loss causation and damages submitted 6 under what I've been asked to opine upon. in your report, did you review any prior CFTC 6 7 7 Q. Do you know if there were any rules settlements to see if similar penlites were 8 or regulations regarding foreign exchange brokers 8 imposed in comparable cases? 9 receiving payments for order flow during the 9 MR. BAKER: Objection to form. 10 class period? 10 A. No, I did not. A. Oh, just as a matter? Well, I mean, Q. And did you review any prior court 11 11 12 we already talked about this, right. We said 12 decisions in cases brought by the CFTC to see if 13 generally paying for order flow is not uncommon. 13 similar penlites were imposed in comparable 14 That's not what -- that's what's at issue in this 14 cases? 15 15 MR. BAKER: Objection to form. case. 16 A. Alright. So maybe I should give a 16 Or I should say that in and of itself 17 is not what is at issue in this case, to the best 17 little clarification. In the context of this 18 of my understanding. 18 case, no. With regards to those two questions, 19 Q. Do you know when FXCM management 19 this question and the last question, I mean, I've 20 became aware of the NFA investigations regarding 20 certainly looked at these types of agreements. 21 21 FXCM's relationship with Effex? But with regards -- but in -- with regards to 22 22 A. Well, it looks like based -- at this case, the answer is, no. 23 23 least, as of the dates that you pointed to -- me Q. Were you aware generally of any 24 to earlier. But, certainly, it could be possible 24 comparable cases where a foreign exchange broker 25 that it was before that. 25 withdrew from the US markets?

1	Page 469 CONFIDENTIAL - ADAM WERNER, Ph.D.	1	Page 471 CONFIDENTIAL - ADAM WERNER, Ph.D.
$\begin{vmatrix} 1 \\ 2 \end{vmatrix}$	A. That's an interesting question.	2	
$\frac{2}{3}$	MR. BAKER: Objection to I'm	3	recall. But we can, certainly, look at my earlier reports or I can look at my earlier
4	sorry. Objection to form.	4	reports to refresh my memory.
5	Go ahead.	5	÷ · · · · · · · · · · · · · · · · · · ·
			Q. We can pull up the opinion as well.
6	A. Not as I sit here today.	6 7	MR. ISAJIW: Evan, can you add that
7	Q. And earlier today we were discussing		to the folder please.
8	the foreseeability from FXCM's perspective of	8	A. Yeah, I mean, it's your deposition,
9	settling regulatory inquiries beginning as early as 2012.	9	whatever you'd like to do.
10		10	MS. ENNIS: It's been introduced. It
11	Do you recall that conversation?	11	was previously marked as Werner Exhibit 7.
12	A. I'm sorry. Can you repeat the	12	(Deposition Exhibit Werner 7, Opinion
13	question?	13	& Order, was previously marked for
14	Q. We had a series of questions and	14	identification.)
15	answers regarding whether or not it would have	15	Q. Okay. Let me know when you have
16	been foreseeable to FXCM in March of 2012 that it	16	access to it?
17	would ultimately have to settle regulatory	17	A. Okay, hold on one second.
18	investigations through an agreement that required	18	Huh. Exhibit 328 ah, there we go,
19	among other things withdrawing from the US	19	alright.
20	market.	20	Wait, wait, wait. The 3/28/19
21	A. I'm not I don't remember that	21	opinion?
22	specific conversation. If you want to point to	22	Q. That's correct.
23	something where we talked about that earlier	23	A. Okay. And so ah, and this is
24	Q. Is it your opinion that it was	24	Exhibit 7. Yeah, okay.
25	foreseeable to FXCM in March of 2012 that they	25	Q. Okay. Did you review this opinion in
	Page 470		Page 472
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which	2	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis?
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market?	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes.
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered.	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion.
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent	2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know.	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to jail for murdering somebody? Yeah, I know I	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose uncharged, unadjudicated wrongdoings or
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to jail for murdering somebody? Yeah, I know I know that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose uncharged, unadjudicated wrongdoings or mismanagement. Thus the Court concludes that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to jail for murdering somebody? Yeah, I know I know that. Q. Okay. Are you aware that the Court	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose uncharged, unadjudicated wrongdoings or mismanagement. Thus the Court concludes that Plaintiffs have failed to allege that FXCM made
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to jail for murdering somebody? Yeah, I know I know that. Q. Okay. Are you aware that the Court issued an opinion and order on the Defendant's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose uncharged, unadjudicated wrongdoings or mismanagement. Thus the Court concludes that Plaintiffs have failed to allege that FXCM made false or misleading statements with respect to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to jail for murdering somebody? Yeah, I know I know that. Q. Okay. Are you aware that the Court issued an opinion and order on the Defendant's motion to dismiss the complaint in this matter on	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose uncharged, unadjudicated wrongdoings or mismanagement. Thus the Court concludes that Plaintiffs have failed to allege that FXCM made false or misleading statements with respect to regulatory investigations that it was
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to jail for murdering somebody? Yeah, I know I know that. Q. Okay. Are you aware that the Court issued an opinion and order on the Defendant's motion to dismiss the complaint in this matter on March 28, 2015?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose uncharged, unadjudicated wrongdoings or mismanagement. Thus the Court concludes that Plaintiffs have failed to allege that FXCM made false or misleading statements with respect to regulatory investigations that it was undergoing."
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to jail for murdering somebody? Yeah, I know I know that. Q. Okay. Are you aware that the Court issued an opinion and order on the Defendant's motion to dismiss the complaint in this matter on March 28, 2015? A. I I'm sorry, what was the date?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose uncharged, unadjudicated wrongdoings or mismanagement. Thus the Court concludes that Plaintiffs have failed to allege that FXCM made false or misleading statements with respect to regulatory investigations that it was undergoing." Have you read that before in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. would enter into a settlement with the CFTC which would involve amongst other things withdrawal from the US market? MR. BAKER: Objection, asked and answered. A. Right. So I refer to my previous answers. I mean, certainly, the Plaintiffs contend that that was foreseeable. I haven't seen any evidence to suggest that it wasn't foreseeable to the extent to the same extent that I talked about a "murder" an example using "murder" previously, you know. If I think about murdering somebody and then actually do it five years later, do I know when I'm thinking about it that I can go to jail for murdering somebody? Yeah, I know I know that. Q. Okay. Are you aware that the Court issued an opinion and order on the Defendant's motion to dismiss the complaint in this matter on March 28, 2015?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. connection with your loss causation analysis? A. Well, to the extent it appears to be an exhibit from my earlier deposition, I suppose the answer is, yes. Q. Okay. And can you turn to Page 27 of that opinion. A. Okay. Q. And from Pages 27 to 29, the Court discusses the complaint's allegation that FXCM should have disclosed the regulatory investigations by the CFTC and NFA and the Court dismissed those claims stating on Page 28 at the bottom, "As courts in this district have repeatedly held, companies do not have an affirmative duty to speculate or disclose uncharged, unadjudicated wrongdoings or mismanagement. Thus the Court concludes that Plaintiffs have failed to allege that FXCM made false or misleading statements with respect to regulatory investigations that it was undergoing."

Page 473 Page 475 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 two times now. I don't have a -might as well read the next sentence. 3 3 "Plaintiffs are correct that in light of this Q. Let's switch gears for a moment. 4 expressed disclosure, the company was acquired to 4 Are you familiar with the "SNB flash 5 speak truthfully about any ongoing investigations 5 crash"? 6 that it was undergoing." 6 A. Are you speaking of the crash in 7 7 2015? Q. In your view, is something that is "speculative," "uncharged," "unadjudicated" 8 8 Q. I am. 9 foreseeable? 9 A. Is there a reason -- so, to the 10 MR. BAKER: Objection to form. 10 extent that this -- I've discussed it numerous 11 A. Again, I mean, I hate to keep going 11 times in my previous reports; is there an back to this simple example. But look, again, if 12 12 indication that I'm not familiar with it? 13 I think about murdering someone five years ago 13 Q. Do you know whether the SNB flash 14 and I end up doing it today, was it foreseeable 14 crash affected the CFTC and NFA investigations? 15 that I could go to jail five years ago when I was 15 MR. BAKER: Objection to form. 16 thinking about killing somebody? Yeah, it was 16 A. As I sit here, I don't know one way 17 17 foreseeable. or the other. 18 I mean, it's the same issue. We keep 18 Q. Do you know whether the CFTC and NFA coming back to this. My understanding is, you investigations concerning the Effex relationship 19 19 20 know, this behavior began in 2010, which is two 20 were paused prior to the SNB flash crash? 21 21 A. I don't have knowledge of that one years before the class period. 22 Look, if I'm doing something illegal, 22 way or the other. 23 is it foreseeable I might go to jail some day? 23 Q. Do you know whether those 24 24 Yeah, I'm certainly going to weigh that in or investigations restarted after the flash crash? 25 look at that as a real possibility. 25 A. I don't know one way or the other. Page 474 Page 476 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 So I'm not sure where all these Q. If those investigations were paused 3 questions going. I mean, I understand where all 3 prior to the flash crash, is it still your 4 these questions are going, but, you know, my position that FXCM should have foreseen that it 5 answer is going to be the same. 5 would have to withdraw from the US business 6 Plaintiffs believe it was 6 before the flash crash? 7 7 foreseeable. I see no evidence to indicate that A. I mean, we're -- we keep going over 8 8 it's not foreseeable. And if you're asking me is this. So that's -- I believe that's what the 9 it foreseeable I'm going to be punished for 9 Plaintiffs are alleging. 10 something that I'm doing in the past which I know 10 Again, I'll go back to the "murder" to be legal? Yeah, it's foreseeable. example because I think it's simple. If I'm 11 11 12 Q. And you are aware that the Court has 12 thinking about committing murder and, you know, I 13 already dismissed Plaintiffs' claims of 13 have committed murder and there's an 14 misstatements relating to the regulatory 14 investigation of me having committed murder and 15 investigation in this case, correct? 15 that investigation pauses and starts up again at 16 A. Right, in the same way that I am 16 some point in the future and I'm charged with 17 familiar with the fact that Plaintiffs are 17 murder, if you're asking me if it was foreseeable 18 correct, that in light of the expressed 18 that I was going to be charged with murder, yeah, 19 disclosure, the company was required to speak 19 it was foreseeable that that was a real 20 20 truthfully about any ongoing investigations that possibility. 21 21 it was undergoing. I mean, if my analogy doesn't work, 22 22 Q. And it dismissed the claims related go ahead and tell me why but... 23 23 to the allegations that it didn't do so, correct? Q. Yeah, I mean, I struggle with that 24 A. I don't -- I'm not sure how else to 24 analogy on a multitude of levels. But I think I 25 answer that question. I think I've answered it 25 now have your best testimony on it, which is all

Page 477 Page 479 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 flow stopped in August 2014, is it your opinion that I'm looking to get. 3 3 I believe I asked you before and you that FXCM continued to have a conflict of 4 conceded that pay for flow arrangements in 4 interest with its customers after August of 2014? 5 general weren't prohibited under the CFTC 5 A. Hmm. That's an interesting question. 6 application's rules and regulations, correct? I don't know what FXCM was doing. But, I mean, 6 7 7 A. I believe that's what I stated, yes. look, this case isn't strictly about payment for 8 MR. BAKER: Objection to the form --8 order flow. It's about not explaining the true 9 THE WITNESS: Go ahead. Sorry, Josh. relationship between the two entities where this 10 MR. BAKER: Objection to the extent 10 order flow is occurring. I mean, this was the 11 that it misrepresents prior testimony. 11 only firm that was paying for order flow. 12 12 But you can answer. I mean, there's all sorts of 13 A. Alright. So I refer to my prior 13 tangential facts here that you're ignoring. So, 14 testimony. But, in general -- in general, so not 14 to the extent that I can give you an accurate 15 in this case specific, you know, there's payment 15 answer with regards to the fact specific issues 16 for order flow. That's not unusual. 16 of this case, it's really -- it's really 17 17 Q. Let's switch gears. difficult to do that. 18 Would you agree that information that 18 If you're asking me as general practice do people pay for order flow? That's my 19 is value relevant to investors -- sorry, let me 19 20 20 ask a better question. understanding. 21 21 So going back to my crime analogy, if Do you agree that information would 22 be value relevant to investors if it has an 22 I stopped committing crimes in 2014, is it 23 23 foreseeable that I might be punished for that? impact on the future cash flows of a company? 24 A. I mean, there's all sorts --24 2019? Yeah, it's foreseeable that I still might 25 generally, I believe your statement is correct. 25 be punished for crimes that I stopped committing Page 478 Page 480 1 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 2 I mean, there's all sorts of qualifiers you in 2014. 3 should probably put in there like material 3 Q. The question that I asked you is 4 information. I mean, look if my cash flows are 4 whether or not you had an opinion as to whether 5 going to increase by a dollar and I earn a 5 FXCM continued to have a conflict of interest 6 billion dollars a years, is that going to make a with its customers after August 2014 when the 6 7 7 big difference to the market? Probably not. payment for order flow stopped? 8 8 So a it's poorly worded question. To MR. BAKER: Objection, asked and 9 the extent that you're talking about in general, 9 answered. 10 it's probably -- it's not an inaccurate 10 A. Yeah, I answered that question. I refer to the same answer I just gave or the 11 statement. 11 12 Q. Are you aware that Effex stopped 12 answer to that specific question that I paying FXCM for order flow before the end of the 13 13 previously gave. 14 class period? 14 Q. Do you have an opinion as to whether 15 15 the nature of the information FXCM should have A. That is my understanding. disclosed to the market changed after August 2014 16 Q. And are you aware that Effex stopped 16 17 paying FXCM for order flow as of August of 2014? 17 when Effex stopped paying FXCM for order flow? 18 A. I believe that jogs with my 18 MR. BAKER: Objection to form. 19 recollection. 19 A. Yeah, I don't understand the 20 Q. And are you aware that FXCM 20 question. 21 publically disclosed in its SEC filings that it 21 Q. Did you do any analysis to determine 22 had stopped receiving payments for order flow as 22 whether or not the nature of the information that 23 of August 1, 2014? 23 FXCM should have disclosed to the market changed 24 A. I am, yes. 24 after August 2014 when the payment for order flow 25 Q. Given that the payments for order 25 stopped?

Page 481 Page 483 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 MR. BAKER: Same objection. date, to make sure I give an accurate response to 3 3 A. Same answer. your question. 4 4 Q. Given that the payment for order flow Right, so to save time, all of my 5 opinions about that and the full scope of what 5 relationship stopped in August of 2014, what was disclosed on that date can be found in 6 impact could the disclosure of FXCM's prior pay 6 7 7 Paragraph 17 of my report. for flow relationship with Effex have on the 8 8 future value of FXCM going forward beyond August Q. Okay. So one of the things the market learned on February 6th, 2017 was of the 9 of 2014? 10 A. Well, presumably, something similar 10 CFTC's allegation that FXCM had an undisclosed interest in Effex. 11 11 to what happened at the end of the class period. 12 12 Q. And you believe what happened at the Would you agree with that? 13 end of the class period was, specifically, 13 A. It had an "undisclosed interest in 14 the market maker that consistently won the 14 related to the revelation of the prior payment 15 15 largest share of FXCM's trading volume." That's for order flow relationship with Effex? 16 from Paragraph 17. And "the market maker" we're 16 A. Most certainly, among other things. discussing there is Effex or Effex, however you 17 I mean, that's what we keep talking. And let's 17 18 want to pronounce it. 18 go back to my report. Where is it? 19 19 I think it's -- and, again, it takes Q. Another piece of information that was 20 disclosed to the market on February 6th, 2017 was 20 me a little while to get there. I'm pretty sure 21 that FXCM had agreed to pay a \$7 million fine and 21 if I remember correctly it's Paragraph 7 or 8 in 22 my report. Bup, bup, bup... 22 withdraw from the US business. 23 23 Yeah, this -- thus correct -- and Do you agree with that? 24 24 this is Paragraph 8 of my report, "Thus A. I believe that's correct. 25 Q. In your analysis for loss causation 25 corrective disclosures and their inextricable Page 482 Page 484 1 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 ramification dissipated artificial inflation of 2 and damages, did you assume that both of these 3 the prices of FXCM securities and thereby caused 3 pieces of information, one, the undisclosed 4 investor losses." 4 relationship with Effex and, two, the withdraw of 5 Q. Okay. Putting aside any regulatory 5 the US business were corrective of the alleged 6 ramifications, is it your opinion that the 6 fraud? 7 7 disclosure of FXCM's prior relationship with MR. BAKER: Objection to form. 8 8 Effex impacted the value of FXCM after A. Yeah, I -- well, again, I turn to 9 August 2014? 9 Paragraph 8 of my report. These things are all 10 MR. BAKER: Objection to form. 10 inextricably linked. Q. And did you assume that both of these 11 A. Yeah, I mean, that's an incomplete 11 12 hypothetical. I mean, it's not even an 12 pieces of information contributed to the decline 13 incomplete hypothetical. It's just a 13 of the price for the FXCM securities? 14 hypothetical that I have no ability to answer one 14 MR. BAKER: Objection to form. 15 way or the other. 15 A. I mean, I think my report speaks for itself with regards to that question. 16 It assumes facts not in evidence. I 16 17 don't know. I'm not a lawyer. 17 Q. Did you attempt to quantify the price 18 Q. Let me try to ask it a different way. 18 impact of each of those pieces of information 19 On February 6, 2017, the market 19 separately? 20 learned of the CFTC's allegation that FXCM had an 20 A. Well, to the extent that I believe 21 they are inextricably linked, I don't think it's undisclosed interest in Effex; is that correct? 21 22 22 A. Are you reading from somewhere? -- it would be very difficult or next to 23 23 Q. I am not. I'm just asking you -impossible to do that type of analysis. 24 A. Alright. So let's go to my 24 Q. Is it possible that the price 25 discussion of the news that's released on that 25 reaction for FXCM securities was entirely

1	Page 485	1	Page 487
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	attributable to the withdraw from its US business	2 3	implications for FXCM of operating as a dealing
3 4	as opposed to attributable to the undisclosed interest in Effex?	3 4	desk versus a no dealing desk in connection with your work in the loss causation and damages
5	MR. BAKER: Objection.	5	report?
	THE WITNESS: I'm sorry. Go ahead,		-
6 7	Josh.	6	A. I valued FXCM well, I don't
8	MR. BAKER: Objection to the form.	8	believe so. I mean, there is an implication that I did do that because we're talking about the but
9	Go ahead.	9	for world and the actual world. And so, to the
10	THE WITNESS: Sorry.	10	extent that there's a corrective disclosure at
11	A. So you're using that word "possible"	11	the end of the class period, it's implied that I
12	again. And I don't know. I mean, I don't know	12	looked at that.
13	what absurd example you want me to come up with.		Q. But you did no explicit analysis in
14	But when you ask the word, "is it	14	connection with that?
15	possible," short of something being a hundred	15	A. "Explicit"? I mean, again, to the
16	percent, something happening with a hundred	16	extent that I looked at the price decline at the
17	percent, something happening with a hundred percent certainty, it's possible.	17	end of the class period, I don't know if that is
18	Q. And is it also possible that the	18	falls under your rubric of "explicit."
19	price reaction was mostly attributable to FXCM's	19	Q. Does your loss causation and damages
20	withdraw from the US market, as opposed to the	20	analysis include an analysis of Plaintiffs'
21	undisclosed interest with Effex?	21	allegation relating to any GAAP violations?
$\begin{vmatrix} 21\\22\end{vmatrix}$	MR. BAKER: Same objection.	22	MR. BAKER: Objection.
23	A. Again, it's again, it's a poorly	23	A. So
24	worded question. "Is it possible?" I mean, I	24	THE WITNESS: Oh, sorry. Go ahead,
25	referred back to my previous discussions about	25	Josh.
25	referred back to my previous discussions about	23	30311.
1	Page 486	1	Page 488
1	CONFIDENTIAL - ADAM WERNER, Ph.D.	1	CONFIDENTIAL - ADAM WERNER, Ph.D.
2	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of	2	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form.
2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility.	2 3	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine.
2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I	2 3 4	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've
2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a	2 3 4 5	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct.
2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible.	2 3 4 5 6	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are
2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not	2 3 4 5 6 7	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of
2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each	2 3 4 5 6 7 8	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation.
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately,	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or
2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct?	2 3 4 5 6 7 8 9	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting.
2 3 4 5 6 7 8 9 10	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and	2 3 4 5 6 7 8 9 10 11	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this
2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered.	2 3 4 5 6 7 8 9 10 11 12	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone
2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that	2 3 4 5 6 7 8 9 10 11 12 13	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they
2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered."	2 3 4 5 6 7 8 9 10 11 12 13 14	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I
2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered,"	2 3 4 5 6 7 8 9 10 11 12 13 14 15	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my previous answer to that question, which I think	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not restate its financial statements following the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my previous answer to that question, which I think has been asked a couple of times now.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not restate its financial statements following the CFTC and NFA settlements; is that right?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my previous answer to that question, which I think has been asked a couple of times now. Q. In connection with your work for the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not restate its financial statements following the CFTC and NFA settlements; is that right? A. At what point in time?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my previous answer to that question, which I think has been asked a couple of times now. Q. In connection with your work for the loss causation and damages report, did you	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not restate its financial statements following the CFTC and NFA settlements; is that right? A. At what point in time? Q. After the CFTC and NFA settlements.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my previous answer to that question, which I think has been asked a couple of times now. Q. In connection with your work for the loss causation and damages report, did you analyze whether an agency or no dealing desk	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not restate its financial statements following the CFTC and NFA settlements; is that right? A. At what point in time? Q. After the CFTC and NFA settlements. A. So immediately after?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my previous answer to that question, which I think has been asked a couple of times now. Q. In connection with your work for the loss causation and damages report, did you analyze whether an agency or no dealing desk model is preferable to a principal or dealing	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not restate its financial statements following the CFTC and NFA settlements; is that right? A. At what point in time? Q. After the CFTC and NFA settlements. A. So immediately after? Q. At anytime after.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my previous answer to that question, which I think has been asked a couple of times now. Q. In connection with your work for the loss causation and damages report, did you analyze whether an agency or no dealing desk model is preferable to a principal or dealing desk model from a valuation standpoint for FXCM?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not restate its financial statements following the CFTC and NFA settlements; is that right? A. At what point in time? Q. After the CFTC and NFA settlements. A. So immediately after? Q. At anytime after. A. Well, I don't know. I haven't seen
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. the possibility about the theory of possibility. You know, "is it possible?" I again, anything's possible, unless there's a hundred percent chance that it's impossible. Q. And, in your analysis, you did not attempt to quantify the price reaction for each of those pieces of information separately, correct? MR. BAKER: Objection, asked and answered. THE WITNESS: I'm glad you said that because I was about to say "asked and answered." A. Or instead of "asked and answered," since I'm not the lawyer here, I refer to my previous answer to that question, which I think has been asked a couple of times now. Q. In connection with your work for the loss causation and damages report, did you analyze whether an agency or no dealing desk model is preferable to a principal or dealing	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	CONFIDENTIAL - ADAM WERNER, Ph.D. MR. BAKER: Objection to form. That's fine. A. So, as I've stated previously, I've assumed that Plaintiffs' allegations are correct. I have not seen anything to suggest that they are incorrect. I mean, based on my understanding of accounting is what they did a GAAP violation. I'm not sure I've been preferred here as or proffered here as an expert on accounting. I believe and don't quote me on this and I, certainly, wouldn't want to charge someone for this opinion, but it was a GAAP what they did was a GAAP violation, but I am not sure as I sit here today. Q. You're aware that FXCM did not restate its financial statements following the CFTC and NFA settlements; is that right? A. At what point in time? Q. After the CFTC and NFA settlements. A. So immediately after? Q. At anytime after.

Page 489 Page 491 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 2 if you use DCF analysis. So it's implied. But if you want to stipulate to that, I'll -- I have 3 no reason to think you're wrong. 3 if you're asking if I separately did a DCF cash 4 Q. Do you offer any opinion in your loss 4 flow analysis for this, I did not. 5 causation and damages report about a purported 5 Q. Okay. And did you apply a return corrective disclosure with regard to GAAP and retribution analysis? 6 6 7 7 FXCM's accounting? A. I'm not sure I've ever heard of that, 8 A. My report speaks for itself as to 8 "a return retribution," like I'm getting revenge 9 what I've considered. And so, you know, I refer 9 on somebody? 10 to Paragraph 7 of my report as to what I looked 10 Q. I'm sorry, a return attribution. at in forming this -- that's what I've been asked 11 11 A. Oh, okay. 12 to do. 12 Q. I apologize. 13 Q. Are you aware that the CFTC and NFA 13 A. It's been a long day. Sorry. settlement do not address FXCM's compliance with 14 14 A "return attribution analysis"? So 15 GAAP? 15 do you mean attributing a return -- different 16 MR. BAKER: Objection, assumes facts 16 parts of a return to different factors? 17 17 not in the record. Q. So I, actually, am looking to get 18 A. I don't know one way or the other as 18 that information from you. What I -- let me back up and maybe this will give it more context. 19 I sit here. 19 20 Q. I think this would be a good time to 20 A. Okay. 21 take another short break. Maybe give us ten 21 Q. In your market efficiency reports, 22 minutes so I can regroup and see how much further 22 you did not perform a loss causation and damages 23 23 analysis, correct? we have. 24 24 MR. ISAJIW: So let's go off the A. That is correct, yes. 25 25 Q. But if you recall, there were record. Page 490 Page 492 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 THE VIDEOGRAPHER: The time is 2 discussions about how you would potentially 3 2:51 p.m. We're going off the record. 3 conduct such analysis in those reports; is that 4 (Lunch recess taken 2:51 to 4 correct? 5 5 A. I do not recall. It's possible. I p.m.) 6 THE VIDEOGRAPHER: The time is don't recall those conversations, as I sit here 6 7 7 3:55 p.m. and we're back on the record. today. 8 8 Q. Dr. Werner, just a few more questions Q. Fair enough. 9 hopefully to finish this up. 9 Can you take a look at your rebuttal 10 In connection with your loss 10 report, which is Exhibit 9. causation and damages analysis, did you use 11 11 A. Exhibit 3... Hold on. Sorry. 12 valuation multiple models? 12 Rebuttal report, okay, I've got it. 13 A. Did I use "valuation multiple 13 Q. And you recall that -- and I'm not 14 models"? Hmm. I think I know what you're 14 looking for specifics here. Just at a very 15 talking about. Can you give me an example? general level, Dr. Hendershott -- Professor 15 16 Q. I can't. But let's put a pin on that 16 Hendershott submitted a report where he had 17 and I'll ask another question and come back to 17 criticisms of your potential loss causation 18 18 analysis; is that correct? it. 19 A. Okay. 19 A. Well, so, to the extent that I didn't Q. Did you use a discounted cash flow 20 20 perform a loss causation analysis for that 21 21 report, I don't -- I'm not sure I would 22 A. Well, I mean -- okay, so that's a 22 characterize it that way or I'm not sure that 23 difficult question to answer only to the extent 23 that's an accurate characterization of what Dr. 24 that, you know, the change in the stock price 24 Hendershott did. 25 will be -- should reflect the same answer you get 25 Q. Fair enough.

Page 493 Page 495 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 If you look at Paragraph 83 of your I did not try to -- to the extent that it was --3 rebuttal report on market efficiency. 3 one would be unable to disentangle those 4 A. Hold on. Sorry. 4 attributes or whatever you want to call it. No, 5 Okay, yeah, I'm there. 5 I did not do that. 6 Q. And then if you take a look at 6 O. Okav. 7 Paragraph 85 of your -- of the same report. 7 A. So, again, I considered doing it, but 8 A. Okay. 8 I did not. 9 9 Q. And in Paragraph 85 in response to Q. Thank you. 10 Dr. Hendershott's criticisms you note, "The 10 In Paragraph 8 of your loss causation 11 Forensic analyst has in their employ a variety of 11 report you state that, "Following the corrective valuation tools designed to accommodate the disclosure, analyst valuation models reflected 12 12 13 potential valuation complexities identified by 13 the reality that the company could no longer 14 Dr. Hendershott. Among the commonly used 14 operate the business in the US and that FXCM had 15 valuation tools that are available are valuation 15 previously misrepresented the veracity of its 16 multiple models such as those based on earnings, 16 agency business model." 17 EBITDA, revenue, book value and cash flow." 17 But you don't cite to any analyst 18 Did you use any of those valuation 18 reports in support of that statement in 19 multiple models in connection with your loss 19 Paragraph 8. 20 causation and damages report? 20 Do you know which analyst reports 21 21 A. So I would answer the question this you're referring to? 22 way. I considered all of those models in 22 A. The collection of analyst reports 23 23 that came out after February 6th of that year. presenting my opinions in my loss causation 24 report, which is Exhibit 8. But I did not -- I 24 Q. Any ones in particular that you're 25 did not present any of those. That's probably 25 referring to where the "analyst valuation models Page 494 Page 496 1 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 the wrong way to say it. 2 reflected the reality that the company could no 3 I did not -- I considered those 3 longer operate its business in the US"? 4 analyses. I did not perform any of them. 4 A. So what I would suggest if we really 5 Q. Okay. And so that's true for the 5 want to go through this is let's look at my --6 discounted cash flow and the return attribution well, I don't know what exhibit, maybe Exhibit 2 6 7 7 analyses as well? to my original report. 8 8 A. Well, to the extent -- and I hate to I guess what I would say is let's 9 keep taking -- bringing you back to this 9 take a look at all of the analyst reports that were issued after February 6th, 2017. I can walk 10 sentence. To the extent that -- let's just make 10 through each one of those and talk about the 11 sure. 11 12 And I'm reading from Paragraph 7 of 12 extent that those -- the information contained in my report in this matter. The alleged fraud --13 13 those are responsive to your question. 14 or I should say so Exhibit 8. The fraud -- "The 14 Q. Is it fair to say that you're 15 alleged fraud also concealed from the market the 15 referring just generally to those analyst reports inextricable ramification that would manifest as opposed to a specific analyst report that 16 16 17 upon corrective disclosures, all of which in turn 17 you're citing in Paragraph 8? So the totality of 18 caused the price of FXCM's securities to be 18 those analyst reports as opposed to one 19 artificially inflated." 19 individual? I'm just trying to get a sense of 20 20 So, to the extent that there were the universe of documents that are relevant? 21 "inextricable ramifications" with regard to those 21 A. Sure. And so I'm not sure that that 22 returns, I did not -- and I think we discussed 22 is a correct characterization. I think to give 23 this at length earlier. 23 you the best possible answer I could, I would 24 I did not attribute -- I attributed 24 need to look at each one of those reports

25

individually.

the entire decline to the corrective disclosures.

25

Page 497 Page 499 CONFIDENTIAL - ADAM WERNER, Ph.D. CONFIDENTIAL - ADAM WERNER, Ph.D. 1 1 2 2 Q. I'm not going to ask you to do that Q. Have you ever used a constant 3 3 here because there are a number of them and I percentage inflation ribbon in a loss causation 4 4 think that would be cumbersome. analysis? 5 5 Have you reviewed the expert report A. So, just so we're clear -- and when of John Barron, which was submitted by Plaintiffs 6 6 you say, "loss causation analysis," do you 7 7 include like any damage analysis? Because, in this matter? 8 8 A. As I sit here, I don't recall. certainly, I have used a percentage base ribbon 9 9 Q. I want to take a look at Paragraph 95 in damage analysis, which I have not submitted as 10 of your report. Again, it's the loss causation 10 expert testimony. It is possible that in a -report when I say "your report." 11 11 that I can think of maybe one case -- excuse me 12 A. Okay. 12 -- where I may have used a percentage ribbon --13 Q. And in Paragraph 95, you conclude --13 constant percentage ribbon in a loss causation 14 14 report. But, you know, that's the best of my I'm sorry. 15 In Paragraph 95 you state, "For a 15 recollection. 16 number of reasons, a stable dollar based ribbon 16 Q. Just to narrow it down to loss 17 is the more conservative inflation ribbon design 17 causation and damages reports that you have 18 in the instant case." 18 submitted in connection with securities fraud 19 Did I read that correctly? 19 cases, have you used a constant percentage 20 20 inflation ribbon methodology? A. You did, yeah. 21 21 Q. Are you saying that in your loss A. Without looking at each one of those 22 causation and damages report you considered using 22 reports, I would say it's not -- it's not likely, 23 both a stable dollar based ribbon and a 23 but it is possible. 24 24 percentage inflation based ribbon? Q. Are you aware of any court decisions 25 A. Did I consider it? I mean, I suppose 25 that have accepted the use of a constant Page 498 Page 500 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 there's an implication that I considered it. I 2 percentage inflation ribbon in connection with 3 mean, to the extent that whenever I calculate 3 loss causation and damages analysis in a 4 damages, I mean, I think about different ways to 4 securities fraud case? 5 calculate inflation. 5 A. As I sit here today, I don't know one 6 Q. So, In Paragraph 90 -- I'm just way or the other what courts have done with 6 7 7 trying to get a sense of the process here. regard to constant percentage ribbon. 8 8 In Paragraph 94 you say, "The design Q. Later on in Paragraph 95, second to 9 of the inflation ribbon can either be dollar 9 last sentence you say, "Empirically observed 10 based or percentage based." 10 declines elicited by disclosure at the end of the class period would therefore have had a bigger 11 And I'm just trying to understand if 11 12 between Paragraphs 94 and 95 you're saying that 12 effect if the disclosure had occurred earlier." 13 you considered a dollar based and a percentage 13 Are you saying there that using 14 based and then determined that the dollar base 14 constant dollar inflation in this case is more 15 15 was the more conservative of the two possible conservative than using some form of time varying 16 16 options? inflation that accounts for differences in --17 A. Well, in this example, by definition 17 earlier in the class period? 18 it's the more conservative of the two options. 18 A. I don't think that's -- I don't think 19 In other words, if I were to use a percentage 19 that's what I'm saying. I'm just suggesting 20 based decline per share -- I mean, I'd have in 20 that, certainly, my estimate of inflation is a 21 21 and out damages and per share damages, floor, not a ceiling. 22 22 ultimately -- you know, I should say aggregate Q. Did you consider conducting an 23 damages, whatever they turn out to be, would be 23 analysis for damages that would measure inflation 24 significantly higher than what would be estimated 24 as it could vary over time during the class

25

period?

when one uses a constant dollar inflation ribbon.

25

Page 501 Page 503 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 2 2 analyst reports and couple of SEC documents. I A. Yes. 3 3 Q. Why did you determine not to use that mean, I basically reviewed documents including 4 methodology for a measure of inflation? 4 reports in this matter. 5 A. Because I saw no evidence to suggest 5 Q. Okay. And is it fair to say 6 that that would be appropriate. consistent with my understanding of your prior 6 7 7 testimony that those documents would have been Q. And what types of evidence would, 8 8 generally speaking, suggest that that type of the documents that you cited to in your reports, 9 9 methodology would be appropriate? any of the three in one way or another? 10 10 A. In this matter, I'm not quite sure. A. Well, so you've given a couple of 11 I mean, it's going to vary from case to case. 11 examples of things that I may have reviewed. So You know, I mean, yeah, I'd be speculating at I don't remember reviewing the Judge's opinion 12 12 13 this point as to what the proper answer to that 13 with regards to market efficiency in preparing 14 question is. But, generally, I mean, there is a 14 for this deposition. I mean, did I -- it's 15 whole host of factors that could influence that 15 possible I glanced at it. I don't think I 16 decision. 16 discussed any of the deposition testimony that 17 17 you referred to earlier that I may have Q. So is it fair to say that you could 18 have performed an analysis for the inflation 18 previously seen. So I think that's a fair 19 19 ribbon that would have taken into account characterization. 20 variations of inflation during different points 20 Q. So, other than the meetings that you 21 21 just discussed with Mr. Baker and, I believe, of the class period, but determined that the 22 constant dollar inflation ribbon methodology was 22 there's one other member of your support staff at 23 the one that you would use in this case? 23 Crowninshield -- the name is escaping me -- were 24 24 A. Well, so, again, I believe to the there any other meetings in preparation for this deposition with anybody else? 25 extent -- based my understanding of the facts and 25 Page 502 Page 504 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 1 CONFIDENTIAL - ADAM WERNER, Ph.D. 2 2 not seeing any evidence to the contrary, I A. I may have just had a discussion with 3 believe, the methodology I used was the most 3 Mr. Walia, who is the other person in the meeting 4 conservative. 4 yesterday. I may have had a couple of 5 Now, ultimately, if the Court were to 5 conversations with him over the course of 6 come out and find that there were other things reviewing for my deposition, but that would be 6 7 7 that changed the inflation during the class it. I mean, those conversations wouldn't have 8 8 period, I'd certainly need to take that into lasted more than a couple of minutes. 9 9 consideration in re-estimating a possible Q. Give me one more minute. 10 inflation ribbon. 10 Okay. With that I think that is all Q. Okay. Thank you for that. the questions I have for you today. Again, I 11 11 12 Give me one second please. 12 thank you for your time today. 13 13 MR. ISAJIW: Josh, do you have 14 Q. How much time did you spend preparing 14 anything? 15 for this deposition? 15 MR. BAKER: No, thank you. A. Total? Less than ten hours. 16 16 Thank you. 17 Q. And what did you to do prepare for 17 Q. So I'll give you back the rest of the 18 this deposition? 18 day. Thank you, sir. 19 A. I re-read most of my -- all of my --19 A. Fantastic. Thank you. 20 THE VIDEOGRAPHER: The time is or all of the reports in this, matter, not just 20 21 21 mine, to the extent that I referred to them in my 4:16 p.m. We're going off the record. 22 22 reports. I had a conversation -- I spoke with (Time noted 4:16 p.m.) 23 23 Mr. Baker for about -- with Nariner Walia for 24 about 45 minutes I believe yesterday. I mean, I 24 25 probably -- I probably looked at a couple of 25

1 2 3 4	Page 505 CERTIFICATE OF DEPONENT I have read the foregoing transcript of my deposition and except for any corrections or	1 2 3 4	1 ERRATA SHEET VERITEXT/NEW YORK REPORTING, LLC 2 CASE NAME: In Re Global Brokerage, Inc. 3 DATE OF DEPOSITION: 6/4/2021 WITNESSES' NAME: Dr. Adam Werner	Page 507
1	• •	5		
5	, ,			
6	subscribe to the transcript as an accurate record	6	6	
7	of the statements made by me.	7	7	
8	·	8	8	
9				_
′		9	9	
1.0	- A DALLA WEED WED. DU D.	10	0	
10	ADAM WERNER, Ph.D.	11	1	
11				
12	SUBSCRIBED AND SWORN before and to me	12		
13	this day of, 20	13	3	
14	,,	14	4	
15		15	5	_
1		13		
16		16	6	
17	NOTARY PUBLIC	17	7	
18		18	8	_
19				
20	My Commission expires:	19	9	
21		20 21		
22		21	Dr. Adam Werner	
23		22	22 SUBSCRIBED AND SWORN TO BEFORE ME THIS DAY OF, 20	
		23	3	
24		24	4	
25		25	(NOTARY PUBLIC) MY COMMISSION EXPIRES:	
	Page 506			
1	CONFIDENTIAL - ADAM WERNER, Ph.D.			
2	CERTIFICATE OF REPORTER			
3	I, SILVIA P. WAGE, a Certified Shorthand			
4	Reporter, Certified Realtime Reporter and Registered			
5	Reporter, herby certify that the witness in the			
6	foregoing deposition was by me duly sworn to tell			
7	the truth, the whole truth, and nothing but the			
8	truth in the within-entitled cause; that said			
9	deposition was taken down in shorthand by me, a			
10	•			
11	therein stated, and that the testimony of the			
12	said witness was thereafter reduced to			
1				
13	typewriting, by computer, under my direction and			
14	*			
15	deposition, review of the transcript [X] was []			
16	was not requested. If requested, any changes			
17	made by the deponent (and provided to the reporter)			
18	during the period allowed are appended hereto.			
19				
1	•			
20	*			
21	the said deposition, nor in any way interested in			
22	nd that I am not			
23	es thereto.			
24	a Comak			
25	License No. 30X100182700 dated: June 8th, 2021.			

[**& - 395**] Page 1

	112.21 111.0 15	162.25 6 0 10	24 249.22
&	443:24 444:8,15	463:2,5,6,8,18	24 348:23 26 363:24 364:6
& 330:9 331:12,23	445:4,22 446:15	478:17,23 479:2,4	
333:22,24 334:2	459:3,25 460:22 462:5	479:22 480:2,6,16	366:5,11,18 420:4 27 331:10 340:25
351:7 380:12,15		480:24 481:5,9	
380:19,22,25	16.31 387:12	482:9	341:6 460:2 472:6
471:13	16th 459:3	2015 353:4 470:22	472:9
0	17 440:21 443:7	470:24 475:7	28 470:22,24
00916 328:4	449:18 483:7,16	2016 456:14	472:13
	18 350:19 351:25	2017 347:16 348:3	28th 470:25 29 472:9
1	371:7 18th 391:4	348:19,23 358:16	
1 331:21 339:21		371:2,20 372:21	2:09 467:24,25
342:20 347:6,6	19046 330:5	374:4,10,22	2:23 467:25 468:3
348:8 391:12	1:10 427:20,21	387:17 442:13	2:51 490:3,4
452:12 478:23	1:17 328:4	443:7 444:2,6	2s 382:18
10 331:11,22	1:19 427:21	445:7 446:17	3
339:23 351:3	429:12	447:17,22 448:17	3 331:20 332:7,8
352:11 363:15	2	449:16,20 450:16	339:14,20 353:20
375:7 379:7 391:6	2 342:10,17 346:14	451:24 456:14	376:21 393:11
100 387:12	349:14 352:6	459:4 463:11,20	492:11
10036-2601	375:18,21 376:14	482:19 483:9,20	3.13. 371:18
330:11	376:24 378:6	496:10	3.39 385:20 387:7
101 330:4	379:5,13 381:12	2018 347:9 392:3	387:18
10th 339:14	381:23 384:18	2019 479:24	3/28/19 471:20
11 331:12 351:6	496:6	2020 331:10,22	30 456:16
385:18 386:23	2.25 347:8 392:2	339:14,23 341:2,6	30x100182700
387:5,22 426:13	20 456:15 505:13	350:24 376:15	506:25
1185 330:10	507:22	378:7 417:3	32 411:24 412:5,6
11:03 329:4 333:3	2010 450:8 461:20	440:21	328 471:18
12 331:13 387:15	461:22 464:25	2021 328:10 329:3	334 331:4
452:2,8,10,14	473:20	331:8 333:4	336 331:7
454:13	2012 347:16 348:3	336:11,17,25	339 331:20
12:12 388:21,22	348:18 358:9,16	350:19 351:25	341 331:9
12:19 388:22,24	358:21 359:18	391:4 506:25	351 331:11,12
14 392:4	442:14 443:4,17	21 331:8 336:11,17	35e 461:2,3
15 338:22 358:16	443:24 444:8,16	336:25	36 462:4
358:21 359:18	445:4,22 446:15	212 330:11	37 343:14,23 344:3
463:2	459:3,10,25	215 330:5	352:9,13 392:23
150 371:6	460:23 464:5	21st 343:24 355:18	39 342:21 343:9,14
15th 347:16 348:3	469:10,16,25	23 350:24 353:20	343:17 344:6
348:18 358:9	2014 348:23 450:9	393:11	395 332:7
442:13 443:3,17	461:5,16 462:5,13		
,	101.2,10 102.2,13		

[**397 - adam**] Page 2

397 332:8	483:9,20 495:23	92 376:16,25	361:21 368:14
3:55 490:7	496:10	93445 334:13	379:17 383:24
4	7	94 498:8,12	384:6 389:8,18
_	-	95 497:9,13,15	400:3 401:11
4 328:10 329:3	7 331:23 349:16	498:12 500:8	414:15 415:7
440:14 454:12	354:13 355:7,15	960 334:12	431:5,21 443:12
40 345:3 354:2	355:18 362:24,24	9932 506:24	479:14 483:2
44 368:16	363:7,23 369:5,14	a	492:23 505:6
440 330:4	370:15 371:25		accurately 358:23
45 426:18 502:24 452 331:13	372:16 432:20,24 432:25 435:16	a.m. 329:4 333:3	378:24 380:3
452 331:13 4577228 328:25	441:3 448:19	ability 359:7 482:14	acknowledge
45 77 226 328:23 471 331:23	450:13 471:11,12	able 356:25	453:2
471 331.23 49.9 369:2	471:24 481:21	400:11 408:12	acquired 473:4
49.9 309.2 4:16 504:21,22	483:21 489:10	425:11 430:25	acquiring 372:5
4.10 304.21,22 4th 333:4	494:12	abrams 331:12	act 331:15 450:14
	70 369:20 370:8	350:20 351:5	452:4,17 453:4
5	76 376:16,24	391:5	acted 450:2
5 363:14	77 450:10	absent 412:11,14	action 333:15
50 338:21 368:22	7th 371:2,19 374:4	absurd 485:13	440:20
51 426:22	387:17 442:13	accept 452:24	actual 487:9
52 372:4	443:7	462:6	adam 328:1,9
54 371:17	8	accepted 365:24	329:1,6 330:1
556-2262 330:11	_	421:22 499:25	331:1,3,8,10,22
6	8 331:7 336:9,15	access 335:12	332:1 333:1,6
6 331:14,14 358:16	336:23 361:24	340:3 341:10	334:1,11 335:1
449:20 452:3,4	367:9,10 368:11 372:25 385:25	452:10 471:16	336:1,16 337:1
482:19	386:5 435:17	accommodate	338:1 339:1,23
6/4/2021 507:3	481:21,24 484:9	406:7 407:18,25	340:1 341:1,5
60 452:17,17 453:3	493:24 494:14	409:14 410:2,17	342:1 343:1 344:1
600-2817 330:5	495:10,19 496:17	411:10 426:19	345:1 346:1 347:1
683 389:2,4,10	83 493:2	427:2 493:12	348:1 349:1 350:1 351:1 352:1 353:1
390:12,21 393:15	85 493:7,9	accommodations	354:1 355:1 356:1
394:14 395:14	88 412:7	407:23	357:1 358:1 359:1
396:19 397:12,17	8th 506:25	account 501:19	360:1 361:1 362:1
398:4,17	9	accounting 365:24	363:1 364:1 365:1
6d 453:4		421:22 488:8,10	366:1 367:1 368:1
6th 347:16 348:3	9 331:9 341:3,4	489:7	369:1 370:1 371:1
348:18,23 369:13	374:2 492:10	accounts 371:11	372:1 373:1 374:1
374:10,12 447:17	90 498:6	500:16	375:1 376:1 377:1
447:22 450:16	91 457:25 458:4	accurate 346:24	378:1 370:1 377:1
451:24 459:25		359:21,24 360:6	370.1 377.1 300.1

[adam - amount] Page 3

		I	T
381:1 382:1 383:1	504:1 505:10	392:18 399:7	allegations 366:12
384:1 385:1 386:1	506:1 507:3,21	400:16,20,24	366:18 367:2
387:1 388:1 389:1	add 398:25 399:3	402:6,16 412:13	422:3,9 454:19
390:1 391:1 392:1	471:6	413:16 414:10,16	455:3,7 474:23
393:1 394:1 395:1	added 365:15	415:23 417:20	488:5
396:1 397:1 398:1	368:4 421:10	418:2,8 442:4	allege 364:10
399:1 400:1 401:1	additional 344:13	448:5 455:17,20	420:13,23 472:19
402:1 403:1 404:1	345:8,15 366:25	456:7 477:18,21	alleged 355:22
405:1 406:1 407:1	414:2 442:8	483:12,23	363:3,9,21 366:6
408:1 409:1 410:1	address 489:14	agreed 386:10	367:7 372:2 374:6
411:1 412:1 413:1	adjectives 442:9	404:15 455:25	401:18,22 404:10
414:1 415:1 416:1	administrative	483:21	404:25 412:11,15
417:1 418:1 419:1	452:21	agreeing 459:5	421:19 423:9
420:1 421:1 422:1	admit 451:3,7,10	460:3,15	440:17,23 441:4
423:1 424:1 425:1	451:17 453:18	agreement 329:6	444:6,7 448:20
426:1 427:1 428:1	454:15 455:8	369:25 450:19	449:6,13 456:8
429:1 430:1 431:1	admitting 452:24	451:20 469:18	461:21 484:5
432:1 433:1 434:1	453:6 454:5	agreements	494:13,15
435:1 436:1 437:1	adopting 331:12	450:22 454:17	allegedly 353:17
438:1 439:1 440:1	350:24 351:7	468:20	393:8 398:5
441:1 442:1 443:1	advance 427:3	ah 343:3 417:14	412:21 413:3,11
444:1 445:1 446:1	advice 395:7	461:3 471:18,23	414:4 416:4,17
447:1 448:1 449:1	affect 424:8,18	ahdout 382:6	449:14
450:1 451:1 452:1	428:16 429:3,18	452:15	alleging 476:9
453:1 454:1 455:1	429:25	ahead 337:15	allow 436:8
456:1 457:1 458:1	affiliations 333:18	356:12 384:23	446:23
459:1 460:1 461:1	affirmative 472:16	386:13 388:15	allowed 506:18
462:1 463:1 464:1	affirmatively	396:7 397:22	allowing 364:24
465:1 466:1 467:1	464:22	398:9 399:2,12	420:17
468:1 469:1 470:1	agencies 352:24	406:23 408:8	alright 355:16
471:1 472:1 473:1	agency 362:14	416:13 445:12	356:14 396:12
474:1 475:1 476:1	434:12,23 458:12	453:15 455:16	397:7 419:25
477:1 478:1 479:1	486:21 495:16	458:8 464:17	467:21 468:16
480:1 481:1 482:1	agent 364:14	465:5 469:5	471:19 477:13
483:1 484:1 485:1	420:8	476:22 477:9	482:24
486:1 487:1 488:1	aggregate 398:15	485:6,9 487:24	amended 358:25
489:1 490:1 491:1	398:18 498:22	alex 337:17 338:3	389:15 390:2
492:1 493:1 494:1	ago 465:14,15	allegation 472:10	440:19
495:1 496:1 497:1	473:13,15	482:20 483:10	americas 330:10
498:1 499:1 500:1	agree 355:16	487:21	amount 415:2,21
501:1 502:1 503:1	363:25 390:20		444:12,14,22

[amount - april] Page 4

anticipated 464:3 anticipation 452:20 anybody 339:5 503:25 anymore 339:8 anyone's 435:7 anything's 486:5 anytime 488:22 apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
452:20 anybody 339:5 503:25 anymore 339:8 anyone's 435:7 anything's 486:5 anytime 488:22 apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
anybody 339:5 503:25 anymore 339:8 anyone's 435:7 anything's 486:5 anytime 488:22 apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
503:25 anymore 339:8 anyone's 435:7 anything's 486:5 anytime 488:22 apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
anymore 339:8 anyone's 435:7 anything's 486:5 anytime 488:22 apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
anyone's 435:7 anything's 486:5 anytime 488:22 apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
anything's 486:5 anytime 488:22 apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
anytime 488:22 apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
apologize 362:20 453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
453:15 491:12 appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
appear 337:16 376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
376:3 appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
appearance 333:21 appearances 333:18 appeared 438:22 appears 337:2
333:21 appearances 333:18 appeared 438:22 appears 337:2
appearances 333:18 appeared 438:22 appears 337:2
333:18 appeared 438:22 appears 337:2
appeared 438:22 appears 337:2
appears 337:2
220 2 2 5 5 5 5
339:2 366:14
386:5 462:25
472:3
appended 506:18
application's
477:6
apply 415:12
491:5
appointed 389:21
390:8
appropriate 501:6
501:9
approximate
462:24
approximately
450:9
approximation
338:20
The state of the s
april 331:8 336:11
april 331:8 336:11 336:17,25 343:24
_

[april - baker] Page 5

364:3 440:21	384:2,10 385:8,9	assumptions 405:4	b
461:5,16 463:5,8	385:15 386:14,22	405:12,14 415:6	b 331:5 353:20
argue 392:10	394:9 399:15	418:15	364:15 393:11
arrangements	400:22 401:9	attempt 409:24	back 344:20
477:4	406:12,13,14	435:5 484:17	354:12 360:25
array 344:14	409:25 422:5	486:8	367:9 370:9
article 371:19	423:11,23 426:11	attorney 333:21	372:12,18 379:6
372:8	428:5 432:7,9,10	506:20	382:24 383:24
articles 367:4	436:19 445:20	attorneys 330:4,10	385:6 386:13,17
375:11 377:15	448:8 455:12	attributable 485:2	386:20 388:24
artificial 362:16	461:23 474:8	485:3,19	424:24 425:12
362:25 367:11,22	476:17 479:18	attribute 494:24	427:23 429:12
373:5 374:7,23	482:23 491:3	attributed 494:24	434:20 435:16
375:4 412:2,8,14	aspect 383:15	attributes 495:4	438:22 439:6
413:4,12 414:18	asset 369:4	attributing 491:15	454:3 468:3
482:2	assigns 454:8	attribution 491:10	473:12,19 476:10
artificially 349:17	assist 337:5 339:6	491:14 494:6	479:21 481:18
354:15 355:24	assisted 337:6,8	august 370:11,14	485:25 490:7,17
356:5 363:11	assisting 337:22	478:17,23 479:2,4	491:18 494:9
448:22 449:11	associated 419:20	480:6,16,24 481:5	504:17
494:19	430:10 458:13	481:8 482:9	background
aside 339:4 482:5	459:20	available 377:10	400:22
asked 335:24	association 333:13	377:16,21 378:2	baker 330:7 334:4
341:25 359:20	370:2	378:19 493:15	334:4 340:12
360:10 383:8	assume 377:17	avenue 330:4,10	341:22 343:8,13
384:21,25 385:11	386:6 403:3,23	334:12	343:18 344:16
388:10,16 410:9	404:8 422:15	aware 350:7	346:6 354:19
411:3 417:12	463:15 467:22	354:16 356:7	356:10,14 357:12
426:20 429:14	484:2,11	357:4,9 419:20	358:13 359:19
434:9 435:8 440:4	assumed 404:6	450:18 451:9,15	360:10,17,20
440:7,15,22	488:5	453:8,13,18,22	361:15 368:2,4
441:19 442:7	assumes 408:3,6	454:18 455:2,6	374:9 383:8,19
453:12 459:23,24	442:19 448:15	457:3 466:20	384:21,25 385:11
466:4,6 467:13	463:13 464:7	467:11 468:23	385:15 388:10,15
470:5 477:3 480:3	482:16 489:16	470:19 474:12	389:12 393:19
480:8 486:11,14	assuming 342:9	478:12,16,20	394:17,23 396:6,8
486:15,18 489:11	394:9 412:25	488:16 489:13	396:24 397:18,23
asking 350:7	413:9 463:3,17	499:24	398:21 399:11
356:4 361:16	assumption		400:9 401:25
366:24 368:9	377:20 403:7		402:22 404:12
373:11,15 383:4	405:17 443:14		405:3,8 406:9,24
			TUJ.J,U TUU.J,4

[baker - bulk] Page 6

407:7 408:3,6	498:20 501:25	377:14,23 382:22	499:14
409:17 410:5,19	basic 353:14 393:5	384:15,16 388:5	bettencourt
410:25 411:13	basically 438:22	389:3,13 390:11	337:17,25
416:19 419:2	503:3	390:17 391:5	better 372:24
422:19 425:14,20	basis 342:6 392:16	394:2,6,19 399:20	477:20
426:4 430:24	396:20 405:21	401:3,11,15	beyond 481:8
431:18 436:10,24	440:25 441:10	402:12 403:7	bidding 369:20
439:5,18 441:23	447:15,19	404:14 405:20	big 478:7
442:15,19 444:9	beach 334:12	407:8 409:10	bigger 500:11
448:18 449:17	335:17	412:17,24 419:9	bill 399:25
451:21 456:20	bear 344:23	419:23 420:4	billable 338:6,23
457:18 459:7	began 460:22	421:15,16,19	billion 478:6
460:5,17 462:15	461:15,22,24	424:23 425:4,8	biopharma 344:14
463:12,22 464:7	462:13,21 463:5	429:9 437:21	blapointe 330:6
464:15,18 468:9	463:18 464:6	440:9,13 442:6	body's 446:10
468:15 469:3	473:20	443:3,5,18 444:13	boilerplate 453:10
470:5 473:10	beginning 333:21	445:3 446:4 451:2	454:2,16 455:11
475:15 477:8,10	335:2 344:3	455:5 456:2,15	bond 372:9
480:8,18 481:2	358:20 359:17	457:6,20,23 460:9	book 493:17
482:10 484:7,14	364:7 368:16	460:18 464:11	bottom 391:11
485:5,8,22 486:11	443:8,21 444:22	467:13 472:25	392:24 393:2
487:22 488:2	459:16 460:20	474:6 476:8 477:3	472:14
489:16 502:23	461:5 463:4,8	477:7,25 478:18	break 388:19
503:21 504:15	469:9	481:12 483:24	426:11,23 427:11
balancing 352:14	begins 343:16	484:20 486:24	427:15 463:6
banking 377:15	376:24	487:7 488:11	467:16,20 489:21
bankruptcy 447:9	behalf 394:15,16	501:24 502:3,24	breaking 465:3
457:7 488:25	396:4	503:21	brent 330:7 334:6
barking 427:7	behavior 473:20	believed 421:15	bringing 494:9
barron 497:6	belief 384:22	benchmarks 353:4	broad 417:5
base 372:6 382:12	385:4,6 443:11	beneficial 433:22	442:23
451:16 498:14	believe 336:4,5,8	434:6,13,24	broker 371:10
499:8	337:6 338:8,11	benefit 364:25	457:4 468:24
based 355:10	339:7 340:7 341:3	420:18	brokerage 328:4
359:5 375:9 379:8	345:2 346:15,23	benefitted 456:18	333:7 507:2
395:3,7 397:7	348:7 353:23	456:21	brokers 465:21
444:10 463:14	357:7 361:11,12	best 344:25 349:12	466:2,8
464:12 466:22	363:17 366:8	373:8 389:5	brought 468:12
488:7 493:16	368:3 369:7	390:15 432:19	bulk 365:18
497:16,23,24	370:11 373:3,8	457:8 466:17	371:13,15 421:12
498:10,10,13,14	374:13 375:15,20	476:25 496:23	

[bunch - change] Page 7

	ı	I	I
bunch 405:4	394:14 395:14	386:23 387:2,25	439:10,25 456:5
bup 481:22,22,22	397:12 398:4	388:3 397:11	461:7,13 465:7,7
burden 352:16	420:15 421:2,8,10	398:19 399:6	466:24 468:20
business 362:7,14	421:13 422:2	403:10,13,19,21	470:8 471:2
369:13,16 370:17	452:14	403:23 404:5	473:24 481:16
434:13,25 437:5,7	capital's 396:19	405:21 408:15	488:12 499:8
437:9,13,16,20,21	397:17 398:18	409:12 410:15	500:20 502:8
437:22 438:3,13	case 335:22	411:8,9,19 417:21	certainty 485:17
438:14,17,21,24	336:25 346:7,12	419:8 422:15	certificate 331:20
439:17 440:12	346:20 354:18	430:13 431:23	339:21 505:1
445:19 449:5	366:7 367:8	432:21 440:9,19	certification
455:25 456:4,14	373:14 376:13	453:17 457:16	349:22 351:14,20
456:19 458:14,20	377:8 378:17	468:5 472:2,24	354:7 389:21
462:8 476:5	381:20 389:15,22	483:25 486:20	390:8
483:22 484:5	390:19,23 407:24	487:4,19 489:5	certified 329:7,8
485:2 495:14,16	415:12,15 442:11	490:11 491:22	356:24 369:10
496:3	445:2 447:23	492:17,20 493:20	392:11 506:3,4
businesses 362:12	459:20 465:9	493:23 495:10	certify 506:5,19
buy 376:13	466:15,17 468:18	497:10,22 499:3,6	certifying 392:20
c	468:22 474:15	499:13,17 500:3	cetera 426:16
c 330:2,14 331:14	477:15 479:7,16	cause 353:6	cfa 369:8
364:23 365:20	497:18 499:11	362:17 506:8,22	cftc 369:5,14,16
452:3 454:12	500:4,14 501:11	caused 355:22	370:3,7,11,15
506:2,2	501:11,23 507:2	363:10 367:24	379:19 446:2
calculate 356:25	cases 344:13	373:6 375:5	447:12,21 448:16
498:3,5	352:19 468:8,12	404:10 440:17	449:15,21 450:11
calculated 396:19	468:14,24 499:19	444:14 446:4	450:14,17,19
	cash 477:23 478:4	448:21 449:10	451:10,24 452:15
398:12,13	490:20 491:3	482:3 494:18	454:19 455:4,6
calculation 350:4 california 334:13	493:17 494:6	causes 404:25	459:5 460:3 462:5
335:17	causation 331:7	ccr 328:24	462:13,20 463:5
call 495:4	336:2,11,16,24	cease 450:13	463:17 465:3,5,17
call 493:4 called 344:7 389:2	339:11 341:18	ceiling 417:8	468:6,12 470:2
	342:19 345:21	500:21	472:12 475:14,18
calls 393:21 camera 353:4	346:4,5,12,18	center 370:25	477:5 488:18,20
camer 353:4 cammer 352:14	347:7 351:14,20	certain 363:2	489:13
	354:13 355:8	404:9,24 425:23	cftc's 482:20
canada 345:7 capital 364:22	357:3,17,22 358:5	certainly 370:18	483:10
_	361:25 364:4	380:5,5,13 381:8	chance 486:6
371:12,23 372:4,5	374:15 375:8,18	405:24 434:3	change 357:16
380:10 389:2,4,10	379:7 386:3,7,11	437:25 438:2,16	358:4 411:9
390:12,22 393:15	, ,	,	

413:17,23 414:8	clarified 402:24	502:7	commonly 493:14
414:13 416:5,18	clarify 349:12	clear 349:7,11	communications
417:24 418:5,11	360:15 406:19	354:23 370:10	395:4
490:24 507:5	407:12 410:9	374:9 395:9	companies 433:12
changed 338:14	411:3	406:10 424:20	472:15
357:21 480:16,23	clarifying 411:4	425:22,25 429:6	company 353:8
502:7	435:4	499:5	362:11 365:12,16
changes 353:8	clarity 426:3	client 372:6	365:19,20 368:20
505:5 506:16	class 347:15,19	379:21,21	369:12 370:4,16
changing 463:24	348:2,6,12,17	clients 446:21	370:18 371:12,24
characterization	349:3,18,21	close 455:17	375:10,11 376:9
492:23 496:22	351:13,19 354:7	closer 407:4	377:7 379:9,10,19
503:19	354:16,17,18,21	closure 456:18	412:21 416:3,16
characterize	355:4,5,25 356:6,8	coffee 372:13	420:15 438:21
492:22	356:23 357:5,15	collection 495:22	456:3 464:25
charge 371:16	358:9,11,15,21	colloquy 425:6	473:4 474:19
488:12	359:18 361:18	combined 345:11	477:23 495:13
charged 450:15	362:4 363:12,16	come 351:24 447:6	496:2
476:16,18	366:4 374:8	485:13 490:17	company's 362:5
charges 369:5	385:21 387:7	502:6	362:7 364:15
370:4,15	389:20,21 390:8,9	coming 473:19	365:3 412:19
chief 369:19	391:14,25 392:10	comment 368:20	420:20 433:2
china 372:9	392:11,18 393:16	commentary	448:24 458:11,14
choose 360:3	394:16 396:4	368:18	458:18
chosen 353:11	413:18 414:8,13	commission 370:3	comparable 468:8
circumstances	414:25 415:4,19	371:23 449:21	468:13,24
413:22 414:12	415:22 416:5,18	452:23 505:20	comparing 344:10
cite 366:12 495:17	417:24 418:5,12	507:25	complaint 366:12
cited 367:5 376:5	419:10,13,14,18	committed 476:13	366:16 369:16
378:22 503:8	422:2 433:22	476:14	370:11,14 379:18
citing 496:17	434:7,14,25 440:2	committing	389:7,14,15
civil 450:12	440:17,20 442:14	476:12 479:22,25	390:15,25 422:4
claim 437:23	443:8,20,22	commodities	440:20,21 470:21
claims 364:16	444:22 448:23	449:21	complaint's
472:13 474:13,22	459:13,16 460:12	commodity 331:15	472:10
clarification	460:13,20,22	370:3 371:22	completion 463:20
355:12,14 410:7	463:11,20 464:5	450:14 452:4,17	506:14
468:17	466:10 473:21	453:4	complex 415:10
clarifications	478:14 481:11,13	common 358:8,14	complexities
459:15	487:11,17 500:11	385:20 387:6,17	493:13
	500:17,24 501:21	391:14,25 408:18	

[compliance - consolidating]

Page 9

compliance	conducting 417:20	443:1 444:1 445:1	390:22 397:13
489:14	500:22	446:1 447:1 448:1	398:5,18 399:5
comply 454:8	confidential 328:1	449:1 450:1 451:1	403:10,12,20
component 368:23	329:1 330:1 331:1	452:1 453:1 454:1	408:15,17 409:13
368:24 445:11	332:1 333:1 334:1	455:1 456:1 457:1	410:3,16 411:11
457:16	335:1 336:1 337:1	458:1 459:1 460:1	411:20 422:5,9,14
comprehensive	338:1 339:1 340:1	461:1 462:1 463:1	424:14 428:24
361:23	341:1 342:1 343:1	464:1 465:1 466:1	429:14,21 430:19
computer 342:25	344:1 345:1 346:1	467:1 468:1 469:1	431:22 433:19
506:13	347:1 348:1 349:1	470:1 471:1 472:1	438:5 440:8
concealed 441:4	350:1 351:1 352:1	473:1 474:1 475:1	450:24 453:16
449:7 494:15	353:1 354:1 355:1	476:1 477:1 478:1	456:9 468:4 472:2
concealing 369:18	356:1 357:1 358:1	479:1 480:1 481:1	472:24 486:19
conceded 477:4	359:1 360:1 361:1	482:1 483:1 484:1	487:3,14 490:10
concerning 440:10	362:1 363:1 364:1	485:1 486:1 487:1	493:19 499:18
475:19	365:1 366:1 367:1	488:1 489:1 490:1	500:2
concerns 369:3	368:1 369:1 370:1	491:1 492:1 493:1	consent 453:2
conclude 349:15	371:1 372:1 373:1	494:1 495:1 496:1	conservative
362:25 367:10	374:1 375:1 376:1	497:1 498:1 499:1	497:17 498:15,18
374:22 375:3	377:1 378:1 379:1	500:1 501:1 502:1	500:15 502:4
497:13	380:1 381:1 382:1	503:1 504:1 506:1	consider 497:25
concluded 385:19	383:1 384:1 385:1	confirm 335:12	500:22
387:5,11,15	386:1 387:1 388:1	383:4 384:10	consideration
concludes 472:18	389:1 390:1 391:1	464:22	502:9
conclusion 357:10	392:1 393:1 394:1	conflict 362:6	considered 342:15
357:16,22 358:5	395:1 396:1 397:1	365:4 420:21,22	346:11,13 375:16
393:21 408:25	398:1 399:1 400:1	433:3,9 448:25	403:25 404:2
409:7,15	401:1 402:1 403:1	449:25 458:12	489:9 493:22
conclusions	404:1 405:1 406:1	479:3 480:5	494:3 495:7
349:15 368:12	407:1 408:1 409:1	conflicts 364:16	497:22 498:2,13
375:9 379:8	410:1 411:1 412:1	confounding	consistent 503:6
382:12 388:8	413:1 414:1 415:1	412:25 413:9	consistently
408:16 432:10	416:1 417:1 418:1	confused 355:3	364:19 420:11
452:25 453:7	419:1 420:1 421:1	373:22	450:5 483:14
condition 453:8	422:1 423:1 424:1	confusing 410:11	consolidated
conditions 454:9	425:1 426:1 427:1	connection 346:11	430:15 440:20
conduct 346:3	428:1 429:1 430:1	350:8 366:17,25	consolidating
374:14 492:3	431:1 432:1 433:1	374:18 375:17	424:3,7,16 428:10
conducted 334:25	434:1 435:1 436:1	379:4 380:8 381:2	428:15 429:2,16
399:5 403:2,14,15	437:1 438:1 439:1	382:20 383:6	429:24 430:22
	440:1 441:1 442:1	384:17 388:8	431:16

[constant - cowen] Page 10

4 4 415 2 22	491 247.0	474 15 10 22	410 < 440 17	
constant 415:3,22	convertible 347:8	474:15,18,23	410:6 440:15	
498:25 499:2,13	392:2	477:6,25 481:23	506:19	
499:19,25 500:7	corp 345:6	482:21 483:24	counsel's 397:7	
500:14 501:22	correct 336:3,6,25	486:10 488:5	couple 356:18	
contained 419:17	340:6,10,11,21,22	491:23,24 492:4	423:5 425:21	
419:22 447:21	341:15,16 342:11	492:18 496:22	486:18 502:25	
448:16 496:12	342:12 343:15	corrected 331:21	503:2,10 504:4,8	
contend 358:10	344:4,5,15,18	339:15,22 340:7	course 349:18	
470:9	345:12 347:9,10	340:17,19 341:18	353:2 354:15	
contended 460:18	347:17 348:4,24	359:2 362:3	355:24 356:6	
contending 441:10	348:25 349:18,19	376:15 421:20	363:12 369:3	
443:6	349:23 350:2,5,9	corrections 505:4	370:23 418:5,11	
contention 357:20	355:18,19 358:17	corrective 362:10	439:20 448:23	
358:3 443:11	358:18 359:8,10	362:14 367:6,13	504:5	
contest 392:9	359:13 363:4	367:20 372:20	court 328:2	
context 395:11	366:13,14 367:24	373:3,12,14,16,19	333:12 334:9	
400:20 407:12	367:25 372:21	374:3,22 401:18	335:4 337:14	
457:14 468:17	374:11,20 375:13	401:23 404:10,25	349:20 352:13	
488:25 491:19	375:14,20,25	412:22 413:3,5,11	354:5,16 356:7	
continue 369:24	377:4,11,21	413:13 414:2	357:4,9,14,19	
continued 479:3	378:14,16,20	417:23 418:4,10	358:2 360:24	
480:5	379:15 381:3	419:17,23 420:2	362:21 382:23,25	
continues 457:3	382:13,21,22	441:6 442:12,16	386:12 391:12	
continuing 458:10	383:7 384:20	443:2,16,19 444:6	392:8,24 393:23	
contract 396:13	386:2 387:8,13	444:7,15 445:6,24	406:19 408:25	
contractual 366:2	388:5,9 389:13,22	447:16,22 448:11	409:7 411:10	
421:24	390:13,17 394:10	448:15 449:8,13	419:13 424:24	
contrary 502:2	395:16 397:14	449:14 458:5	425:9 440:5,7	
contravention	401:15,18 403:14	481:25 484:5	454:18,24 455:2	
365:2 420:19	404:20 409:3,9	487:10 489:6	468:11 470:19	
contributed	412:11,17,23,24	494:17,25 495:11	472:9,12,18	
484:12	413:14,20 415:25	correctly 353:22	474:12 499:24	
control 366:3	416:4,17 418:19	354:10 367:15	502:5	
421:25	418:25 424:22	387:9 412:12	court's 351:12,18	
conversation	429:8 437:16	433:5 435:15,24	409:14 410:3,17	
469:11,22 502:22	441:22 444:18	458:24 462:11	411:17	
conversations	447:14,17 455:21	481:21 497:19	courts 454:22	
394:24 396:10,25	460:23,24 461:6	counsel 333:17	472:14 500:6	
397:4 492:6 504:5	462:10,14 463:11	383:19 394:20,25	cover 366:10	
504:7	463:16,21 464:23	395:4,7,10 396:11	cowen 368:19	
	471:22 473:3	396:21,25 397:5	370:25	

[crack - deposition]

Page 11

crack 417:9	1	david 364:22	367:8 392:9
crash 475:5,6,14	d	day 414:17 442:14	defer 394:19
475:20,24 476:3,6	d 331:2,14 364:21	473:23 491:13	396:21 404:7
create 413:22	365:5 452:4	504:18 505:13	409:11
created 358:20	dahan 330:14	507:22	
	333:24,24		define 347:7,15,25
364:23 420:16	damage 406:2	dcf 491:2,3	348:17 358:15
433:8	499:7,9	deal 446:8	408:10 412:8
credit 364:15	damages 331:8	dealing 367:6	436:11,20
420:8 450:2	336:2,12,16,24	434:12,15,24	defined 347:23
crime 479:21	339:10 346:4	435:2 437:11	348:7,11,22
crimes 479:22,25	350:4 357:2 364:4	438:5,11 450:3	354:21 441:20
criticisms 492:17	369:6 370:16	486:21,22 487:2,3	defining 436:19
493:10	387:16 388:4	dealt 349:24 350:7	definition 408:19
crowninshield	394:15 396:20	439:23	445:8 498:17
337:9 339:4	397:12,17 398:3,4	debt 370:21	definitions 349:5
345:24 396:17	398:11,13,13,15	decide 419:12,13	354:23
503:23	398:18 403:19,21	440:5	demonstrates
crr 328:24	408:15 409:13	decision 351:13,19	413:3,11
crytobloc 345:6	411:19 417:21	351:24 354:3	demonstrating
cumbersome	422:15 430:13	501:16	352:16
497:4	431:23 440:9,25	decisions 446:11	denied 354:8
current 338:23	457:16 468:5	468:12 499:24	391:25
457:10,15,20,21	484:2 486:20	declarations	deny 451:4,8,10
currently 335:15	487:4,19 489:5	344:13	451:17 453:18
curriculum 344:4	490:11 491:22	declared 457:6	454:14 455:8
344:10	493:20 497:22	decline 368:22	denying 452:24
customer 365:10	498:4,21,21,23	413:2,10 414:17	453:7 454:6
371:11 421:4	499:17 500:3,23	415:3,21 446:5	depend 401:19
433:3,9 448:25	daniel 337:17,25	458:5 484:12	depending 456:9
customer's 364:12	data 376:5 378:22	487:16 494:25	deponent 505:1
364:17 420:6	459:19	498:20	506:17
customers 364:7	date 445:12	declines 414:24	deposition 328:8
364:25 365:2,4	460:11,19 461:15	415:19 500:10	329:5 332:3 333:5
369:19 370:5	462:22,24 463:25	decreased 353:2	334:23,24 336:5
371:14 420:18,19	470:23 483:2,6	deemed 368:18	336:10,15 339:20
420:21 433:22	507:3	defendant's	341:4 345:17
434:7 449:24,25	dated 345:4 371:2	353:17 392:17	351:3,6 359:22
450:11 479:4	371:19 372:8	393:8 440:17,23	381:5,9,10,17,19
480:6	440:21 506:25	470:20	381:20,25 382:5
cv 328:4 342:21	dates 466:23	defendants 330:10	399:21,24 433:25
343:9	uates 400.23	333:23,25 334:3	452:2 471:8,12

[deposition - doing]

Page 12

472:4 502:15,18	150 / 500 / 5 / 6	415 45 46 4	11 1 0 0	10 / 10 - 0
504:6 505:4 506:6 506:9,15,21 507:3 431:15 482:18 47:3,23 404:10 506:9,15,21 507:3 437:3,23 404:10 506:10	472:4 502:15,18	417:17 424:2	disclosure 362:3	disentangle 495:3
506:9,15,21 507:3 491:15,16 498:4 374:3,23 404:10 disinterested depositions 337:17 501:20 412:22 413:3,5,11 506:10 dismiss 470:21 describing 410:19 406:25 417:23 418:4,10 dismiss 470:21 describing 410:15 difficult 335:4 418:15 419:18,23 474:13,22 dissipated 362:16 331:19 368:15 dimution 458:16 442:12,16 444:6,7 367:12,22 373:5 374:6,23 482:2 dissipated 362:16 367:12,22 373:5 374:6,23 482:2 dissipated 362:16 367:12,22 373:5 374:6,23 482:2 dissipated 362:12 374:6,23 482:2 dissipated 362:12 374:6,23 482:2 472:14 472:14 472:14 472:14 472:14 472:14 473:4474:19 418:15,49:13 472:14 472:14 472:14 473:4474:19 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14	, ,			_
depositions 337:17 501:20 412:22 413:3,5,11 506:10 dismiss 470:21 described 407:9 406:25 417:23 418:4,10 418:15 419:18,23 472:13 472:13 describing 410:15 difficult 335:4 418:15 419:18,23 474:13,22 472:13 description 331:6 490:23 420:2 441:6 367:12,22 373:5 374:6,23 482:2 482:12,16 444:6,7 367:12,22 373:5 374:6,23 482:2 dissipation 375:3 447:16,20,23 district 328:2,2 473:4 474:19 482:2 449:12 449:14 458:6 473:4 474:19 481:6 482:7 481:6 482:7 487:10 489:6 472:14 472:13 480:13 376:17 391:16 480:13 376:17 391:16 480:13 376:17 391:16 480:13 376:17 391:16 480:13 376:17 391:16 480:13 376:17 391:16 480:13 376:17 391:16 480:13 376:17 391:16 490:13 376:17 391:16 490:13 376:17 391:16 490:13 376:17 490:13 376:17 391:16 490:13 376:17 391:16 490:13 376:17 391:16				
described 407:9 440:19 differentiated 406:25 413:13 414:3 417:23 418:4,10 dismiss 470:21 dismissed 470:21 dismissed 470:21 dismissed dismissed 470:21 dismissed dismissed 470:21 dismissed dismissed 470:21 dismissed dismissed 470:21 dismissed dismissed 470:21 dismissed differentiated dufficited 417:23 418:4,10 dismissed 470:21 dismissed dre113,22 dre113,22 dre213 dre214:6 440:21 dissipated 362:16 dre216 dissipated 362:16 dre216 dre216 dre216 dre216 dre216 dre217 dre218 dre216 dre218	, ,	· · · · · · · · · · · · · · · · · · ·	·	
440:19 406:25 417:23 418:4,10 dismissed 472:13 411:8 479:17 484:22 420:2 441:6 474:13,22 description 331:6 331:19 368:15 490:23 420:2 441:6 367:12,22 373:5 331:19 368:15 diminution 458:16 442:12,16 444:6,7 367:12,22 373:5 423:8 dipping 353:3 447:16,20,23 dissipation 375:3 designed 493:12 498:8 direct 353:5 365:2 420:19 448:12,15 449:13 448:12,15 449:13 448:14 458:6 472:14 designed 493:12 498:8 directly 461:20 473:4 474:19 ditamin 382:2 document 339:12 desk 434:12,15,24 directly 461:20 481:6 482:7 487:10 489:6 340:13 376:17 435:2 437:11 438:5,11 446:8 447:2 disclosures 362:15 367:13,21 373:4 342:16,23 344:20 487:3,3 425:3 448:3,5,14 49:12 373:25 374:6 40cument 32:2 360:23 349:16 determine 401:13 412:18,20 414:12 429:23 459:16 429:34 50:14 429:32 35:16 429:17,25 376:5,13 377:3,9 376:5,13 377:3,9 377:10,21,25 378:12,19,22 <th< td=""><td>_</td><td></td><td>· ' '</td><td></td></th<>	_		· ' '	
describing 410:15 difficult 335:4 418:15 419:18,23 474:13,22 dissipated 362:16 description 331:6 331:19 368:15 diminution 458:16 442:12,16 444:67 367:12,22 373:5 374:6,23 482:2 dissipated 362:16 362:16 362:16 442:12,16 444:67 367:12,22 373:5 374:6,23 482:2 dissipated 362:16 442:12,16 444:67 367:12,22 373:5 374:6,23 482:2 dissipated 362:16 442:12,16 444:67 374:6,20,23 dissipated 374:6,20,23 dissipation 375:3 dissipation 375:3 dissipation 375:3 dissipation 375:3 dissipation 375:3 dissipation 375:3 dissipation 375:53 dissipated 362:12 472:14 478:14 478:19 448:12 449:12 472:14 dittami 382:2 472:14 472:14 472:14 472:14 472:14 473:44 478:19 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14 472:14				
411:8 479:17 484:22 420:2 441:6 dissipated 362:16 description 331:6 490:23 442:12,16 444:6,7 367:12,22 373:5 374:6,23 482:2 423:8 diminution 458:16 444:15 445:21,24 dissipation 375:12,22 373:5 design 497:17 498:8 420:19 447:16,20,23 dissipation 375:3 designed 493:12 direct 353:5 365:2 448:12,15 449:13 district 328:2,2 designed 493:12 direction 332:6 473:4 474:19 dittami 382:2 desist 450:13 disagregate 447:2 487:10 489:6 495:12 500:10,12 360:13 376:17 391:16 despite 364:15 despite 364:15 425:3 448:3,5,14 373:12,14,17,20 346:13 351:22 detarmine 401:13 412:18,20 414:12 425:3 448:3,5,14 433:21 449:7 376:5,13 377:3,9 412:18,20 414:12 436:16 494:17,25 376:5,13 377:3,9 422:18,23 450:13 472:16 494:17,25 378:12,19,22			· · · · · · · · · · · · · · · · · · ·	
description 331:6 490:23 442:12,16 444:6,7 367:12,22 373:5 374:6,23 482:2 482:2 482:1 482:2 482:1 482:2 482:1 482:2 482:1 482:2 482:1 482:2 482:1 482:2 482:1 482:2 482:3 482:2 482:3 482	describing 410:15	difficult 335:4	418:15 419:18,23	474:13,22
331:19 368:15 diminution 458:16 dipping 353:3 design 447:16,20,23 dissipation 375:3 dissipation 375:3 dissipation 375:3 dissipation 375:3 dissipation 375:3 dissipation 375:3 district 328:2,2 dissipation 375:3 district 328:2 discipation 472:14 district 328:2,2 dissipation 375:3 district 472:14 district 472:14 district 472:14 district 472:14 district 472:14 discounted 472:14 discounted 472:14 document 339:12 document 331:16 document 342:16,23 344:20 dascint 342:23 66:23 dascint 342:13 377:3,9 dascint <td>411:8</td> <td>479:17 484:22</td> <td>420:2 441:6</td> <td>dissipated 362:16</td>	411:8	479:17 484:22	420:2 441:6	dissipated 362:16
423:8 dipping 353:3 447:16,20,23 dissipation 375:3 design 497:17 498:8 420:19 448:12,15 449:13 district 328:2,2 designed 493:12 direction 332:6 473:4 474:19 dittami 382:2 desk 434:12,15,24 directly 461:20 481:6 482:7 document 339:12 435:2 437:11 438:5,11 446:8 447:2 disagregate 495:12 500:10,12 340:13 376:17 391:16 487:3,3 425:3 448:3,5,14 473:12,14,17,20 346:13 351:22 342:16,23 344:20 4espite 364:15 449:12 373:25 374:6 354:22 366:23 determine 401:13 46:16 49:12 443:20 445:7 376:5,13 377:3,9 412:18,20 414:12 49:12 472:16 499:17,25 377:10,21,25 429:23 439:16 472:16 494:17,25 377:10,21,25 429:21 501:3 472:16 494:17,25 378:12,19,22 458:17 356:7 416:4 419:12,14 496:0 490:20 379:3,9,10,19	description 331:6	490:23	442:12,16 444:6,7	367:12,22 373:5
design 497:17 direct 353:5 365:2 420:19 448:12,15 449:13 472:14 district 328:2,2 472:14 designed 493:12 desist 450:13 desk 434:12,15,24 direction 332:6 506:13 481:6 482:7 487:10 489:6 473:11 446:8 47:2 disaggregate 475:12 500:10,12 475:12 500:10,12 475:12 500:10,12 475:12 500:10,12 475:12 500:10,12 475:13 486:21,23 486:21,23 486:21,23 486:33,3 425:3 448:3,5,14 47:2 disaggree 355:16 473:14,17,20 346:13 351:22 373:25 374:6 354:22 366:23 344:20 373:25 374:6 354:22 366:23 344:20 445:7 472:16 494:17,25 494:17,25 494:17,25 494:17,25 494:17,25 494:17,25 494:17,25 494:17,25 494:17,25 494:17,25 494:17,25 378:12,19,22 494:14 401:14 458:6 478:17 478:19 478:19 478:19 478:19 478:19 478:19 478:10 478:10 448:17 478:10 483:6,20 482:25 504:2 474:10 479:6 discussions 485:25 495:7 448:12,15 449:13 448:12 472:16 478:21 480:16,23 449:14 489:12 478:10 479:6 discussions 485:25 495:7 448:12,15 449:13 448:14 446:14 478:19 481:6 482:7 480:16,23 440:13 376:17 379:11,16 400cments 332:19 472:10 479:10 412:8 478:17 478:11 478:21 480:16,23 478:17 478:11 478:21 480:16,23 478:17 478:11 478:21 480:16,23 478:17 478:10 479:6 474:10 479:6 479:6 474:10 479:6 479:6 474:10 479:6 479:6 474:10 479:6 479:6	331:19 368:15	diminution 458:16	444:15 445:21,24	374:6,23 482:2
498:8 420:19 449:14 458:6 472:14 designed 493:12 direction 332:6 473:4 474:19 dittami 382:2 desk 434:12,15,24 directly 461:20 487:10 489:6 340:13 376:17 438:5,11 446:8 447:2 disagregate 495:12 500:10,12 391:16 487:3,3 425:3 448:3,5,14 367:13,21 373:4 342:16,23 344:20 489:12 368:15 367:13,21 373:4 342:16,23 344:20 349:16 449:12 373:25 374:6 354:22 366:23 362:14 449:18 449:12 373:25 374:6 354:22 366:23 362:14 449:18 448:17,23 419:9 375:11,16,24 420:23 439:16 370:5 416:16 494:17,25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 480:21 501:3 472:16 494:6 379:22,25 380:9 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 381:5,21 388	423:8	dipping 353:3	, , ,	dissipation 375:3
designed 493:12 direction 332:6 473:4 474:19 dittami 382:2 desk 434:12,15,24 directly 461:20 481:6 482:7 document 339:12 435:2 437:11 disagregate 495:12 500:10,12 340:13 376:17 391:16 450:3 486:21,23 disagree 355:16 367:13,21 373:4 342:16,23 344:20 487:3,3 425:3 448:3,5,14 373:12,14,17,20 346:13 351:22 despite 364:15 disagreements 418:17,23 419:9 375:11,16,24 determine 401:13 363:14 443:20 445:7 376:5,13 377:39 412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 480:21 501:3 472:16 494:6 379:39,10,19,21 480:21 501:3 472:16 494:6 379:22,25 380:9 determined 342:8,10,16,23,24 441:408:24 383:5 384:17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 <tr< td=""><td>design 497:17</td><td>direct 353:5 365:2</td><td>448:12,15 449:13</td><td>district 328:2,2</td></tr<>	design 497:17	direct 353:5 365:2	448:12,15 449:13	district 328:2,2
desist 450:13 506:13 481:6 482:7 document 339:12 desk 434:12,15,24 directly 461:20 487:10 489:6 340:13 376:17 438:5,11 446:8 447:2 disagregate 495:12 500:10,12 391:16 450:3 486:21,23 disagree 355:16 367:13,21 373:4 342:16,23 344:20 487:3,3 425:3 448:3,5,14 373:12,14,17,20 346:13 351:22 despite 364:15 d49:12 373:25 374:6 354:22 366:23 determine 401:13 363:14 43:20 445:7 376:5,13 377:3,9 412:18,20 414:12 disclose 365:25 499:9 481:25 377:10,21,25 429:23 439:16 472:16 494:17,25 378:12,19,22 420:23 450:11 472:16 494:6 379:22,25 380:9 determined disclosed 342:4 481:4 409:20 379:39,10,19,21 451:19,23 455:3 422:8,10,16,23,24 441:7 475:10 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 385:5 384:17 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 499:20 503:2,37,8	498:8	420:19	449:14 458:6	472:14
desk 434:12,15,24 directly 461:20 487:10 489:6 340:13 376:17 435:2 437:11 disaggregate 495:12 500:10,12 391:16 438:5,11 446:8 447:2 disclosures 362:15 450:3 486:21,23 disagree 355:16 367:13,21 373:4 342:16,23 344:20 487:3,3 425:3 448:3,5,14 373:12,14,17,20 346:13 351:22 despite 364:15 449:12 373:25 374:6 354:22 366:23 detail 419:8 disagreements 418:17,23 419:9 375:11,16,24 determine 401:13 363:14 443:20 445:7 376:5,13 377:3,9 412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 440:16 454:24 421:23 450:11 494:6 379:22,25 380:9 determined disclosed 342:4 494:6 379:22,25 380:9 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 422:8,10,16,23,24	designed 493:12	direction 332:6	473:4 474:19	dittami 382:2
435:2 437:11 disaggregate 495:12 500:10,12 391:16 438:5,11 446:8 447:2 disclosures 362:15 450:3 486:21,23 disagree 355:16 367:13,21 373:4 342:16,23 344:20 487:3,3 425:3 448:3,5,14 373:12,14,17,20 346:13 351:22 despite 364:15 449:12 373:25 374:6 354:22 366:23 detail 419:8 disagreements 418:17,23 419:9 375:11,16,24 determine 401:13 363:14 443:20 445:7 376:5,13 377:3,9 412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 400:16 454:24 421:23 450:11 494:6 379:22,25 380:9 determined disclosed 342:4 387:24 399:21 380:15,21,25 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 498:14 501:21 423:3,12,19 494:22 503:16,21 <	desist 450:13	506:13	481:6 482:7	document 339:12
438:5,11 446:8 447:2 disclosures 362:15 documents 332:9 450:3 486:21,23 425:3 448:3,5,14 367:13,21 373:4 342:16,23 344:20 342:16,23 344:20 487:3,3 425:3 448:3,5,14 373:12,14,17,20 346:13 351:22 despite 364:15 449:12 373:25 374:6 354:22 366:23 detail 419:8 disagreements 418:17,23 419:9 375:11,16,24 determine 401:13 363:14 443:20 445:7 376:5,13 377:3,9 412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 440:16 454:24 421:23 450:11 494:6 379:22,25 380:9 determined disclosed 342:4 494:6 379:22,25 380:9 determined 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 458:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 438:14 469:7 496:20 503:2,	desk 434:12,15,24	directly 461:20	487:10 489:6	340:13 376:17
450:3 486:21,23 disagree 355:16 367:13,21 373:4 342:16,23 344:20 487:3,3 425:3 448:3,5,14 373:12,14,17,20 346:13 351:22 despite 364:15 449:12 373:25 374:6 354:22 366:23 detail 419:8 disagreements 418:17,23 419:9 375:11,16,24 determine 401:13 363:14 443:20 445:7 376:5,13 377:3,9 412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 440:16 454:24 421:23 450:11 discounted 490:20 480:21 501:3 472:16 discussed 375:15 354:17 356:7 416:4 419:12,14 387:24 399:21 380:15,21,25 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 43:17,24 444:8 438:14 469:7 496:20 503:2,3,7,8 difference 406:19 458:23 472:11	435:2 437:11	disaggregate	495:12 500:10,12	391:16
487:3,3 425:3 448:3,5,14 373:12,14,17,20 346:13 351:22 despite 364:15 449:12 373:25 374:6 354:22 366:23 detail 419:8 disagreements 418:17,23 419:9 375:11,16,24 determine 401:13 363:14 443:20 445:7 376:5,13 377:3,9 412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 440:16 454:24 421:23 450:11 discounted 490:20 379:3,9,10,19,21 480:21 501:3 472:16 494:6 379:22,25 380:9 determined disclosed 342:4 discussed 375:15 380:15,21,25 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discussing 396:14 496:20 503:2,3,7,8 478:7	438:5,11 446:8	447:2	disclosures 362:15	documents 332:9
despite364:15449:12373:25 374:6354:22 366:23detail419:8disagreements418:17,23 419:9375:11,16,24determine401:13363:14443:20 445:7376:5,13 377:3,9412:18,20 414:12disclose365:25449:9 481:25377:10,21,25429:23 439:16370:5 416:16494:17,25378:12,19,22440:16 454:24421:23 450:11discounted490:20379:3,9,10,19,21480:21 501:3472:16494:6379:22,25 380:9determineddisclosed342:4discussed375:15354:17 356:7416:4 419:12,14387:24 399:21382:10,10,13,17357:5,15 452:23419:15 420:5,9404:14 408:24383:5 384:17454:19,23 455:3422:8,10,16,23,24441:7 475:10386:15,21 388:7498:14 501:21423:3,12,19494:22 503:16,21393:24 394:6,11detrimental427:25 443:3,7,8discusses472:10459:20 462:7433:21 434:2,6445:3 446:14438:14 469:7496:20 503:2,3,7,8407:10 412:8458:23 472:11483:17doing465:4 473:14,22478:7478:21 480:16,23483:6,20482:25 504:2474:10 479:6difference500:16483:6,20482:25 504:2474:10 479:6different348:13disclosing431:25discussions485:25	450:3 486:21,23	disagree 355:16	367:13,21 373:4	342:16,23 344:20
detail 419:8 disagreements 418:17,23 419:9 375:11,16,24 determine 401:13 363:14 443:20 445:7 376:5,13 377:3,9 412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 440:16 454:24 421:23 450:11 discounted 490:20 379:3,9,10,19,21 480:21 501:3 472:16 494:6 379:22,25 380:9 determined disclosed 342:4 387:24 399:21 380:15,21,25 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 458:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 407:10 412:8 458:23 472:11 483:17 469:20 503:2,3,7,8 478:7 478:21 480:16,23 482:25 504:2	487:3,3	425:3 448:3,5,14	373:12,14,17,20	346:13 351:22
determine 401:13 363:14 443:20 445:7 376:5,13 377:3,9 412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 440:16 454:24 421:23 450:11 discounted 490:20 379:3,9,10,19,21 480:21 501:3 472:16 494:6 379:22,25 380:9 determined disclosed 342:4 387:24 399:21 380:15,21,25 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 445:3 446:14 438:14 469:7 406:20 503:2,3,7,8 478:7 478:21 480:16,23 483:17 465:4 473:14,22 478:7 478:21 480:16,23 482:25 504:2 474:10 479:	despite 364:15	449:12	373:25 374:6	354:22 366:23
412:18,20 414:12 disclose 365:25 449:9 481:25 377:10,21,25 429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 440:16 454:24 421:23 450:11 494:6 379:22,25 380:9 determined disclosed 342:4 494:6 379:22,25 380:9 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 458:23 472:11 483:17 406:20 503:2,3,7,8 478:7 478:21 480:16,23 483:17 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	detail 419:8	disagreements	418:17,23 419:9	375:11,16,24
429:23 439:16 370:5 416:16 494:17,25 378:12,19,22 440:16 454:24 421:23 450:11 discounted 490:20 379:3,9,10,19,21 480:21 501:3 472:16 494:6 379:22,25 380:9 determined disclosed 342:4 discussed 375:15 380:15,21,25 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	determine 401:13	363:14	443:20 445:7	376:5,13 377:3,9
440:16 454:24 421:23 450:11 discounted 490:20 379:3,9,10,19,21 480:21 501:3 472:16 494:6 379:22,25 380:9 determined disclosed 342:4 discussed 375:15 380:15,21,25 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	412:18,20 414:12	disclose 365:25	449:9 481:25	377:10,21,25
480:21 501:3 472:16 494:6 379:22,25 380:9 determined disclosed 342:4 discussed 375:15 380:15,21,25 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	429:23 439:16	370:5 416:16	494:17,25	378:12,19,22
determined disclosed 342:4 discussed 375:15 380:15,21,25 354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	440:16 454:24	421:23 450:11	discounted 490:20	379:3,9,10,19,21
354:17 356:7 416:4 419:12,14 387:24 399:21 382:10,10,13,17 357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	480:21 501:3	472:16	494:6	379:22,25 380:9
357:5,15 452:23 419:15 420:5,9 404:14 408:24 383:5 384:17 454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	determined	disclosed 342:4	discussed 375:15	380:15,21,25
454:19,23 455:3 422:8,10,16,23,24 441:7 475:10 386:15,21 388:7 498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	354:17 356:7	416:4 419:12,14	387:24 399:21	382:10,10,13,17
498:14 501:21 423:3,12,19 494:22 503:16,21 393:24 394:6,11 detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	357:5,15 452:23	419:15 420:5,9	404:14 408:24	383:5 384:17
detrimental 427:25 443:3,7,8 discusses 472:10 459:20 462:7 433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	454:19,23 455:3	422:8,10,16,23,24	441:7 475:10	386:15,21 388:7
433:21 434:2,6 443:17,24 444:8 discussing 396:14 496:20 503:2,3,7,8 difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	498:14 501:21	423:3,12,19	494:22 503:16,21	393:24 394:6,11
difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25	detrimental	427:25 443:3,7,8	discusses 472:10	459:20 462:7
difference 406:19 445:3 446:14 438:14 469:7 dogs 427:6 407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25	433:21 434:2,6	443:17,24 444:8	discussing 396:14	496:20 503:2,3,7,8
407:10 412:8 458:23 472:11 483:17 doing 464:25 478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	difference 406:19	445:3 446:14	_	
478:7 478:21 480:16,23 discussion 445:9 465:4 473:14,22 differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	407:10 412:8	458:23 472:11	483:17	
differences 500:16 483:6,20 482:25 504:2 474:10 479:6 different 348:13 disclosing 431:25 discussions 485:25 495:7	478:7	478:21 480:16,23	discussion 445:9	
different 348:13 disclosing 431:25 discussions 485:25 495:7	differences 500:16	· · · · · · · · · · · · · · · · · · ·	482:25 504:2	
		· · · · · · · · · · · · · · · · · · ·		

[dollar - esq] Page 13

dollar 478:5	earlier 337:16	480:17 481:7,15	employees 339:5
497:16,23 498:9	375:15 382:16	482:8,21 483:11	encourage 335:2
498:13,14,25	385:12,17 386:9	483:17,17 484:4	engaged 449:22
500:14 501:22	408:24 409:11	485:4,21	engagement
dollars 478:6	412:22 419:21,24	effex's 462:7,9	345:23 438:6
dow 371:18	439:8 441:7,19,22	efficiency 331:9	engagements
download 342:25	442:2 466:24	331:22 338:10	345:15
343:6	469:7,23 471:3,3	339:3,16,22 340:6	ennis 330:14 334:2
downloaded	472:4 494:23	340:8 341:2,5,15	334:2 336:18
343:22 391:7	500:12,17 503:17	341:19,20 344:11	339:19,25 341:8
dr 331:8,9,22	early 456:14	345:16 349:25	350:22 351:2,9
333:6 334:20	461:22 469:9	350:8 353:5 359:3	452:7 471:10
336:16,20 339:23	earn 478:5	366:22 374:19	ensure 389:7
340:2 341:5,9	earnings 493:16	376:16,21 387:25	ensured 365:17
343:20 350:14	easier 394:8	389:19,24 390:2,6	421:12
353:9 354:25	ebitda 493:17	403:6,9,16 410:3	enter 456:3 470:2
383:16 386:22	economic 366:2	410:18 411:11,18	entire 376:6
388:25 407:8	421:23	491:21 493:3	459:13 494:25
417:15 429:13	economist 400:24	503:13	entirely 484:25
452:9 468:4 490:8	405:19	efficient 352:17	entirety 433:17
492:15,23 493:10	edge 447:8	353:13 357:11,21	entities 479:9
493:14 507:3,21	eennis 330:12	358:4 392:12	entitled 411:25
draft 425:23	effect 353:6	393:4 400:7,8,14	506:8
drafted 357:3	364:13 420:7	400:25 401:14,16	entity 389:2
drafting 337:7,11	445:21 500:12	401:24,24 403:4	396:13 398:14
339:6 351:14,20	effex 364:22,22,23	403:24 404:6,9,15	424:4 428:11
453:17	365:6,7,10,12,13	404:21 405:22	430:23 431:10,12
drew 381:6,11,17	365:15,18,20	406:3,7,10,20,21	431:17 457:11
drop 371:17	366:3 380:10	407:11 409:2,5,8	461:19 463:25
404:11 405:2	420:14 421:2,5,7	409:16,21	entry 453:2
dror 452:15	421:10,13,16,25	either 345:23	equals 458:16
due 347:9 353:10	422:16 423:3,13	389:16,17 406:14	equity 348:5 349:8
392:2 440:23	423:20 424:3,7,16	416:9 498:9	370:21 387:23
duly 334:13 506:6	428:2,10,15 429:2	506:20	ernst 380:12,15,19
duty 472:16	429:16,24 430:15	election 417:3	380:22,25
e	430:22 431:16	elicited 500:10	errata 331:20
e 330:2,2,17,17	432:2 433:21	eliminate 383:14	339:21 340:14,17
331:2,5 365:7,7	434:6 445:4	embody 341:20	505:5 507:1
366:4 420:15	446:13 448:21	empirically 500:9	escaping 503:23
421:3,8,10,13	466:21 467:12	employ 493:11	esq 330:7,7,13,14
	475:19 478:12,16		330:14

[essentially - fact] Page 14

	I	I	1
essentially 342:9	448:6,7 449:19	exhibits 331:18	expresses 397:11
364:23 369:15	examination 331:4	335:9 350:17	extent 349:10
420:16	334:19	380:18	356:23 378:21
establish 392:15	examined 334:14	exit 371:9 372:3	379:17 380:4
established 353:12	example 438:17	expansive 413:24	381:22 382:9,19
393:3	470:12 473:12	expects 371:11,13	383:23 384:5,16
estimate 337:21	476:11 485:13	371:14	388:2 393:20
357:2 500:20	490:15 498:17	expense 365:2	394:23 396:9
estimated 498:24	examples 414:2,7	420:19	397:4 398:12,23
estimating 502:9	503:11	experience 456:2	401:5 403:5
et 426:16	excellent 338:25	expert 335:25	411:22 416:22
evan 330:14 334:2	exchange 331:15	344:7 386:6	419:19 423:22
336:13 339:17	371:10 439:23,25	399:15 422:6	425:7 428:4 430:3
350:21 451:23	449:23 450:14	423:2 424:15	430:16 431:3
471:6	452:4,17 453:4	428:25 429:16,23	432:5,12 433:24
event 353:9	465:21 466:2,8	430:13 433:20	435:13 442:3,7
358:10,20 359:17	468:24	434:5 436:14,19	449:3 457:19,22
361:18 374:14,17	excuse 333:6	439:24 440:3,6,10	459:8,21 470:11
374:21 375:2,12	371:25 449:9	465:24 467:10	470:11 472:3
399:5 401:13	499:11	488:10 497:5	475:10 477:10
403:2,14,16,22	exhibit 331:7,9,11	499:10	478:9 479:14
405:20,25 406:6	331:12,13,20,21	expertise 436:7,11	484:20 487:10,16
407:17,24 408:14	331:23 335:10	436:21 439:15,20	490:23 492:19
408:17 506:22	336:8,9,14,15	experts 439:22	494:8,10,20 495:2
events 353:11	339:14,20,21	expires 505:20	496:12 498:3
374:6	340:15,24 341:3,4	507:25	501:25 502:21
evidence 353:5	342:10,17,20	explain 409:23	extra 372:7
443:13 444:11	346:14 351:3,6	explained 441:21	extreme 411:6
450:23 455:8	352:6,10 375:18	explaining 426:21	extremely 399:18
459:11 460:21	375:21 376:3,14	479:8	414:6 415:10
464:19 470:10	376:21,24 378:6	explicit 487:13,15	423:16
474:7 482:16	378:13 379:5,13	487:18	f
501:5,7 502:2	381:12,23 382:18	explore 414:11	f 328:5 333:7
evidentiary	384:18 385:25	417:22 418:3,9	365:7,7 506:2,2
349:21	386:5 391:6 452:2	exploring 405:13	fact 357:14,19
evidently 391:8	452:8,10,14	exposure 435:13	358:2 364:18
exact 372:12	454:13 471:11,12	436:2,8,22 449:4	369:21 407:18
462:22	471:18,24 472:4	458:19	411:10 414:13
exactly 345:13	492:10,11 493:24	expressed 457:17	440:6 446:8
377:6 378:16	494:14 496:6,6	473:4 474:18	474:17 479:15
424:25 436:18			7/4.1/ 4/7.13

[factor - foreseeable]

Page 1	15
--------	----

	T = =	m	
factor 411:18,21	445:7 446:17	fine 343:18,25	flowing 417:9
factored 411:23	447:17,22 448:17	364:5 371:25	flows 477:23 478:4
factors 352:15	449:15,20 450:16	393:25 402:22,24	focus 362:23
456:9 491:16	451:24 459:3,25	427:5 459:5 460:4	418:14
501:15	463:11,20 482:19	460:15 465:5	focusing 345:20
facts 408:4,6	483:9,20 495:23	467:20 483:21	358:14
415:11,15 442:19	496:10	488:3	folder 336:19
463:13 464:7	file 328:4	finish 377:24	471:7
479:13 482:16	filed 336:12	383:18,21,22	follow 368:20
489:16 501:25	340:14 346:17	490:9	391:13,23
failed 472:19	351:25 366:13	firm 330:3 334:5,7	followed 352:23
failing 365:25	filing 339:9 352:2	345:24 479:11	following 362:9
421:23	371:17	firm's 380:17	371:8 413:2,10
fair 382:9 397:10	filings 478:21	439:9	454:8 458:5
492:8,25 496:14	finally 371:3,4,21	firms 436:16,18	488:17 495:11
501:17 503:5,18	finance 375:10	first 336:8 344:20	follows 334:15
fairly 352:22	439:21,22	350:18 363:6	427:23 434:21
fall 444:14,21	financial 364:18	391:20 392:7	footnote 376:7
466:5	365:23 369:10	426:25 442:14	footnotes 381:13
fallen 444:12	370:18 372:7	444:17 452:13,19	382:19 384:20
falls 487:18	380:20 420:10	fit 361:14	forced 369:15
false 353:17 362:6	421:20 424:3,7,17	five 386:15 388:19	370:20 371:9
369:17 393:8	428:9,16 429:2,17	427:3 465:12,14	foregoing 505:3
449:22 472:20	429:24 430:15,22	465:15 467:15,17	506:6
falsely 364:10	431:25 436:16,17	470:15 473:13,15	foreign 370:19
familiar 334:23	457:10 462:8	flash 475:4,13,20	371:10 439:23,25
381:7 388:25	488:17	475:24 476:3,6	449:23 465:20,25
389:3 436:12,13	financially 333:15	flip 344:6 375:21	466:8 468:24
455:10 464:24	364:25 420:18	floor 500:21	foremost 439:22
465:19,22,22	financials 380:17	flow 365:18,21	forensic 493:11
474:17 475:4,12	424:9,18 428:17	421:13,17 422:18	foreseeability
fantastic 504:19	429:4,18 430:2	423:4,8,9,14 433:8	469:8
far 338:15 359:6	431:16 457:9,15	433:13,14 461:19	foreseeable 458:22
fast 362:21	457:20,21 488:24	466:9,13 477:4,16	459:4 460:2,14,19
february 347:16	find 352:14 379:2	478:13,17,22	465:2,4,13,14
348:3,18,23	382:24 425:18	479:2,8,10,11,19	469:16,25 470:9
358:16 369:13	457:11 502:6	480:7,17,24 481:4	470:11 473:9,14
371:2,19 372:21	findings 331:16	481:7,15 490:20	473:17,23 474:7,8
374:4,10,12,22	452:5,18,25 453:5	491:4 493:17	474:9,11 476:17
387:17 442:13	453:7	494:6	476:19 479:23,24
443:7 444:2,6			ĺ
, -			
Varitant Lacal Colutions			

[foreseen - gaap] Page 16

	T	T	Г
foreseen 476:4	483:6	fx 365:8 439:25	449:10,22,23,24
forex 371:23	foundation 406:2	fxcm 328:5 333:8	450:3,8,9,10,12,19
437:11 439:4,15	founding 369:17	333:23 347:7,11	451:9 452:14
440:11 449:24	371:24	349:16,17,25	457:3 458:15
452:14 457:4	four 345:14	350:8 352:16,23	459:4 460:2,14
form 341:22 342:6	fraud 392:14	352:24 353:9,12	461:18 462:6,8,10
354:19 356:15	412:11,15 441:4	353:24 354:8,9,14	464:3 466:19
357:12 358:13	449:6 455:9 484:6	354:18 355:23,23	467:10 469:16,25
385:14 389:12	494:13,14,15	356:5,8 357:11,16	472:10,19 476:4
393:19 394:17	499:18 500:4	357:20,22 358:3,5	478:13,17,20
397:18,23 398:21	fraudulent 414:4	358:8 362:8,13,17	479:3,6 480:5,15
399:11 404:12	416:4,17	363:2,10,11	480:17,23 481:8
405:3,21,25 406:9	free 365:4 372:4	364:10,18,23,24	482:3,8,20 483:10
406:17 408:3	420:22 458:12	365:5,8,11,17,19	483:21 484:13,25
409:17 410:5	frequency 352:25	365:21,23 367:11	486:23,24 487:2,6
411:13 416:20	friday 328:10	367:23 368:21,22	488:16 495:14
419:2 422:19	front 335:14	369:2,2,5,13,16,21	fxcm's 364:13,14
430:24 431:18	341:13 342:17	369:24 370:10,15	364:21 365:23,25
436:10,24 439:5	351:11 358:24	371:3,6,24 372:2	370:7,9 385:19
439:18 442:15	364:23 365:8	373:6 374:7,24	387:6,11,16
444:9 449:17	370:24 386:16	375:4,25 376:13	391:14,25 420:7
456:20 459:7	391:9 420:16	377:4,6 378:3,13	420:11 424:7,8,17
460:5,17 463:12	421:3 446:21	378:16 379:3,22	424:18 428:15,17
464:15 468:9,15	fta 379:20	379:24 392:11	429:2,3,17,18,24
469:4 473:10	full 388:2,6 392:7	393:4,12 397:14	429:25 433:4,10
475:15 477:8	483:5	398:6 403:3,4,22	433:21 434:5,13
480:18 482:10	fully 380:6 400:15	403:24 404:6,11	434:25 435:13
484:7,14 485:8	401:2,17,22 402:9	408:2,18,18 409:2	436:2 437:5,9,20
488:2 500:15	402:18 404:17,24	409:8,15 418:17	437:23 438:5
formation 457:24	fundamental	418:23 419:9,12	439:3,17 440:11
formed 423:11	375:9	419:14,19,23	447:21 449:2,3,6
443:11	further 352:14	420:5,7,16,17,24	450:5 456:13,17
forming 388:8	441:3 450:13	421:7,12,14,18,23	466:21 469:8
441:13 444:25	489:22 506:19	422:8,16 423:2,12	481:6 482:7
489:11	furthermore	423:19 424:2	483:15 485:19
forth 354:6 386:17	440:22	427:25 428:8	489:7,14 494:18
386:20 454:9	future 449:6,21	429:24 430:14,21	g
464:14	458:20 476:16	431:15,24 432:25	g 371:12
forward 481:8	477:23 481:8	435:12 436:9,22	gaap 365:25
found 338:13	futures 370:2,3	445:3 446:7,14	424:10 428:18
370:7 449:21	371:22	448:21,22,23	487:21 488:8,13
			707.21 700.0,13

[gaap - hereto] Page 17

488:14 489:6,15	491:19 496:22	goes 376:25	h
gain 371:11,13	502:12 504:9,17	going 333:3 343:5	h 331:5
372:5,9	given 334:22,24	354:12 362:21	happened 442:22
gears 475:3	432:19 478:25	366:22 368:13	461:13 481:11,12
477:17	481:4 503:10	378:23 386:17,20	488:25
general 350:4	giving 360:5 415:6	388:21 395:8	happening 485:16
401:9,10 402:6,13	457:13	401:19 402:21	happy 358:24
402:23 411:23	glad 486:13	405:11 407:4	359:22 360:4
413:19,20 415:10	glanced 503:15	416:19 426:6	361:2 376:6
415:14,17,24	global 328:4 333:7	427:20 429:12	380:18 382:23
417:25 419:19	507:2	433:15,17 445:12	386:12 389:14,16
423:7 436:15	globally 437:13	454:5,11 455:15	390:14,20,24
437:22 448:13,13	go 336:22 337:15	463:9 465:12,16	393:23 394:21
451:5 456:11	338:9 343:23	467:18,22,24	400:17,19 401:6
477:5,14,14 478:9	344:19 351:22	473:11,24 474:3,4	424:25 425:10
479:18 492:15	355:17 356:12	474:5,9 476:7,18	426:19 427:2,14
generally 350:5	360:25 365:18	478:5,6 479:21	427:17 439:8
365:24 401:11	372:12 376:6,23	481:8 490:3 497:2	450:21 451:12
404:18 405:19	378:10 379:20	501:11 504:21	hard 447:7
406:17 412:15	380:16 382:23	good 333:2 334:20	hate 473:11 494:8
413:21 417:18	383:24 384:23	370:19 388:18	head 394:4 417:10
421:22 437:11	385:6 386:13	426:10 489:20	hear 397:22 427:6
439:4,17 466:13	388:15 396:7	gotten 391:16	heard 409:5
468:23 477:25	397:22 398:9	govern 465:25	426:25 451:3
496:15 501:8,14	399:2,12 400:2	governing 465:20	467:21 491:7
generate 365:19	406:23 408:8	government 446:2	hearing 349:21,24
421:14	415:6 416:13	grade 426:6,24	350:7,11,15,18
generated 370:9	420:2 421:13	graduate 439:21	held 349:21
456:13	427:14,17 435:11	graduation 426:7	387:16 472:15
generous 396:15	448:10 449:18	426:9,13,24	help 401:13
getting 347:23	453:15 454:2,3	granted 354:8	425:25
407:5 411:6 491:8	455:16 458:7	391:14,24	helped 337:11
give 339:19 361:20	464:17 465:5,13	greenwood 330:4	helping 355:14
361:22 368:14	465:15 467:16	gross 456:13	hendershott
380:6 383:10	469:5 470:16	guess 350:6 423:7	350:14 492:15,16
389:7 408:12	471:18 473:15,23	426:18 451:22	492:24 493:14
413:25 415:9	476:10,22 477:9	496:8	hendershott's
425:17 427:3	481:18 482:24	guys 360:22	493:10
431:5,20 468:16	485:6,9 487:24	383:12 427:9	herby 506:5
479:14 483:2	489:24 496:5	447:8	hereto 506:18
489:21 490:15			
	l .	l	I

[higher - information]

Page 18

1.1.1		400.7	'' '.l 220 12
higher 498:24	i	499:7	individuals 338:12
hit 371:23	i.e. 440:18,25	included 342:2	industry 454:15
hmm 456:25 479:5	idahan 330:13	344:11 381:22	inefficient 400:6
490:14	idea 338:5	including 458:13	402:7,16,17 406:3
hold 338:8 341:12	identification	462:9 503:3	406:7,10,20
344:19 364:24	336:17 339:24	inclusive 380:6	407:11,16,19,25
368:25 377:23	341:7 351:5,8	incomplete 400:9	409:5,20
378:8 392:25,25	452:6 471:14	401:25 482:11,13	inextricable
412:3 420:17	identified 447:20	incorporate	362:15 367:13,16
461:3 471:17	493:13	400:14,25 402:8	367:21 368:10
492:11 493:4	ignoring 479:13	402:17 404:23	372:15,19 373:4
holders 357:6	ii 452:13,19	incorporated	373:10,17 441:5,8
398:11	illegal 473:22	372:3,5 404:16	441:11,17 445:10
holdings 344:14	immediately 413:5	incorrect 464:20	446:6 449:7
345:12 371:24	413:13 488:21	488:7	481:25 494:16,21
372:5 452:15	impact 412:14	increase 414:5	inextricably
honorable 331:12	418:3,9 436:16	478:5	372:12 484:10,21
350:20 351:4	477:23 481:6	increased 456:21	inflated 349:17
391:5	484:18	independent 365:9	354:15 355:24
hope 399:25	impacted 482:8	421:3	356:6 363:11
hopefully 490:9	implication 487:7	independently	385:20 387:6,12
hopping 354:22	498:2	422:7,11 439:16	448:22 449:11
host 379:22	implications 487:2	443:10	494:19
501:15	_	index 332:3	inflation 362:16
hour 426:6,17	implied 487:11 491:2	indicate 415:2,20	362:25 367:11,23
hours 338:21,22		443:14 474:7	373:5 374:7,23
502:16	imposed 468:8,13	indicates 459:11	375:4 412:2,8,14
huang 337:17	imposing 331:16	462:4	413:4,12,17,23
338:3	452:5,18 453:5	indicating 340:18	414:5,8,11,13,19
huh 471:18	impossible 484:23	indication 475:12	415:2,20 482:2
hundred 485:15	486:6	individual 343:2	497:17,24 498:5,9
485:16 486:6	imprecise 398:10	357:2 392:16	498:25 499:3,20
hypothesis 392:14	399:18	393:16 394:7,14	500:2,14,16,20,23
hypothetical	improved 456:22	395:15 396:2,20	501:4,18,20,22
383:13 400:10,13	456:23	397:13,17 398:2	502:7,10
402:2,5,11,12	inaccurate 443:14	408:22 496:19	influence 501:15
445:14 482:12,13	478:10	individual's	information
482:14	inarticulate	381:21	384:17 388:7
hypothetically	356:20 363:18	individually	395:10,16 396:23
459:9	include 345:8	353:16 393:7	401:18,23 404:25
4 33.3	396:16 437:23	496:25	413:2,10 414:18
	454:16 487:20	470. <i>43</i>	413.2,10 414.18
	I .	ral Calutions	

[information - knew] Page 19

			T
416:3,16 419:17	interested 333:15	investor 362:17	jenkintown 330:5
419:20,22 443:2,6	506:21	367:24 373:6	jersey 329:10
443:16,19,24	interesting 377:12	375:5 401:13	job 328:25 384:5
444:13,24,25	434:8 456:25	482:4	jogs 478:18
446:18 448:14,16	469:2 479:5	investors 364:11	john 382:2 497:6
449:13 462:7	intermediary	365:3 387:16	joining 334:21
477:18,21 478:4	364:15 420:8	420:20 477:19,22	jones 371:18
480:15,22 483:19	450:2	involve 470:3	josh 334:4 356:13
484:3,12,18 486:9	internal 375:11	involves 397:4	361:13,13 384:24
491:18 496:12	379:9,10,18,21,24	isajiw 330:13	385:13 388:13
informs 454:14	international	331:4 333:22,22	397:20 398:8
initially 352:21	439:21,22	334:18,19 336:13	399:25 402:20
injecting 442:8	interrupted	339:17 343:12,15	405:7,10,15
innocoll 344:14	453:14	344:18 346:8	406:16 407:3
345:12	interrupting	350:21,23 360:19	411:5 442:18
inquiries 469:9	397:21	374:11 385:13	477:9 485:7
inquiry 455:21	introduce 336:7	388:18 406:16	487:25 504:13
instance 437:10	339:12 340:24	411:5 425:11,15	joshua 330:7
instant 497:18	350:17 380:17	425:19 426:2	judge's 503:12
instituting 331:13	389:6 450:22	434:18 451:23	july 331:10 340:25
452:3,16 453:3	451:23	471:6 489:24	341:6 378:7
institution 452:21	introduced 335:10	504:13	jumbling 409:20
institutional	471:10	israel 330:14	jump 362:19
371:19	investigated	333:24	june 328:10 329:3
instruct 395:5	423:20 428:3	issue 352:18	333:4 348:23
397:5	investigation	370:12 435:8	506:25
instruction 395:3	459:5 460:3 461:4	466:14,17 473:18	k
396:9 397:3	461:15 462:13,21	issued 344:12	k 328:5 333:7
interbank 372:9	463:4,5,7,9,17	424:2 428:8	keep 342:23
interest 362:6	474:15 476:14,15	430:21 431:15,25	386:20 397:21
364:13,16,19	investigations	470:20 496:10	410:10 473:11,18
366:2 370:5 420:7	460:14 461:24	issues 370:13	476:7 481:17
420:10 421:24	464:4,6 466:20	479:15	494:9
424:4 428:10	467:11 469:18	j	kicking 438:22
430:23 431:10,12	472:12,21 473:5	j.p. 372:8	killing 473:16
431:17 433:3,9	474:20 475:14,19	j.p. 372.8 jail 465:14,15	king 330:9 333:22
448:25 449:25	475:24 476:2	470:17 473:15,23	333:24 334:2
450:4 479:4 480:5	investment 368:24	january 331:22	kitchen 467:19
482:21 483:11,13	368:25 377:14	339:14,23 376:15	knew 411:22
485:4,21	439:7	jbaker 330:6	450:20 465:12,15
		Juanci 330.0	750.20 405.12,15

[know - looked] Page 20

	I	Ι	I
know 334:23	477:15 479:6	leave 423:17 427:7	little 386:19 411:6
338:9,15 340:2	482:17 485:12,12	leaving 426:13	457:13 468:17
341:9 342:22	486:4 487:17	led 368:21	481:20
343:19 344:8	488:23 489:9,18	left 446:7 451:22	live 426:14
345:7 349:11,20	490:14,24 495:20	legal 333:10,13	llc 452:14,15 507:1
359:19 360:21	496:6 498:22	393:21 474:11	llp 330:9
362:22 363:14	499:14 500:5	length 494:23	load 350:21
376:7 377:5,6,13	501:12	letters 365:8	loaded 339:25
377:23 378:4,15	knowledge 395:2	level 370:22 413:4	341:8 351:2,9
378:16 379:12	457:8 475:21	413:12,16,23	452:7
380:2,19 381:18	known 459:15	492:15	loading 341:11
381:21 382:3,7	krogman 352:15	levels 476:24	located 335:16
383:12 385:7	kslaw.com 330:12	license 506:25	long 349:7 400:2
390:21 392:5	330:12,13	licenses 372:10	427:4 457:12
394:3,5,18 395:4	l	lied 447:4	491:13
396:18,22 397:24	1 330:17	life 344:14	longer 362:7,12
400:12 402:5,10	lack 362:5 433:2	light 473:3 474:18	445:13 446:3
406:24 408:9	448:24	likelihoods 416:11	458:14 495:13
409:19 411:15	laid 436:5	limited 353:10	496:3
414:21 416:24,24	language 372:13	462:9	look 336:19
417:11 419:4,5	453:10 454:2,14	line 332:6,10,13	351:22 355:8
426:12,14,15,16	453:10 454:2,14	332:16,19,22	376:6,14 378:6
427:3,7 430:8,17	lapointe 330:7	507:5	380:18 386:14,23
431:4,5,8,12,20	334:6,6	lines 425:24	387:3 389:14,16
432:14,14,22	large 414:6	linked 484:10,21	390:24 391:3,11
433:11 435:9	largest 364:21	liquidity 422:17	393:23 394:11
436:6,13,18	370:6 420:11	423:3,13 462:10	395:19 399:14
438:20,20 439:19	450:5 483:15	list 366:23 375:24	400:2 411:24
439:24 440:2	lasted 504:8	377:20 418:16,22	427:9 432:20
441:9 442:23	late 369:25	listed 342:16	433:12 447:4,12
447:5 450:20	laugh 405:15	346:13 352:6	451:12,19 457:25
451:24 452:9	law 330:3 334:5,7	361:23 366:18	461:9 462:3 471:2
453:20 454:11,22	345:24	375:18 377:4	471:3 473:12,22
456:12,17 457:9	lawsuit 464:12	378:13,19 379:4	473:25 478:4
458:2 461:17,18		379:13,23 382:10	479:7 492:9 493:2
462:2 466:7,19	lawyer 482:17 486:16	382:17 383:5	493:6 496:5,9,24
467:2 470:13,16		384:18	497:9
470:17,18 471:15	layoff 371:6	literally 426:2	looked 457:9
473:20 474:4,10	lead 440:15	litigation 328:5	468:20 487:12,16
475:13,16,18,23	learned 458:11	333:8 431:7	489:10 502:25
475:25 476:12	482:20 483:9		

[looking - matter] Page 21

looking 342:19	losses 362:18	march 347:16	410:17 411:11,17
364:6 375:7	364:8,13 367:24	348:3,18 350:19	420:10,25 421:3,6
385:22 390:15	373:7 375:5	350:24 351:25	421:9,11,18 433:2
415:14,17 426:2	401:13 420:6	358:9,16,21	435:12 437:4,18
447:24,25 477:2	440:16 482:4	359:18 371:16	441:5 443:17
491:17 492:14	lot 405:17	391:4 442:13	445:11,25 446:23
499:21	loud 435:20	443:3,17,24 444:8	447:7 448:24
looks 343:14 345:5	loves 431:7	444:15 445:4,22	449:3,7 450:4,7,10
426:8 466:22	luck 426:10	446:15 459:3,25	458:11 459:6
loss 331:7 335:25	luk's 368:24	460:22 464:5	460:4,16 469:20
336:11,16,24	lunch 490:4	469:16,25 470:22	470:4 478:7
339:10 341:18	lying 446:7,9,22	470:24,25	480:16,23 482:19
342:19 345:21	465:3	marked 331:18	483:9,14,16,20
346:3,5,12,18	m	332:15 336:17	485:20 491:21
347:7 351:14,20		339:13,24 341:6	493:3 494:15
354:13 355:8	macroeconomics 440:2	351:5,7 359:17	503:13
357:3,16,22 358:5		452:6 471:11,13	market's 370:23
361:25 364:4	maintaining 443:18	market 331:9,21	458:17,21
374:15 375:8,18	maker 364:19	338:10 339:3,15	markets 371:23
379:7 386:3,7,11	365:22 369:19	339:22 340:6,8	400:14,25 402:17
386:23 387:2,24	370:6,8 420:10	341:2,5,15,19,20	439:23 452:14
388:3 397:11	421:18 450:4,10	344:11 345:16	468:25
398:19 399:6	483:14,16	349:24 350:8	marks 358:10
403:10,13,19,21	makers 365:9,11	352:17 353:5,13	361:18 364:20
403:23 404:5	365:14,17 421:3,6	357:11,21 358:4	markups 365:15
405:21 408:15	421:9,12 450:7	359:3 362:4	421:10
409:12 410:15	making 331:15	364:11,19 365:9	master 328:4
411:8,9,19 417:21	353:18 365:22	365:11,14,17,22	material 366:17
419:7 422:14	386:4 393:9	366:22 369:19	367:4 441:12
430:13 431:23	405:16 421:18	370:6,8 371:10	478:3
432:21 440:8,18	426:9 452:4,18	372:9 374:19	materials 335:21
440:23 453:17	453:4	376:16,20 387:25	342:4,5,8 345:22
457:16 468:5	management	389:19,24 390:2,6	346:10,19 366:25
472:2,24 483:25	466:19 467:11	392:12,14 393:4	379:23
486:20 487:4,19	manifest 441:6	400:6,6,8 401:14	matter 333:7
489:4 490:10	449:8 494:16	401:16,23,24	334:23 336:2,12
491:22 492:17,20	manipulated	402:7 403:4,16,24	339:9 340:20
493:19,23 495:10	365:5 420:25	404:6,9,15,21	341:21,25 342:7
497:10,21 499:3,6	manner 436:20	405:22 406:2,8	345:21 349:22
499:13,16 500:3	marcelo 330:18	407:15,18,25	359:6 366:10,13
	333:9	409:3,8,15 410:3	367:3 370:10

[matter - motion] Page 22

375:17 378:3	461:12,20 463:14	502:3	misrepresents
380:9 381:6 388:3	463:15,23 464:24	miasma 433:14	477:11
389:7,11 390:9	465:10 466:3,11	michael 345:5	missing 345:3,11
393:17 394:7	467:4 468:19	microphone 407:5	misstatement
400:23 410:4,18	470:8 471:8	middle 392:7	416:5,17
411:12,18 422:6	473:11,18 474:3	458:7	misstatements
424:16 428:25	476:7,21,23	million 369:5,14	474:14
429:16,22 430:14	477:24 478:2,4	370:15 371:25	misstates 462:16
430:20 431:24	479:6,10,12	370:13 371:23	model 362:7,14
433:20 436:3,23	481:17 482:11,12	483:21	434:12,15,24
438:6 440:13	484:15 485:12,24	mind 370:23 379:6	435:2 437:6,7,9,14
441:2,14 448:13	487:7,15 488:7	mindful 335:3,6	437:16,20,21,23
454:25 464:14	490:22 491:15	mine 502:21	437.10,20,21,23
466:2,11 470:21	497:25 498:3,4,20	minute 388:19	438:24 439:17
494:13 497:7	501:11,12,14	415:16 427:16	440:12 449:5
501:10 502:20	502:24 503:3,14	447:13 467:15	458:12,14,20
503:4	502.24 505.5,14	504:9	486:22,23 490:21
matters 345:14			495:16
	meaning 353:15 392:13 393:6	minutes 363:15	
mean 333:6		426:14,18,22	models 362:10
344:16 347:3	means 353:19	427:3 467:18,18	490:12,14 493:16
348:2 355:13	368:23 393:10	489:22 502:24	493:19,22 495:12
361:21,22 363:7	451:7	504:8	495:25
369:10,11 372:11	meant 369:9 373:9	mischaracterizing	modification
372:14 377:22	438:23	361:12	410:2,15
379:17,21,22	measure 414:18	misleading 353:17	modifications
382:23 395:24	500:23 501:4	369:18 392:17	406:6 407:16
397:21 398:3,4	meeting 504:3	393:9 449:22	408:10,11,16,20
399:24 403:15	meetings 503:20	472:20	410:8
408:9 409:19,23	503:24	misled 432:25	modify 409:12,20
411:21 413:24,25	member 503:22	435:12 437:4,19	409:23
414:6 415:5,8	memory 359:23	448:23 449:2	mom 426:15
416:23 417:2,6,18	390:17 393:24	mismanagement	moment 425:18
422:21 423:9	394:12 471:4	472:18	475:3
433:12,24 436:14	mention 374:2	misrepresentation	monetary 369:6
437:21,23 438:8,8	mentioned 407:10	363:9	370:16 450:12
438:16,17 439:6	merely 364:14	misrepresentatio	morgan 372:9
439:19,20 440:4	420:8	363:3,22 366:7	morning 333:2
442:23 444:3,10	met 352:15	367:3,7 372:2	334:20
447:18 451:6,13	methodology	440:18,24 448:20	motion 332:21
451:14 453:9	406:6 407:17,24	misrepresented	351:13,19 354:7
454:23 460:6	499:20 501:4,9,22	362:13 495:15	389:20 390:7

[motion - objection]

Page 23

391:13,24 470:21	need 358:23	notary 329:9	number 352:22
move 361:15	360:17 386:19	505:17 507:25	413:24 451:25
384:11 385:2	394:11 406:5	note 340:12 347:8	497:3,16
multi 414:20,25	407:21 412:19	348:12,15 353:15	numbered 452:12
415:19 464:4	414:11 417:22	355:5,6 357:5	numbers 336:9
multiple 342:23	418:3,9 467:16	369:7 393:6	343:10,10,12,13
354:22 373:14	496:24 502:8	398:11,11 440:25	456:16
388:17 410:10	needs 410:7	493:10	numeral 452:13
467:14 490:12,13	negative 368:19	noted 504:22	452:19
493:16,19	negatively 424:8	505:5	numerous 392:19
multitude 476:24	424:17 428:16	notes 347:8,11,13	410:6 475:10
murder 465:12,16	429:3,17,25	347:18 348:21	0
470:12,13 476:10	negotiated 450:18	349:3,9,17,25	o 330:17 506:2,2
476:12,13,14,17	455:20	350:9 352:16,18	object 341:22
476:18	negotiation 456:10	352:20,23 353:9	361:13 389:12
murdered 465:11	neither 454:5	353:13,15,21,24	398:9 404:12
murdering 470:14	net 456:17	354:9,14,18	408:3 409:17
470:17 473:13	new 328:2 329:10	355:23 356:5,8,21	410:5 416:19
myriad 441:20,25	329:10 330:11,11	356:22,24 357:11	objecting 388:14
n	370:12,12 458:17	357:16,17,20,22	objecting 358.14 objection 354:19
n 330:2,17 331:2	507:1	358:4,5 363:11,16	356:10,15 357:12
name 333:9	news 353:8 368:18	363:17,19,20	358:13 360:10
337:16 371:12	368:19 371:19	387:11,13,21,23	368:2 383:8
381:7 422:16	375:11 399:8	390:22 392:2,11	384:25 385:11,13
423:3,6,13 503:23	400:5,14,25 402:8	392:12,18 393:4,6	388:10 393:19,20
507:2,3	402:17 404:15,22	393:12 394:16	394:17 396:6,8
nariner 337:13,22	482:25	396:4 403:3,4,22	394:17 396:6,8
502:23	nfa 369:6,9,11	403:24 404:6,8,11	398:21.23 399:11
	370:2,16 447:12	408:2,18 409:2,8	400:9 401:25
narrow 499:16 national 370:2	447:22 448:17	409:13,15 410:4	
nature 353:10	449:15 451:10	410:16,18 411:12	405:3,16 406:9,17 410:19,25 411:13
	454:19 455:4	411:18,20 448:22	410:19,25 411:15
480:15,22	461:4,15 463:3,7	notice 331:20	
ndd 364:17,21	466:20 467:11	339:20 340:14,16	430:24 431:18
365:5,5 420:11,22	472:12 475:14,18	340:18	436:10,24 439:5
420:25 433:4,10 437:24 449:2	488:18,20 489:13	noticing 333:21	439:18 441:23 442:15 444:9
	niv 381:6,11,17	notion 408:20	
nearly 463:10	452:15	noun 442:9	448:18 449:17
necessarily 402:19	noise 353:3	nouns 442:9	451:21 456:20
402:25 406:11	normal 455:23	nova 344:14	457:18 459:7
necessary 383:3			460:5,17 462:15
389:9			463:12,22 464:7

464:15 468:9,15	491:11	472:6,8 482:5	opinion 331:23
469:3,4 470:5	okay 335:7,9,15	483:8 490:19,22	335:25 354:12
473:10 475:15	335:21,24 336:7	491:5,11,20	357:10 372:17
477:8,10 480:8,18	336:22,23 339:4	492:12 493:5,8	374:5 392:5 396:3
481:2 482:10	339:12 340:4,5,16	494:5 495:6	397:11 398:17
484:7,14 485:5,8	340:23 341:13,17	497:12 502:11	399:15 400:4
485:22 486:11	342:13,18 343:3,7	503:5 504:10	422:6 423:2,12,15
487:22 488:2	343:18,21 344:2,9	omission 440:24	423:18,25 427:24
489:16	344:24 346:22	omissions 355:22	428:7 429:23
objections 333:19	347:13 348:20	363:3,10,22 366:7	431:14 433:7
411:6	349:2,6,10,12,14	367:3,7 440:18	435:25 436:21
observed 500:9	349:20 350:22	448:21	438:4 439:2
obviously 369:21	351:11,12 352:2,9	omitted 364:11	443:15,23 445:20
399:24	352:12,13 354:4	once 385:15	454:14 459:2,24
occur 399:23	354:12 355:20	ones 344:11	464:14,20,22
occurred 443:20	356:9,18 359:10	441:18 495:24	467:10 469:24
443:21 447:16	360:24 361:6	ongoing 370:19	470:20 471:5,12
459:10 500:12	364:6 366:21	463:19 473:5	471:21,25 472:7
occurring 461:22	367:9,16 368:16	474:20	479:2 480:4,14
479:10	375:23 376:22	online 457:4	482:6 488:13
occurs 455:24	377:2,19 378:10	open 335:14	489:4 503:12
october 353:4	378:10 384:4,13	342:23,25 386:15	opinions 341:21
462:5 463:2	385:18 386:25	391:16	341:24 342:6
offer 398:17	387:4 390:6,21	opening 331:21	345:15 346:20
452:22 489:4	391:9,11,22 392:6	339:15,22 340:5,8	375:17 380:20
offered 353:6	392:25 395:6,17	340:10 341:18	382:20 388:2
365:14 421:9	401:12 402:14	376:15,20	400:23 436:5
offering 433:7	403:12 404:19	operate 362:12	441:13,13 444:25
435:25 436:21	411:24 412:4,6	445:13 446:3,24	457:24 465:24
438:4 439:2	418:6,14 423:5	457:4 465:6	483:5 493:23
454:10 465:24	425:7 426:4,10	495:14 496:3	oppenheimer
467:10	427:6,8,11,13,18	operating 487:2	368:19 369:22
oh 341:11 345:9	429:19 432:20,24	operational 457:8	opposed 352:23
346:23 356:12	435:21,24 441:3	operations 370:19	365:7 394:15
368:24 371:3,14	444:17 445:17	371:8 434:13,25	396:3 423:6,7
372:8 373:22,23	452:11 456:12	437:12,13 439:4	485:3,20 496:16
391:9,22 399:10	458:3,7,7 462:3	455:18	496:18
417:15 446:7	463:3 464:2	operative 340:9	opposite 364:24
447:8 453:12	465:11 467:17	opine 422:8 434:5	420:17
461:10 464:17	470:19 471:15,17	434:9 436:8 466:4	options 498:16,18
466:11 487:24	471:23,24,25	466:6	

[order - period] Page 25

and an 221,12 12	222.22.242.21	406.17.407.0.12	450.12 450.5
order 331:12,13	332:22 342:21	496:17 497:9,13	450:12 459:5
331:23 350:24,24	343:9,10,12,13,17	497:15 498:6,8	460:3,15 477:4
351:6 365:18,21	343:23 344:6,20	500:8	479:19 481:6
370:7 412:18	345:3 347:6,23	paragraphs	483:21
421:13,17 433:8	349:14 352:9,13	498:12	paying 433:14
433:12,14 450:11	354:2 376:16,24	parent 370:21	466:13 478:13,17
451:24 452:2,16	391:12,21 392:4,8	371:23	479:11 480:17
453:3 461:19	392:23 411:24	parse 447:11	payment 365:21
466:9,13 470:20	412:4 452:12	parsing 368:6	433:8 461:19
471:13 477:16	472:6,13 507:5	part 340:15	477:15 479:7
478:13,17,22,25	pages 425:24	345:22 354:8,9	480:7,24 481:4,14
479:8,10,11,19	472:9	356:20 368:7	payments 365:22
480:7,17,24 481:4	paid 370:8	370:13 381:24	421:17 422:18
481:15	papers 386:16	391:17 425:23	423:4,8,14 466:9
orders 365:10	par 387:12	437:15 438:2,2,18	478:22,25
421:4	paragraph 345:11	438:23 444:19	pdf 343:10
original 338:10,10	347:6 348:2,8	446:9 448:10,10	penalty 450:12
339:3 340:19	349:16 354:13	457:23	pending 427:4
359:2 370:14	355:7,11,15,18	participants	penlites 456:8
383:25 384:9	361:24 362:23,24	364:12 435:12	468:7,13
389:23 403:16	362:24 363:7,23	437:4,18 447:7	pennsylvania
496:7	363:24 364:6	449:3	330:5
outcome 333:16	366:5,11,18 367:9	particular 346:17	people 337:6
464:3	367:10 368:11,16	376:2 447:3 448:2	338:6 479:19
outside 342:16	372:16,25 374:2	451:16 495:24	percent 347:8
394:24 395:2	375:7 379:7	parties 506:20,23	368:22 369:2,20
396:25 457:4	384:12 385:18	partners 371:24	370:8 371:7,17
overall 439:3	386:23 387:3,5,10	partnership 366:3	392:2 456:16
overly 417:5	387:15,22 391:19	parts 491:16	485:16,17 486:6
oversight 381:24	391:20 392:8	party 333:14	percentage 416:24
ownership 369:2	393:2 412:7 420:4	421:24 432:2	497:24 498:10,13
р	432:20,24,25	patient 386:19	498:19 499:3,8,12
p 328:24 329:7	435:11,16 437:3	pattern 369:22	499:13,19 500:2,7
-	440:14 441:3	pause 386:25	perform 432:16
330:2,2,17 506:2,3	448:19 449:18	426:7 427:10	491:22 492:20
p.m. 388:21,22,24	452:12,20 457:25	paused 475:20	494:4
427:20,21 429:12	458:4 461:2 462:4	476:2	performed 432:8
467:24,25 468:3	481:21,24 483:7	pauses 476:15	501:18
490:3,5,7 504:21	483:16 484:9	pay 369:5 370:15	period 347:15,19
504:22	489:10 493:2,7,9	422:17 423:4,8,9	348:2,6,12,12,13
page 331:3,6,19 332:6,10,13,16,19	494:12 495:10,19	423:14 433:12	348:14,15,17,22

[period - portions] Page 26

349:3,4,18 352:18	333:1 334:1,11	455:1 456:1 457:1	421:16 422:3,22
353:3 354:16,18	335:1 336:1 337:1	458:1 459:1 460:1	440:15,16 443:5
354:21 355:4,5,6,6	338:1 339:1 340:1	461:1 462:1 463:1	443:18 460:18
355:25 356:6,21	341:1 342:1 343:1	464:1 465:1 466:1	464:12 470:8
358:9,11,15,15,21	344:1 345:1 346:1	467:1 468:1 469:1	472:19 473:3
359:18 361:19	347:1 348:1 349:1	470:1 471:1 472:1	474:6,13,17 476:9
362:4 363:12,16	350:1 351:1 352:1	473:1 474:1 475:1	487:20 488:5
363:17,20 366:4	353:1 354:1 355:1	476:1 477:1 478:1	497:6
374:8 385:21	356:1 357:1 358:1	479:1 480:1 481:1	plans 371:6
387:8,13 413:18	359:1 360:1 361:1	482:1 483:1 484:1	platform 334:25
414:9,14,20,25	362:1 363:1 364:1	485:1 486:1 487:1	335:5,11 364:17
415:4,19,22 416:6	365:1 366:1 367:1	488:1 489:1 490:1	365:6 370:9
416:18 417:24	368:1 369:1 370:1	491:1 492:1 493:1	420:25 433:4,10
418:5,12 419:10	371:1 372:1 373:1	494:1 495:1 496:1	437:24 449:2
419:13,15,18	374:1 375:1 376:1	497:1 498:1 499:1	450:3
422:2,23 433:23	377:1 378:1 379:1	500:1 501:1 502:1	played 446:9
434:7,14 435:2	380:1 381:1 382:1	503:1 504:1	457:23
442:14 443:9,21	383:1 384:1 385:1	505:10 506:1	please 333:20
443:22 444:23	386:1 387:1 388:1	piece 446:18	334:10 336:14
448:23 459:14,16	389:1 390:1 391:1	483:19	339:18 349:11
460:12,13,20,22	392:1 393:1 394:1	pieces 484:3,12,18	351:17 362:22
463:11,20 464:5	395:1 396:1 397:1	486:9	399:2 402:15
466:10 473:21	398:1 399:1 400:1	pin 490:16	413:8 416:8 418:7
478:14 481:11,13	401:1 402:1 403:1	pisajiw 330:12	418:21 432:21
487:11,17 500:11	404:1 405:1 406:1	pismo 334:12	434:17,19 471:7
500:17,25 501:21	407:1 408:1 409:1	335:17	502:12
502:8 506:18	410:1 411:1 412:1	place 386:8 422:7	point 343:16
periods 354:24	413:1 414:1 415:1	506:10	358:20 369:8
permitting 365:10	416:1 417:1 418:1	plaintiff 334:7	400:18 412:10,22
421:5	419:1 420:1 421:1	393:16 394:14	426:5 448:9
person 455:23	422:1 423:1 424:1	395:15 396:2	454:12 459:2,25
504:3 506:10	425:1 426:1 427:1	plaintiffs 330:4	469:22 476:16
personal 439:14	428:1 429:1 430:1	334:5 335:24	488:19 501:13
perspective 435:6	431:1 432:1 433:1	351:13,19 352:15	pointed 466:23
435:7 469:8	434:1 435:1 436:1	352:20 353:12,19	points 501:20
peter 330:13	437:1 438:1 439:1	354:7 357:2	poorly 478:8
333:22 343:8	440:1 441:1 442:1	364:10 386:6	485:23
425:23	443:1 444:1 445:1	389:11,20 390:7	portion 343:16
ph.d. 328:1,9	446:1 447:1 448:1	390:13,19 393:3	368:13 456:12
329:1,6 330:1	449:1 450:1 451:1	393:10 394:7	portions 366:9
331:1,3 332:1	452:1 453:1 454:1	420:4,13,23	371:4

[position - profits] Page 27

position 455:7	pre 371:15	503:18	468:6,11 475:20
464:2 476:4	preceding 340:13	price 353:8 363:10	476:3 477:11,13
positions 364:24	precise 383:11	365:13 367:11	481:6,14 482:7
420:17	predominance	368:22 374:7,24	503:6
possibilities	353:20 392:9	375:4 385:19	private 457:10
399:22	393:11	387:6,11 400:15	488:24
possibility 416:12	preferable 486:22	401:2,21 402:8,18	privileged 394:20
417:22 418:3,9	preferred 488:9	404:10,16,23,25	394:21 395:11,15
473:25 476:20	premise 413:20	412:9,10,13,16,19	396:23
486:2,3	preparation	412:20 413:2,10	probable 417:4,10
possible 338:12	503:24	414:5,17,19,24	417:16
345:18 347:3,4	prepare 502:17	415:3,18,21	probably 337:15
352:4 359:22,24	preparing 502:14	418:11 421:8	337:16 356:19,20
361:21,21 380:13	503:13	444:5 445:5 446:5	363:18,20 373:24
381:8 383:13,15	present 333:17	446:16 448:21	388:18 396:16
383:17,24 384:6	493:25	449:10 459:12,13	455:24 478:3,7,10
395:21 399:7,13	presented 398:15	484:13,17,24	493:25 502:25,25
399:16,20 400:3	presenting 493:23	485:19 486:8	proceed 334:17
405:25 416:2,15	presumably 447:5	487:16 490:24	proceeding 333:20
416:23 417:2,3,7,7	454:23 481:10	494:18	454:4
417:8,10,14,14,16	presumption	prices 349:16	proceedings
417:16,19 431:6	353:14 393:5	355:23 362:16	331:14 426:8
432:17 442:25,25	pretty 370:20	363:2 365:16,16	452:3,16,21 453:3
456:5,6 465:7	453:9 481:20	367:23 370:21	process 334:24
466:24 484:24	previous 344:17	373:5 401:17	498:7
485:11,15,17,18	359:23 360:12,14	421:11,11 482:3	produced 375:25
485:24 486:4,5	360:25 364:9	principal 434:14	376:13 377:4,7,7
492:5 496:23	366:9 399:21	435:2 486:22	378:3,13 379:3
498:15 499:10,23	404:7 406:25	principals 369:17	380:9,15,25
502:9 503:15	407:8 410:12	principle 417:25	production 332:9
possibly 359:2	424:5 425:12	419:19 424:10	462:6
360:6 380:22	428:12 460:6	428:18 451:5	professional 329:9
418:13 446:20	470:7 475:11	456:11	professor 492:15
potential 414:12	485:25 486:17	principles 365:25	proffered 488:10
417:23 418:4,10	previously 331:18	375:9 421:23	profitability 449:6
436:8 492:17	339:13,23 362:13	prior 336:10	458:20
493:13	402:23 403:15	344:11 352:2	profits 364:8,12
potentially 492:2	409:11 433:25	374:5,10,12,18	365:19 420:6
practice 454:15	442:8 470:13	375:19 387:25	421:14 438:22
479:19	471:11,13 480:13	398:24 453:16	450:8
	488:4 495:15	458:21 461:13	

$[prohibited \hbox{-} ramifications]$

Page 28

nnohibited 477.5	numantadly	207.2 4 0 208.24	avostions 261.45
prohibited 477:5	purportedly 458:12	397:3,4,9 398:24 399:17 400:13	questions 361:4,5 383:13 394:9
pronounce 483:18			
proper 501:13	purposes 336:5	401:9 402:5,11,13	397:8 399:19
properly 371:22	pursuant 329:6	402:14 404:13	408:21,23 416:10
405:20	331:14 452:3,16	405:9,13,14,18	417:12,13 423:5
proposition 401:9	453:3	406:22 407:14	425:13 427:22
401:10 402:7,13	purview 423:24	408:13,22 409:4,6	432:13 435:4
402:23	424:22 428:6	409:10,22,24	467:14 468:18
prove 353:16	429:8 430:12	410:13,22 411:16	469:14 474:3,4
393:7 403:6,9	434:4,11,23	413:8 414:6,22	490:8 504:11
422:22	put 336:13 339:17	415:9,11,18 416:7	quickly 400:15
provide 335:25	370:21 416:24	416:8,13 417:6	401:2,17,22 402:9
341:25 394:14	478:3 490:16	418:20 419:5,6	402:18 404:16,24
396:3	putting 365:6	422:13,21 424:5	quite 433:16
provided 361:4	421:2 464:13	424:13 425:14	447:11 501:10
362:4 365:12,16	482:5	426:20 427:4,24	quotation 364:20
380:19 395:11	q	428:7,13,14,19,22	quotations 365:14
421:7,11 506:17	qibs 352:22	428:23 429:6,20	421:9
provider 422:17	qualification	430:4,8,11,17	quote 368:5 401:4
423:3,13 462:10	441:25	431:3,4,20 432:5,6	418:13 450:6
public 329:9	qualifiers 478:2	432:17 433:12,13	488:11
447:20 505:17	quantify 440:22	433:17,18 434:8	quotes 434:2
507:25	484:17 486:8	434:16,19,20,22	439:7,14 441:21
publically 377:10	quarter 371:16	435:4 436:4 437:2	quoting 401:5,8
377:15,21 378:2	quarter 371.10 question 332:15	438:7 440:7	r
378:18 478:21	338:25 342:14	441:19 442:6,7,10	r 330:2,17 506:2,2
pull 471:5	347:21 349:11	442:24 445:14	506:2,2
pulling 372:3		453:11,14 456:25	ra 328:4
punished 474:9	351:17 355:2,10 357:7,25 358:12	457:13 459:23	ra 528:4 raised 369:3
479:23,25	358:22 359:7,11	460:10 463:24	ransed 309.3
purchase 397:13	358:22 359:7,11	464:9 468:19,19	445:10 482:2
398:6	' '	469:2,13 474:25	
purchaser 353:15	360:13 361:2,7,8	477:20 478:8	494:16
390:22 393:7	361:16,17 367:19	479:5 480:3,10,12	ramifications
purchasers 392:13	368:8,15 370:22	480:20 483:3	362:15 367:14,17
purchases 353:18	370:24,25 372:24	484:16 485:24	367:22 368:10
393:9	377:6,12,18	486:17 490:17,23	372:15,20 373:4
purported 362:5	378:24 380:3	493:21 496:13	373:10,12,18
433:2 448:24	382:24 383:16,25	501:14	441:5,8,10,15,17
489:5	385:8,10,15	question's 398:10	449:8 458:13,22
	388:17 390:25		482:6 494:21
	395:13,22 396:12		

[range - regards] Page 29

range 338:11,12	real 473:25 476:19	499:15	referred 376:8
rate 338:6,24	reality 362:11	recommend 354:6	379:18,20 380:21
339:2	495:13 496:2	391:13,24 392:19	384:19 412:15
rated 352:25	really 387:21	recommendation	439:7 441:18
rates 338:11,12	390:16 435:3	331:13 350:19,25	450:17 454:13
ratings 352:24	442:23 479:16,16	351:7 352:10	485:25 502:21
reached 369:25	496:4	391:4	503:17
react 399:8 400:5	realtime 329:8	recommendations	referring 342:9
400:8	365:13 421:8	331:11 351:4	347:12 355:5,7,15
reacted 443:25	506:4	record 333:3,19	361:25 363:23
reaction 444:5	reason 354:6	353:6 360:16	367:17 368:11
445:6 446:16	475:9 489:3 507:5	363:8 385:5,6	372:16 373:2
459:12,13 484:25	reasonable 386:21	388:21,24 408:7	379:11 389:23
485:19 486:8	reasons 391:12,23	425:22 427:14,17	420:3 424:21
reactions 399:22	401:12 456:4	427:20,23 429:12	425:16,21 429:7
read 353:22	497:16	429:14 442:20	437:8,10,14,17
354:10 355:11	rebuttal 331:9	452:13 462:16	441:16 495:21,25
360:25 363:7	341:2,5,14,19	463:13 464:8	496:15
364:9 367:15	359:3 378:7 492:9	467:24 468:3	refers 354:20
368:17 372:22	492:12 493:3	489:17,25 490:3,7	reflect 388:6
376:7 381:5	recall 338:19	504:21 505:6	401:17,22 490:25
386:13 387:9	347:5 350:5 352:4	recorded 384:10	reflected 346:5
400:17 412:12	380:11,14,14,25	reduced 506:12	362:11 415:3,21
416:8,13 418:6,20	381:8 384:2 448:6	refer 358:24	459:21 495:12
424:24 425:12	469:11 471:2	359:23 360:4,12	496:2
427:23 433:5,25	491:25 492:5,6,13	360:24 379:24	refresh 359:23
434:16,19,20	497:8	380:22 385:17	381:15 393:24
435:15,24 439:8	receive 345:23	386:10 394:19	394:11 471:4
441:22 442:2	received 422:17	399:20 410:12	regard 364:4
449:19 458:24	423:4,14 450:9	425:9,24 439:6	376:9 489:6
462:11 472:23	receiving 423:8	442:10 445:8	494:21 500:7
473:2 497:19	433:8 461:18	448:19 454:12	regarding 335:25
502:19 505:3	466:9 478:22	460:6 470:7	345:16 351:13,19
reading 363:5,6	recess 388:22	477:13 480:11	388:3 397:12
391:17 400:18	427:21 467:25	486:16 489:9	435:25 466:8,20
440:14 482:22	490:4	reference 359:7,11	467:12 469:15
494:12	recognize 371:13	359:15 360:8	regards 339:10
reads 435:19	371:15	361:7 366:15	356:22 363:15,19
ready 343:20	recollection	376:12 439:13	426:15 468:18,21
360:22,23	344:25 381:15	referenced 381:11	468:21 479:15
	390:16 478:19	381:13	484:16 503:13

[registered - reports]

Page 30

registered 329:8	relatively 352:18	338:11,18 339:3,6	440:9,14 441:21
506:4	release 353:7	339:9,15,22 340:6	448:10,11,20
regroup 489:22	released 482:25	340:7,8,10,14,17	453:17 457:17,24
regulations 365:24	relevant 346:20	340:19,20,25	458:2 460:25
421:22 450:15	477:19,22 496:20	341:2,5,14,18,19	461:9 462:4 467:3
465:3,18,20,25	reliance 353:14	341:20 342:20,21	467:6,8 468:6
466:8 477:6	393:5	343:10,12,13,24	472:24 481:18,22
regulator 456:4	relied 342:6	344:12,17 345:4,6	481:24 483:7
regulators 423:21	346:11 351:23	345:7,21 346:5,15	484:9,15 486:20
428:3 436:15,17	352:19 353:16	346:16,18 347:7	487:5 489:5,8,10
445:12 446:21	366:25 374:21	349:15 350:19	492:10,12,16,21
447:6 456:10	375:2 379:3,24	351:3,7,15,21	493:3,7,20,24
regulatory 362:9	381:2 382:11,19	352:3,7,10 354:13	494:13 495:11
371:9,17 435:13	383:6 384:17	355:8,15,18 357:4	496:7,16 497:5,10
435:22 436:2,9,22	388:7 392:17	359:2,3,8,12,15	497:11,11,22
446:10 449:4	393:8 403:17,22	360:9 361:7,24,25	499:14
455:21 456:7	rely 353:14 385:5	362:2 363:25	reported 328:24
458:16,19 469:9	392:14 393:5	364:2,3 366:9,22	reporter 329:7,8,9
469:17 472:11,21	relying 396:10	367:10 368:7,14	333:12 334:9
474:14 482:5	remedial 331:16	368:17 369:8,23	335:4 337:14
rejected 357:10,20	452:5,18 453:5	371:2 372:16	360:25 362:21
358:3 408:25	remember 361:3	374:15,19 375:8	382:23,25 386:13
409:7	394:5 469:21	375:19,22 376:5,6	406:19 424:24
related 333:14	481:21 488:24	376:15,18,20	425:9 506:4,4,5,17
335:22 350:18	503:12	378:7,23,23,25	reporting 424:8
366:2 421:24	remote 328:8	379:7 381:3	424:17 428:16
432:2 461:20	329:5	382:18 383:6,7	429:3,17,25
474:22 481:14	remotely 333:6,17	385:19,23,23,24	430:15 507:1
506:23	repeat 347:20	386:3,6,7,10,11,24	reports 338:15
relating 346:19	351:16 357:24	387:2,25 388:2	341:17 342:2,5,10
462:7 474:14	402:14 409:4,22	389:20,24 390:3,7	342:17 344:7,12
487:21	413:7 415:9	391:4 397:2,11,16	345:8 346:14
relationship 353:7	469:12	398:13,16,19	352:20 359:23
421:25 423:20	repeatedly 411:3	399:6 401:8	360:5 366:10
428:2 433:21	472:15	403:10,14,17,18	367:5 375:12,18
434:5 445:4	repercussions	403:19,21 404:2	379:4,5,14 380:22
446:13,20 462:8,9	362:9 458:16	410:14 411:8,25	381:12,14,23
466:21 467:12	report 331:7,9,11	412:7 418:16,22	382:11 384:18,19
475:19 479:9	331:12,21 336:11	419:8 420:4 422:7	384:20 401:4,5
481:5,7,15 482:7	336:15,24 337:3	431:23 432:21,23	459:22 471:3,4
484:4	337:12,23 338:10	436:5 438:15	475:11 491:21
	,,		

[reports - sanctions]

Page	31	
1 ugc	\mathcal{I}	

			I
492:3 495:18,20	respect 341:25	returns 494:22	447:23 453:13,25
495:22 496:9,15	346:6 349:25	reveal 395:10	455:22 459:8
496:18,24 499:17	353:21,24 393:12	revelation 444:5	466:12 470:7
499:22 502:20,22	472:20	446:13 481:14	474:16 483:4
503:2,4,8	respectfully 354:6	revenge 491:8	488:18
represent 379:2	391:13,24	revenue 369:20	risks 458:22
381:10 388:2	respondents	456:13,18 493:17	rivera 330:18
390:18	452:22,25 454:7	revenues 370:9	333:9
representation	responding 373:2	review 351:12,18	role 364:14 400:23
442:4 463:15	response 389:8	380:9 381:25	420:7
representations	445:25 454:5	382:5 400:19	roman 452:13,19
355:22 365:3	483:2 493:9	401:6 450:23	ronnie 331:12
397:8 420:20	responsive 368:8	468:6,11 471:25	350:20 351:4
representative	460:10 496:13	506:15	391:5
389:22 390:9	rest 504:17	reviewed 346:19	room 335:19
393:17	restarted 475:24	366:23 377:9	rosen 330:3 334:4
represented	restate 488:17	381:16,20 441:12	334:7 345:24
364:11	restricted 352:21	444:11,25 450:24	rosenlegal.com
represents 366:5	restructured	459:18,19 497:5	330:6,6
439:11	457:7	503:3,11	rough 338:20
reputation 445:18	restructures 371:8	reviewing 503:12	roughly 369:20
request 332:9	restructuring	504:6	370:8
462:6	371:15	ribbon 412:2	routing 365:9
requested 345:22	result 362:6	497:16,17,23,24	421:4
506:16,16	367:12	498:9,25 499:3,8	rpr 328:24
required 353:16	resulted 363:2	499:12,13,20	rubric 487:18
392:15 393:7	retail 364:7,12,17	500:2,7 501:19,22	rule 353:20 393:11
407:17 410:2	365:9 420:6 421:4	502:10	rules 465:20,25
450:12 469:18	449:23	rid 373:24	466:7 477:6
474:19	retailer 449:24	right 335:13 343:4	ruling 410:3,17
requirement	retained 394:13	349:22 350:12	411:11,17
353:20 393:11	395:14,23,24	367:14 368:13,25	run 369:9
reservation	396:3,14 430:13	374:15,24 375:5	S
332:18	440:10 441:2	375:19 376:22	
resetting 336:21	retention 424:15	385:6,10,21,23,24	s 330:2,17,17
residual 413:2,10	428:25 429:15	386:4,8,15 387:18	331:5 373:25
414:17 458:5	retribution 491:6	388:4 390:10	507:5
resolution 455:20	491:8	398:10 399:9	s&l 372:7
resolves 370:12	return 491:5,8,10	401:3,14 404:17	sake 377:17
resort 395:15	491:14,15,16	405:6 413:6 417:7	sanctions 331:16
	494:6	417:16 432:12	452:5,18 453:5

[satisfy - sit] Page 32

		110-110-1	1.50 - 105 1.5
satisfy 353:19	375:5 392:13	418:7 442:5 473:2	450:5 483:15
393:10	397:14 398:6	494:10 500:9	498:20,21
save 483:4	412:9 440:20	separate 356:18	shared 450:7
saw 347:4 501:5	449:10 482:3	396:13	shares 371:17
saying 373:23	484:13,25 494:18	separately 394:13	sheet 505:5 507:1
406:15,20 420:5	499:18 500:4	395:14,24,25	shocks 458:19
445:13 446:2,2	security 399:8	484:19 486:9	short 485:15
455:22 457:12	400:5,15 401:2,20	491:3	489:21
497:21 498:12	401:22 402:8,18	sequential 336:9	shorthand 329:7
500:13,19	404:16,23 405:22	series 408:22	349:5 506:3,9
says 352:13 354:5	407:15 412:14,19	469:14	show 353:6
391:12 392:8,24	412:20 413:4,12	serve 414:4	showed 340:4
393:2 425:16	413:17 414:19	service 331:20	shut 446:23
452:20 453:6	418:11	339:21 453:2	455:25
school 426:14	see 336:20,20	services 370:18	shutting 369:12
schools 439:21	345:9 354:5 356:2	set 354:6 424:2	370:17
scope 424:15	356:3 368:21	428:9 430:22	sic 460:2
428:24 429:15,22	373:23 376:12	431:15 454:9	signature 506:24
430:19 431:22	392:21 393:13	settle 369:4 370:14	signed 396:13
438:6 483:5	460:20 468:7,12	459:4 460:3,14	significantly
screens 343:2	474:7 489:22	469:17	498:24
scrutiny 435:14,22	seeing 502:2	settlement 369:14	silvia 328:24 329:7
436:2,9,22 449:4	seen 381:19 394:5	370:12 447:13	333:12 425:22
458:19	443:13 457:19,21	450:16,18 451:4	506:3
sec 365:24 421:21	457:22 459:10	451:19 452:23	similar 468:7,13
478:21 503:2	464:19 465:8	456:3 470:2	481:10
second 334:22	470:10 488:6,23	489:14	simple 395:20
338:8 339:19	503:18	settlements 371:9	473:12 476:11
348:8 350:23	sees 361:14	447:15,21 448:17	simply 394:8
355:9 361:8	sell 369:15	449:15 451:9,11	singular 374:2,3
427:10 471:17	selling 371:11,13	451:13,16,18	sir 504:18
500:8 502:12	semantics 348:9	453:19 455:4,8	sit 337:19,20 338:7
section 344:7	senior 347:8 392:2	468:7 488:18,20	338:19 345:2,18
411:25 419:7	sense 343:6 416:23	settling 370:4	347:5 350:4 352:5
452:17 454:3	437:22 438:12	469:9	360:3 377:22
sections 331:14	496:19 498:7	seven 435:18	378:5 379:12
452:3	sent 399:25 462:5	share 335:11	380:2,6,11 382:3,7
securities 328:5	sentence 348:8	336:14 364:21	382:15 391:2
333:8 362:17	353:23 355:21	368:22 370:6	402:4 431:8,12
363:2 367:12,23	356:19 363:6,19	385:21 387:7,18	435:10 438:24
373:6 374:8,24	364:9 373:21	420:11 440:25	447:10 448:6
, , , , , , , , , , , , , , , , , , ,			

[sit - stock] Page 33

	T	T	I
450:21 453:21	372:18 373:13,22	specific 353:8	458:4 495:11
457:2 461:25	376:18 379:20	380:15,25 397:12	497:15
462:22 469:6	383:10,21 384:13	418:17,23 437:13	stated 338:9
475:16 488:15	384:23 385:22	438:13 443:16	361:10 416:14
489:19 492:6	388:13 391:15,18	445:11 469:22	420:14 424:23
497:8 500:5	393:20 396:7	477:15 479:15	429:10 477:7
sitting 359:5,16,20	397:20 398:22	480:12 496:16	488:4 506:11
360:8 368:9	402:20 405:7	specifically 376:9	statement 355:11
380:24 385:10,12	407:3,6,7 412:4	437:7 441:16	361:13 379:17
386:16 395:12	413:7 416:7	481:13	400:16,19,24
404:4 422:25	426:20 427:10	specifics 492:14	412:24 413:19,20
451:15	435:16 441:21	specified 356:21	414:3,4 415:7,23
situation 406:14	442:18 446:10	specify 364:2	415:24 447:3
413:22	453:12 456:23	397:16	459:14 477:25
situations 414:7	461:10 464:17	speculate 391:2	478:11 495:18
sixth 426:6,24	469:4,12 470:23	472:16	statement's
size 352:18	477:9,19 485:6,10	speculating	414:15
slightly 355:3	487:24 491:10,13	501:12	statements 353:18
slow 362:22	492:11 493:4	speculative 473:8	365:23 375:10
small 352:19,22	497:14	spell 337:14	392:17 393:9
smaller 352:19	sort 407:9	spend 338:17	421:21 423:10
365:15 421:10	sorts 383:12 415:5	502:14	424:3 428:9
snb 475:4,13,20	477:24 478:2	spent 337:22	430:22 431:25
solicitations	479:12	spinoff 438:21	459:14 472:20
369:18 449:23	sounds 369:21	spoke 502:22	488:17 505:7
solutions 333:10	381:7	stable 497:16,23	states 328:2
333:13	source 345:25	staff 503:22	329:10 437:12
solvency 370:22	sources 366:16	stage 336:4	457:5
370:23	southern 328:2	stake 369:2	stating 472:13
solvent 447:9	space 345:3,10	standalone 446:25	stemming 458:17
somebody 470:14	spalding 330:9	standpoint 486:23	stenographer
470:17 473:16	333:23,25 334:3	start 358:11	334:16 342:24
491:9	speak 335:3	460:12 464:4	407:3 425:17
somewhat 356:20	340:10 473:5	started 347:23	427:8
son 426:6,23	474:19	416:9 461:4 463:4	stipulate 393:25
451:22	speaking 383:22	463:7	394:10 425:2
sorry 344:19	385:25 405:19	starts 343:14	489:2
347:20 351:16	411:5 413:21	426:13 476:15	stipulations
356:12 357:24	475:6 501:8	state 333:18,20	332:12
361:9 363:5	speaks 467:4	354:14 356:5	stock 349:16
367:18 371:14	484:15 489:8	424:25 437:3	352:24 354:8

[stock - terms] Page 34

	I	I	
355:23 358:8,14	substance 416:2	441:24 442:3,5,25	501:19 506:9
363:10 385:20	416:15 417:23	444:20 446:25	takes 344:20
387:6,17 391:14	successors 454:7	447:2,11 454:21	481:19
391:25 392:10	sudden 417:15	466:5 474:2,24	tale 416:12
406:3 408:18	suffered 398:5,11	481:20 483:2	talk 396:15 427:9
414:5 443:25	sufficient 385:14	488:9,14 491:7	448:11 454:4
444:4 445:5	385:16 406:17	492:21,22 494:11	496:11
446:16 448:22	439:15	496:21,21 501:10	talked 339:5 405:5
490:24	sufficiently 392:19	502:13	466:12 469:23
stopped 435:21	suggest 420:23	sustainability	470:12
478:12,16,22	434:2 460:21	437:5,19 439:3,10	talking 343:9,9
479:2,22,25 480:7	464:20 465:8	439:12,16 440:11	348:9,18,22 349:8
480:17,25 481:5	470:10 488:6	449:5	355:4 363:16
strictly 479:7	496:4 501:5,8	sustainable 362:8	364:3 374:3,10
strike 332:21	suggesting 500:19	458:15	376:19 378:22
structured 442:5	suggestion 386:9	swear 334:10	386:5 391:18
struggle 476:23	suite 330:4	switch 399:4 475:3	398:14 399:4
study 353:9	sum 366:5	477:17	403:18 408:21
374:14,17,21	superseding	switching 358:8	410:8 416:11
375:3,12 399:5	340:19	sworn 334:14	420:15 430:9
401:13 403:2,14	supervision	505:12 506:6	445:23 459:9
403:16,22 405:20	506:14	507:22	465:17 467:7,9
405:25 406:6	support 332:3	systemic 458:19	478:9 481:17
407:17,24 408:14	389:20 390:7	t	487:8 490:15
408:17	495:18 503:22	t 330:17 331:5	tangential 479:13
subject 362:8	suppose 411:21	506:2,2,2	tax 371:15
366:10 458:15	417:3 434:3 440:4	ta'ed 439:20	teach 439:25
submitted 336:24	472:4 497:25	tabs 386:18	technology 345:6
340:20 389:19	sure 335:8 342:15	take 336:19 355:8	teetering 447:8
452:22 468:5	347:22 348:16,20	376:14 378:6	tell 400:19 404:4
492:16 497:6	349:4 359:24	386:25 389:14	465:5 476:22
499:9,18	360:5 372:22,23	391:3 411:24	506:6
submitting 404:2	378:9 379:16	426:23 427:11,15	ten 426:14 489:21
subpoint 364:7	385:24 386:4,8	457:25 467:15,20	502:16
365:5	389:17 394:20	489:21 492:9	term 347:11,25
subscribe 505:6	395:18 405:24	493:6 496:9 497:9	348:6,7,17,21
subscribed 505:12	406:13 407:13	502:8	354:20 411:2,4
507:22	415:12 422:12,20	taken 333:5	451:3
subsection 454:12	425:5,19 426:25	388:22 427:21	terms 347:24
subset 348:13	431:13 433:16	448:16 455:7	349:3
	434:9 438:23	467:25 490:4	

[terrible - trying] Page 35

terrible 369:21	414:7,15 415:8,24	502:14 504:12,20	totality 341:20
test 390:17	416:9 422:21	504:22 506:10	496:17
testified 334:14	446:9 462:17	times 360:17	touched 350:3
350:11,14 384:15	466:3 467:4	388:17 410:6,10	tracking 427:12
384:16	470:14 473:13	425:21 467:14	trade 392:12
testimony 344:7	474:25 476:11,24	475:2,11 486:18	traded 352:17,22
399:21 476:25	481:19 484:15,21	timing 353:11	353:13 357:11,21
477:11,14 499:10	486:17 489:3,20	today 334:21	358:4 370:6 393:4
503:7,16 506:11	490:14 494:22	335:10,22 337:19	409:2
tfa 379:19,20	496:22 497:4	337:20 338:7	trades 449:21
thank 334:16,18	498:4 499:11	341:23 345:19	trading 353:2
334:20 342:18	500:18,18 503:15	347:5,12 349:2	364:17,22 365:4
495:9 502:11	503:18 504:10	359:5,16,20 360:3	370:3,7 371:22
504:12,15,16,18	thinking 347:2	360:8 368:9	372:2 420:12,21
504:19	408:11 426:15	372:13 377:22	420:22 437:11
thanks 353:25	470:16 473:16	378:5 379:12	439:4,15 440:2,11
theory 464:11,13	476:12	380:2,7,11,24	446:20 450:6,8
486:2	third 355:21	382:3,7,15,16	455:17 483:15
thereto 506:23	440:19	385:10,12,17	traffic 426:16
therewith 458:13	thought 385:2	386:9 391:2	transactions 432:2
thing 370:19	391:7 405:24	395:12 402:4	432:3 433:3,9
387:20 406:11	407:20 445:18	404:4 407:21	448:25
things 350:10	three 341:17	418:15 422:25	transcript 381:6
356:19 374:25	342:17 344:13	431:8,12 435:10	381:10 382:2,6
375:6 379:9,23	367:5 459:21	438:25 447:10	427:9 505:3,6
417:17 425:25	463:10 503:9	451:15 453:21	506:15
433:15 438:3,25	ties 365:11 421:5	457:2 461:25	true 454:20 455:4
441:20 445:9	tietz 345:6	462:23 465:11,11	479:8 494:5
447:3 467:7	time 333:20	465:16 469:6,7	trump 417:2
469:19 470:3	337:21 338:17	473:14 488:15	truth 458:11,18,22
481:16 483:8	348:2,14 349:5	492:7 500:5	506:7,7,8
484:9 502:6	358:15 388:19,20	504:11,12	truthfully 473:5
503:11	388:23 412:10,23	told 420:24 445:11	474:20
think 337:20	413:17,23 422:24	449:24	try 382:24 400:2
342:3 343:4,21	426:11,12 427:8	ton 405:12	416:14 482:18
345:19 348:9,12	427:19 429:11	tools 493:12,15	495:2
368:4 382:16	433:13 455:13,15	top 394:4	trying 355:10,12
388:12,16 389:9	459:3 467:23	topic 410:13	360:15 361:20
402:13,22,24	468:2 483:4	436:12,13	383:10,23 386:8
403:6 404:3,18	488:19 489:20	total 366:6 502:16	386:14 395:20
406:16 407:21	490:2,6 500:15,24		403:5,9 406:18
	1	1	

[trying - volume] Page 36

407:12 438:12	uncommon 466:13	482:21 483:10,13	variations 501:20
496:19 498:7,11	underestimation	484:3 485:3,21	variety 493:11
turn 342:13,20	458:21	united 328:2	various 407:11
347:6 352:9	undergoing	437:12 457:5	vary 456:8 500:24
353:18 354:2	472:22 473:6	universe 388:6	501:11
392:4,23 393:10	474:21	496:20	varying 500:15
449:2,9 472:6	understand	unnecessary 384:8	veracity 362:13
484:8 494:17	347:12 354:25	unregistered	495:15
498:23	356:16 358:12	352:21	verbatim 448:7
turned 378:17	367:18 373:19	unsure 347:2	verify 390:14
turning 349:14	389:10 393:15	377:25	veritext 333:10,13
363:24 367:9	395:20 404:13	unusual 477:16	507:1
379:6	405:8 406:13	unusuai 477.10 upload 335:9	versus 345:6
		use 347:11 348:16	
twice 360:20 two 343:6 350:17	409:6 410:21 424:13 428:21	348:21 349:5	354:21 355:4 408:18 487:3
353:11 369:16	429:19 430:3,5,7	371:21 414:17 431:7 441:24	viability 437:5,19
371:4,8,24 407:2	430:17 431:2,4,9		438:5,9 439:3,9,11
414:7,7 417:17	431:11,19 432:4,6	463:23 490:11,13	449:4
463:19 464:5	432:13,17 435:3	490:20 491:2	video 328:8
467:18 468:18	436:4,15,25 438:7	493:18 498:19	videographer
473:20 475:2	447:18 455:16,19	499:25 501:3,23	330:19 333:2,11
479:9 484:4	460:9 464:9 474:3	uses 498:25	334:9 388:20,23
498:15,18	480:19 498:11	utility 353:10	427:19 429:11
type 411:8 454:2	understandably	V	467:23 468:2
454:16 455:10	410:11	vague 395:21	490:2,6 504:20
484:23 501:8	understanding	vaguely 417:12	videotape 329:5
types 454:17	358:19 359:16	valia 337:13	view 365:13
468:20 501:7	362:5 366:6 367:2	valuable 368:24	368:23 421:8
typewriting	394:4 407:13	valuation 362:10	441:7 442:11
506:13	438:2,10 439:9,11	369:4 375:10	447:15 473:7
u	458:18 461:14	486:23 490:12,13	vigorously 392:10
ultimately 419:11	462:12,18,19	493:12,13,15,15	violate 421:21
422:21 440:5	466:18 473:19	493:18 495:12,25	violated 365:23
469:17 498:22	478:15 479:20	value 458:17	violation 461:21
502:5	488:7 501:25	477:19,22 481:8	461:21 488:8,14
unable 457:11	503:6	482:8 486:25	violations 450:14
495:3	understood	493:17	456:8 487:21
unadjudicated	359:17 444:21	valued 487:6	vitae 344:4,10
472:17 473:8	undertaking 454:9	variable 424:4	volume 352:25
uncharged 472:17	undisclosed	428:10 430:23	353:3 364:22
473:8	364:18 450:4	431:9,11,16	370:7 420:12
.,		,11,10	

[volume - witness] Page 37

450:6 483:15	409:14 414:23	356:1 357:1 358:1	468:1,4 469:1
w	415:13 421:12	359:1 360:1 361:1	470:1 471:1,11,12
	422:22 423:16	362:1 363:1 364:1	472:1 473:1 474:1
wadsworth 334:12	424:11 428:19	365:1 366:1 367:1	475:1 476:1 477:1
wage 328:24 329:7	430:9 431:5 435:9	368:1 369:1 370:1	478:1 479:1 480:1
333:12 425:11	442:4 443:25	371:1 372:1 373:1	481:1 482:1 483:1
434:18 506:3	444:3 448:5	374:1 375:1 376:1	484:1 485:1 486:1
wait 341:11	450:20 451:13	376:21 377:1	487:1 488:1 489:1
346:23 351:23	453:20 457:12	378:1 379:1 380:1	490:1,8 491:1
361:9 461:10,10	461:17 462:18,19	381:1 382:1 383:1	492:1 493:1 494:1
471:20,20,20	474:16 475:16,22	383:16 384:1	495:1 496:1 497:1
walia 337:13,22	475:25 482:15,18	385:1 386:1,22	498:1 499:1 500:1
502:23 504:3	489:18 492:22	387:1 388:1,25	501:1 502:1 503:1
walk 496:10	493:22 494:2	389:1 390:1 391:1	504:1 505:10
want 335:2 336:7	500:6 503:9	392:1 393:1 394:1	506:1 507:3,21
339:12 342:14	506:21	395:1 396:1 397:1	werner's 353:9
343:16 347:22	ways 498:4	398:1 399:1 400:1	406:25 407:8
348:16 349:4	we've 376:11	401:1 402:1 403:1	whoa 453:23,24
350:17 354:23	387:24 388:16	404:1 405:1 406:1	453:24,24,24
355:17 359:15,21	466:3	407:1 408:1 409:1	455:13,13,13,14
360:3,21 366:21	weigh 473:24	410:1 411:1 412:1	455:14 461:10,11
376:10,11 390:18	went 379:14	413:1 414:1 415:1	461:11,11
390:25 393:25	429:13	416:1 417:1,15	william 382:6
395:9,18 398:8	werner 328:1,9	418:1 419:1 420:1	452:15
399:4 400:2,17	329:1,6 330:1	421:1 422:1 423:1	win 365:11 421:5
406:12 409:4,22	331:1,3,7,8,9,10	424:1 425:1 426:1	wish 426:9,23
410:9 415:8,9	331:11,12,13,20	427:1 428:1 429:1	withdraw 459:6
418:14 425:2,5	331:22,23 332:1	429:13 430:1	460:4,15 476:5
441:9 444:20	333:1,7 334:1,11	431:1 432:1 433:1	483:22 484:4
445:14 448:9	334:20 335:1	434:1 435:1 436:1	485:2,20
450:22 469:22	336:1,8,15,16,20	437:1 438:1 439:1	withdrawal 470:3
483:18 485:13	336:23 337:1	440:1 441:1 442:1	withdrawing
488:12 489:2 495:4 496:5 497:9	338:1 339:1,13,15	443:1 444:1 445:1	469:19
wanted 335:6	339:20,23 340:1,2	446:1 447:1 448:1	withdrew 468:25
wanted 335:6 wants 337:14	341:1,2,3,4,6,9	449:1 450:1 451:1	witness 331:3
	342:1 343:1,20	452:1,2,9 453:1	332:6 334:5,8,10
360:25 water 417:9	344:1 345:1 346:1	454:1,13 455:1	343:3 356:12
water 417:9 467:16	347:1 348:1 349:1	456:1 457:1 458:1	362:20 383:19
way 342:23 365:17	350:1 351:1,3,6	459:1 460:1 461:1	384:23 388:13
way 342:23 365:17 378:4 382:4,8,14	352:1,11 353:1	462:1 463:1 464:1	395:6 396:7
389:5,16 403:7	354:1,25 355:1	465:1 466:1 467:1	397:20 398:8
307.3,10 403.7			

[witness - zoom] Page 38

402:20 405:6,10	wrote 367:20	york 328:2 329:10
411:2 435:19	369:8 373:3,16	330:11,11 507:1
442:18 464:17	387:14,19,20	young 380:12,15
477:9 485:6,10	425:9	380:19,23 381:2
486:13 487:24	X	Z
506:5,12	x 331:2,5 365:7	zoom 329:5
witnesses' 507:3	506:15	334:25 335:5
won 364:20,20		334.23 333.3
417:3 420:11	y	
450:5 483:14	yeah 336:21	
word 365:7 371:21	344:22 346:16	
407:5 431:6	347:22 348:9	
441:25 446:6	350:6 351:18	
485:11,14	358:13 368:6	
worded 478:8	391:9 394:23	
485:24	400:12 402:4	
words 410:11	419:5 422:20	
498:19	435:9,24 436:13	
work 339:8 359:5	442:22 453:9	
380:8 424:15	456:11 457:6	
428:24 429:15,22	460:6 461:7,12,25	
430:20 431:22	462:11,17 463:14	
433:20 450:25	465:14 470:17	
476:21 486:19	471:8,24 473:16	
487:4	473:24 474:11	
workers 371:7	476:18,23 479:24	
workforce 371:7	480:10,19 481:23	
world 487:9,9	482:11 484:8	
woven 447:4	493:5 497:20	
write 337:3	501:12	
writing 363:18	year 345:4 362:2	
written 400:21	414:20,25 415:19	
wrong 341:12	464:4 495:23	
385:22 432:23	years 463:10,19	
447:14 451:14	464:5 465:12,14	
455:23 489:3	465:15 470:15	
494:2	473:13,15,21	
wrongdoing 451:8	478:6	
454:6	yesterday 368:20	
wrongdoings	369:25 502:24	
451:8 472:17	504:4	

Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1,

2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.